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Abstract 
The atypical PKCζ is a promising therapeutic target in inflammatory diseases and B cell 
lymphoma. Therefore, there is an increasing need to develop selective inhibitors for this enzyme 
without affecting the closely related PKC family members. Allosteric inhibitors were found to be 
an effective tool in achieving this aim. Optimization yielded the 1,3,5-trisubstituted pyrazoline 
scaffold which proved to be rich in modifiable sites, all acting as hot spots for improving binding 
affinity. The phenolic group at the 5-phenyl was essential for activity. The presence of a 
lipophilic substituent at the 1-phenyl was important for high potency. The 3-position was tolerant 
for diverse types of substituents, acting as a means to optimize polarity and physicochemical 
characteristics. A methyl group at the 4-postion of the pyrazoline increased the potency, and was 
reported to enhance pyrazoline’s chemical stability. The optimized compounds showed two 
orders of magnitude improvement in the cell free assay potency and more than 10 times increase 
in cellular potency in U937 cells. The compounds showed high selectivity for PKCζ vs. the 
closely related PKCɩ and other PKCs, and were most likely targeting the PIF-pocket. Since the 
pyrazoline scaffold showed shape complementarity also to the p53-Mdm2 interaction site, the 
ability to compete this other protein-protein interaction was tested. However, the compounds 
which showed potent growth inhibition in cells failed to show activity in the binding assay. 
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Zusammenfassung 
Die atypische PKCζ ist ein vielversprechendes Target bei Entzündungserkrankungen und 
B-Zell-Lymphomen. Daher besteht ein Bedarf, selektive Inhibitoren dieses Enzyms zu 
entwickeln, welche eng verwandte PKC-Isoformen nicht hemmen. Allosterische Hemmstoffe 
stellten gute Ansatzpunkte zum Erreichen dieses Zieles dar. Eine Optimierung führte zu 1,3,5-
trisubstituierten Pyrazolinen, die an vielen Positionen vorteilhaft modifiziert werden konnten, 
was jeweils in einer effektiven Erhöhung der Bindungsaffinität resultierte. Der Phenolrest in der 
5-Position war dabei essentiell für die biologische Aktivität. Ebenso war die Anwesenheit eines 
lipophilen Substituenten am 1-Phenylrest wichtig für eine hohe Potenz. An der 3-Position 
wurden verschiedene Arten von Substituenten toleriert, so dass hier die Polarität der 
Verbindungen und weitere physikochemische Eigenschaften optimiert werden konnten. Eine 
Methylgruppe an der 4-Position des Pyrazolins erhöhte die Wirkstärke zusätzlich und wurde 
zugleich als stabilisierend auf die chemische Stabilität beschrieben. Die optimierten Hemmstoffe 
zeigten eine um zwei Größenordnungen höhere Potenz im zellfreien Assay und eine 10-fach 
bessere Wirksamkeit im U937-Zellassay als die Ausgangsverbindungen. Die Verbindungen 
besaßen eine hohe Selektivität für PKCζ gegenüber der stark homologen PKCι und weiteren 
PKC-Isoenzymen, und griffen wahrscheinlich an der PIF-Tasche an. Da das Pyrazolingerüst 
auch eine Formkomplementarität zur p53-Mdm2-Interaktionsstelle aufwies, wurde die Fähigkeit, 
diese andere Protein-Protein-Interaktion zu kompetitieren, gestestet. Für diejenigen 
Verbindungen, die eine potente Hemmung des Zellwachtums zeigten, konnte jedoch keine 
Aktivität im Bindungsassay nachgewiesen werden.  
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1 General Introduction  
1.1 Kinases and Protein Phosphorylation  
Protein phosphorylation is a post-translational modification that regulates most cellular 
activities. It is a specific enzymatic reaction in which one protein serves as a substrate for protein 
kinases, namely phosphotransferases, that catalyze the transfer of the γ-phosphate of ATP to an 
acceptor amino acid in the protein substrate.1, 2 
In eukaryotes, proteins are either phosphorylated on serine/threonine residues or on 
tyrosine residues. Thus, protein kinases can be considered broadly to be Ser/Thr kinases or Tyr 
kinases, or in some instances, dual-specificity kinases when they phosphorylate Ser/Thr as well 
as tyrosine residues.1 For regulation of enzyme activity, the phosphorylation of serine and 
threonine residues is the most important. Analysis of the human genome showed that there are 
518 protein kinases (1.7% of the proteins encoded). 
1.1.1 Regulation of Enzyme Activity by Phosphorylation 
Phosphorylation of enzymes and proteins by specific protein kinases is the most wide 
spread mechanism for the regulation of enzyme activity; it represents a flexible and reversible 
means of regulation and plays a critical role in signal transduction where the added phosphate 
group can be removed by one of the phosphatases, allowing different specificities to be used in 
the forward and reverse reactions. The biological processes may be switched on or off to meet 
different demands.2 
  The added phosphate group can form an extensive network of hydrogen bonds which can 
link different parts of a poly peptide chain, in addition to its ability to make electrostatic 
interactions especially with arginine residues hence attracting a cluster of positively charged 
amino acid side chains. Both types of interactions are important for control of protein function on 
phosphorylation through induction of large to small scale allosteric conformational changes. 
Sometimes the introduced phosphate affects the enzyme activity solely by its electrostatic effect 
without apparent change in enzyme conformation, where an attached phosphate group can form 
part of a structure that is directly recognized by binding sites of other proteins.1, 2 
Phosphorylation results in a number of diverse responses in different proteins, for 
example, it may result in the activation or inhibition of enzyme activity or, as mentioned above,  
it can create a protein recognition site for another protein. Each of these events allows a 
phosphorylated protein to signal downstream proteins initiating a cascade of reactions.3 
Introduction 
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1.1.2 Protein kinase structure  
Protein kinases share a common catalytic domain with highly conserved architecture but 
they have a variety of different regulatory mechanisms. The kinase may be present as a single 
domain or it may be covalently linked to other regulatory domains. The fold of the catalytic 
kinase domain, comprising about 300 amino acid residues, consists of a smaller N-terminal lobe 
of about 80 residues (the small lobe) with the conserved regulatory helix αC and about 200 
residues C-terminal large lobe. The two lobes are linked by a hinge region. The protein substrate 
binding site faces the ATP-binding site between the small and the large lobes. The ATP-binding 
site is a conserved site in all protein kinases. 4, 5  
The active site contains a number of highly conserved motifs that are essential for 
catalytic activity. Key catalytic motifs include the ATP/Mg2+ binding motifs and the activation 
loop. A large number of kinases are activated by phosphorylation of the activation loop, which is 
typically disordered in its inactive state but assumes a stable structure in its phosphorylated 
active state. 
In most of the AGC kinases, the C-terminal folds back onto the catalytic domain and ends 
in the hydrophobic motif (HM), where it binds a particular hydrophobic pocket in the small lobe 
termed the ”PIF pocket” which will be discussed later in more details.6 Figure 1 shows a cartoon 
representation for PKA highlighting most of the described elements. 
1.1.3 AGC Kinases  
The AGC kinase family is a subgroup of Ser/Thr protein kinases including cAMP-
dependent protein kinase  (PKA), cGMP-dependent protein kinase (PKG) and protein kinase C 
(PKC)(reviewed in 6).  It includes 60 of the 518 human protein kinases, of which 42 possess 
functional domains, other than the kinase core, which are involved in regulating kinase activity 
and localization. 
Activation of many AGC kinases involves phosphorylation of two highly conserved 
regulatory motifs namely the activation loop, which is located in the catalytic domain (in the C-
lobe), and the hydrophobic motif (HM) found in a non-catalytic region following the kinase 
domain. Additionally, several AGC kinases need another important phosphorylation of a further 
site that promotes their integrity, which is termed the “turn motif”.  
Introduction 
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Figure 1: Cartoon representation of protein kinase A (PKA). Some of the critical components of the kinase active 
site: the activation loop, helix αC, ATP, magnesium ion. The C-terminal HM peptide and PIF pocket are also shown. 
(Adapted from 7). 
1.1.3.1 PKCs 
The protein kinase C (PKC) family (reviewed in8) represents around 2% of the human 
kinome. There are 10 mammalian PKCs sharing a highly conserved catalytic domain, carrying 
motifs required for ATP/substrate binding and catalysis, in addition to a more divergent 
regulatory domain at the N-terminus. Both the catalytic and regulatory domains are linked 
through more variable hinge regions. 
PKCs regulatory domains contain an auto-inhibitory isoform-specific sequence called 
pseudosubstrate domain which contains an alanine instead of the serine/threonine 
phosphoacceptor site, but otherwise resembles a PKC substrate. The regulatory domain usually 
contains C1 and C2 domains, which are structural domains that influence the sensitivity of each 
PKC to different stimuli as well as their function and mechanism of regulation.  
1.1.3.1.1 Classification of PKCs 
Based on the structural differences found in their regulatory domains, PKCs can be 
classified into three distinct subgroups (shown in Figure 2-A): the conventional or classical 
PKCs (cPKCs), the novel PKCs (nPKCs) and the atypical PKCs (aPKCs).  
P
P
P
Helix αϹ
Activation
loop
HM
peptide
PIF 
pocket
C-lobe
N-lobe
Mg2+
P
ATP
pocket
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1) The cPKCs comprise PKCα, PKCβI, PKCβII and PKCγ. They have a conserved C1 
domain that contains a double zinc finger and a pocket that binds diacylglycerol (DAG) 
and phospholipids. They also contain a C2 domain which has a binding site for calcium, 
rendering this subfamily sensitive to calcium. 
2) The nPKCs comprise PKCδ, PKCε, PKCη, and PKCθ. Similar to the cPKCs, the novel 
PKCs are activated by DAG and phospholipids, but they are calcium independent as their 
C2 domain lacks the critical calcium-coordinating acidic residues. 
 
Figure 2: (A) Structure of the PKC family. Schematic representation of the different PKC subfamilies and their 
domain structural organization. The PKC family is divided into three structurally and functionally distinct subgroups 
according to their regulatory domains: the classical isoforms (cPKC), novel isoforms (nPKC) and atypical isoforms 
(aPKC). Conserved region 1 (C1) confers binding to diacylglycerol and phospholipids, and C2 senses calcium. PB1 
(Phox ⁄ Bem domain 1) is specific for aPKC and acts as a dimerization domain (adapted from9). (B) Detailed 
schematic representation of domain structure of the aPKCζ. PKCζ consists of a PB1 domain in the N-terminus, a 
pseudosubstrate (PS), a C1 domain, and a Ser/Thr kinase domain in the C terminus. The kinase domain includes an 
ATP-binding region, an activation loop, a turn motif, and a hydrophobic motif. Thr410 in the activation loop is 
phosphorylated by PDK1. Thr560 in the turn motif is the phosphorylation site. (Adapted from 10). 
3) The aPKCs include PKCζ and PKCι (also known as PKCλ in mice). They are insensitive 
to calcium due to the lack of a C2 domain and insensitive to DAG as they have an 
Kinase
KinaseC2C1 C1
KinaseC2 C1 C1
KinaseC1PB1
cPKC
nPKC
aPKC
PKCζ
hydrophobic motif
turn motifactivation loop
ATP binding region 
PB1 PS C1
A
B
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atypical C1 domain with only a single zinc-finger structure. At the N-terminus, they have 
a distinct structural domain called Phox⁄Bem 1 (PB1) that is unique for this PKC 
subfamily; it is a protein-protein interaction domain that mediates interactions with other 
PB1-containing scaffolding proteins thus links them as a network. Figure 2-B shows a 
schematic representation of the domain structure of PKCζ. 
1.1.3.1.2 Regulation of PKCs 
During the inactive state, PKC is auto-inhibited by its pseudosubstrate, which blocks the 
substrate-binding pocket located in the kinase domain.11  As mentioned before with many AGC 
kinases, to attain an active state, phosphorylation of the kinase domain has to take place on three 
(cPKCs and nPKCs) or two (aPKCs) Ser or Thr sites to stabilize the active kinase conformation. 
While cPKCs and nPKCs are phosphorylated on their turn motif, hydrophobic motif peptide and 
activation loop, aPKCs do not require HM phosphorylation as will be explained later. Two 
upstream kinases seem to be required for this process. The first one is phosphoinositide-
dependent kinase-1 (PDK1) to phosphorylate the activation loop in the kinase domain,12 where 
this phosphorylation requires docking of the phosphorylated HM peptide from the substrate 
kinase to the PIF pocket of PDK1.13 The other kinase is the mammalian target of rapamycin 2 
complex (mTORC2), which controls phosphorylation of the turn motif and hydrophobic sites in 
the C-terminal tails of these kinases.  
In the case of aPKCs, there is an acidic phosphomimetic Asp or Glu which is present in 
the HM peptide instead of a phosphorylatable Ser or Thr. This acidic residue can replace the 
phosphate (of HM-phosphate) in its interaction with the PIF pocket of PDK1, escaping the 
requirement for the hydrophobic site phosphorylation.13, 14 After the PKC gets the required 
two/three required phosphorylations, the kinase becomes only active after lipid second 
messenger or allosteric stimulation to release the pseudosubstrate peptide from the active site and 
reach the fully active state.6  
As this thesis is concerned with the aPKCζ, its activation and regulation will be discussed 
in more details as follows. 
1.1.3.1.2.1 Activation/regulation of aPKCs: 
1) Activation by lipids: where, unlike the cPKCs and nPKCs, aPKCs cannot be activated by 
DAG or Ca2+, rather they have been suggested to respond to other lipids such as 
phosphatidylinositols, phosphatidic acid, arachidonic acid, and ceramide (reviewed in 15 and 
9). However, it is unclear whether some of these effects are physiologically relevant. 
2) Regulation through interaction with specific binding partners: an important mechanism to 
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• Par-4,  which is found to bind the zinc-finger at the C1 domain of the aPKCs,  
inhibiting   their enzymatic activity.16 Par-4 is considered a specific inhibitor of 
aPKCs.  
• Adapters, which bind the PB1 domain affecting localization but not the enzymatic 
activity of the aPKCs: PB1 is a modular scaffold domain, which can be involved in 
polar heterodimeric interactions.17 In addition to the aPKCs, PB1 domains exist in 
adapter⁄scaffold proteins (such as p62 and Par-6), and also in other kinases of the 
mitogen-activated protein kinase (MAPK) family, including MEK5α and MEKK3. 
p62 and Par-6 are selective adapters for the aPKCs.18, 19 Par-6 has been shown to be 
crucial to the control of cell polarity and, through its PB1 domain, to allocate the 
aPKCs specifically in polarity-related functions. On the other hand, the p62⁄aPKC 
signaling platform plays a critical role in NF-ĸB activation.20  It is not a substrate and 
does not seem to significantly affect the intrinsic kinase activity of the aPKCs.19   
Thus, the formation of aPKC complexes with different adapters, scaffold proteins, and 
regulators such as Par-6, p62, and Par-4 serves to confer specificity and plasticity to the actions 
of these kinases and to establish a signaling network. However, the factors that determine which 
complex is formed at a given time remain to be identified.9  
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1.2       Physiological Importance of PKCζ  
1.2.1 Relevance of PKCζ in Immunology and Inflammation 
1.2.1.1 PKCζ and NF-κB Signaling 
The transcription factor NF-ĸB is critical in a number of cell functions including growth, 
survival and key inflammatory and immune responses. Uncontrolled activation of NF-ĸB can 
induce cancer development, autoimmune, and chronic inflammatory diseases as a result of 
exacerbated lymphocyte function.21   
The most classical form of NF-ĸB is a heterodimer of p50 and p65 (RelA), which is 
sequestered in the cytosol by the inhibitory protein IĸBα preventing its nuclear translocation. 
Upon cell activation by tumor necrosis factor-α (TNFα) or interleukin-1 (IL-1), IĸBα is 
phosphorylated, which triggers its ubiquitination and subsequent degradation through the 
proteasome. This serves to release NF-ĸB, which translocates to the nucleus, where, in 
collaboration with coactivator proteins, it stimulates the transcription of its target genes. The 
kinase responsible for the signal-induced phosphorylation of IkB is a heterodimer of three 
subunits: two catalytic subunits (IKKα and IKKβ) and a regulatory subunit termed IKKγ. The 
IKK complex can be activated by direct phosphorylation of the β subunit by a putative IKK 
kinase, as shown Figure 3 (reviewed in 22) . 
PKCζ was shown to play a significant role in NF-ĸB activation at two different levels, 
IKK activation and NF-ĸB transcriptional activity: 
1. PKCζ has IKK kinase function. In the lung where PKCζ is abundantly expressed, it is 
required for IKK activation in response to TNFα, IL-1b, or lipopolysaccharide (LPS), as 
shown in Figure 3.23 
2. Phosphorylation of Ser311 in the RelA subunit is a fine control of NF-κB transcriptional 
activity. As mentioned earlier, NF-κB is initially controlled by an all-or-nothing nuclear 
translocation pathway. Fine tuning is required as NF-ĸB regulates the expression of a large 
number of genes, thus mechanisms need to be in place to fine-tune the process. PKCζ 
represents one of the most important fine controls, where PKCζ-mediated phosphorylation 
of RelA regulates transcription.24 PKCζ is found to phosphorylate Ser311 on the RelA 
subunit of NF-κB, which has been shown to be required for full NF-κB transcriptional 
activity in vivo and in cell culture experiments.23 Under basal conditions, RelA is 
methylated at Lys310 by the methyl transferase SETD6 , promoting recruitment of GLP 
protein which, along with its partner G9a, promotes methylation of histones leading to 
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closed chromatin and inhibited transcription of κB-dependent genes. After activation of 
cells by TNF, PKCζ phosphorylates Ser311, leading to release of GLP, demethylation of 
Lys310 and recruitment of the transcriptional coactivator CBP to the phosphorylated RelA, 
which promotes acetylation of Lys310 and of histones, which, together with their 
diminished methylation, resulting in enhanced transcription.9, 25 This way, both acetylation 
and methylation have been shown to have a functional interplay with phosphorylation to 
fine-tune NF-ĸB transcriptional activation. The role of PKCζ in NF-κB dependent genes 
transcription is summarized in Figure 4.   
 
 
Figure 3: NF-ĸB activation and possible roles for PKCζ.  The binding of different ligands to their respective 
receptors in the plasma membrane triggers the recruitment of specific adapters for each receptor which orchestrate 
the formation of a signalosome complex that is constituted of two catalytic (IKKα and IKKβ) and one regulatory 
subunit (IKKγ). In the lungs, PKCζ act as an IKK kinase leading to activation of the complex. This complex in turn 
phosphorylates IkB, that is subsequently ubiquitinated and degraded through the proteasome system, releasing NF-
ĸB (the most classical components of which are p65-p50 heterodimers) to translocate to the nucleus and interact 
with elements in the promoter of inflammatory and survival genes harboring ĸB-elements in their promoters. The 
second role for PKCζ in Ser311 phosphorylation will be discussed in the next figure with more details. (Adapted 
from 9). 
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Figure 4: PKCζ-mediated phosphorylation of RelA and its regulation of NF-κB transcriptional activity. (Adapted 
from 24). 
1.2.1.2 Role of PKCζ in Secondary Lymphoid Organ Maturation and B 
Cell Differentiation, Activation and Survival 
In PKCζ deficient mice, the formation and maturation of secondary lymphoid organs 
(Peyer’s patches and spleen) is altered during the first weeks after birth. However, most of these 
defects are overcome in adult animals indicating that PKCζ could have an important role in B 
cell maturation in young animals which that can be compensated by other molecules in adult 
mice.23 
PKCζ is required for an optimal survival rate, cell cycle entry, and proliferation after B 
cell receptor (BCR) stimulation in adult animals.26 It was found that PKCζ mediates B cell 
proliferation and survival by activation of the extracellular signal-regulated kinase (ERK) 
pathway. Even more importantly, after B cell receptor stimulation, PKCζ induces the 
transcription of IκB and other NF-κB-dependent genes, such as IL-6 or Bcl-XL which are 
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impotent for B cell survival. Although PKCζ is an important mediator of the NF-ĸB pathway as 
previously discussed, the activation and nuclear translocation of this transcription factor is not 
inhibited in BCs in PKCζ-deficient mice.26 The role of PKCζ in B cell development is 
summarized in Figure 5-A. 
1.2.1.3 PKCζ and T helper cells differentiation  
PKCζ is essential for the development and differentiation of naïve T cells into Th2 cells. 
PKCζ-deficient CD4+ T cells which are differentiated in vitro under Th2 polarizing conditions 
secrete low levels of Th2-related cytokines IL-4, IL-5, IL-10 and IL-13, compared to the amount 
of cytokines released by CD4+ T cells from wild type mice.27 In PKCζ-deficient mouse, the T-
dependent humoral immune responses are very faint; these mice are not able to mount a proper 
humoral response against T-dependent antigens. The nuclear translocation of RelA was impaired 
in PKCζ-deficient cells.27 However, the role of PKCζ is not restricted to NF-ĸB activation during 
Th2 differentiation, but rather PKCζ has a more fundamental role in this process by playing a 
pivotal function in IL-4 signaling, which, along with signals arising from the T-cell receptor 
(TCR), is essential for the activation of the Th2 differentiation program.27 Stat6 phosphorylation 
in response to IL-4 stimulation was impaired even in mature undifferentiated PKCζ-deficient T 
cells. It was found that PKCζ directly interacts with and phosphorylates Jak1 in response to IL-4 
stimulation, which is important for the activation of the Jak1/Stat6 pathway in vitro and in vivo. 
28
 The role of PKCζ in Th2 cell differentiation is summarized in Figure 5-B. 
On the other hand, Th1 differentiation from PKCζ-deficient naïve CD4+ T cells appears 
not to be affected in this function, as the release of the typical Th1-associated cytokine IFN-
gamma is not affected by the lack of PKCζ.  
1.2.1.4 PKCζ in Asthma 
Asthma is a disease of chronic airway inflammation in which Th2 cells play a critical role 
(reviewed in 29 and 30). Thus, CD4+ T cells producing Th2 cytokines play a prominent role in the 
lungs of asthmatic subjects, particularly because IL-4 and IL-13 enhance immunoglobulin E 
(IgE) production, IL-4, IL-9 and IL-10 enhance mast cell growth, IL-5 enhances eosinophil 
accumulation, and IL-9 and IL-13 directly enhance mucus hypersecretion and airway 
hyperreactivity (AHR).29, 30 PKCζ can be considered as an important key player in asthma based 
on these previously mentioned findings: 
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Figure 5: PKCζ in signaling pathways leading to lymphocyte activation and/or differentiation.  (A) Signaling 
through B cell antigen receptor (BCR) in B-lymphocytes. PKCζ is required for the activation of ERK after antigen 
challenge and is necessary for IkB transcription. The transcription of NF-ĸB-dependent genes IL-6 and Bcl-XL, and 
the secretion of T-dependent immunoglobulins depend on PKCζ-mediated signaling. (B) Signaling pathways in T 
lymphocytes. After antigen presentation, downstream signaling through T cell receptor (TCR) takes place. PKCζ is 
important for IKK activation and NF-ĸB nuclear translocation. Signaling through IL-4 receptor (IL-4R) requires 
PKCζ to fully activate Jak1/Stat6 pathway and therefore to promote Th2 differentiation. (Adapted from 31). 
1) In lung tissue, PKCζ is abundantly expressed and was found to be required for both IKK 
and NF-κB phosphorylation in response to TNFα, IL-1b, or LPS.23 
2) PKCζ is a critical modulator of the Th2 response and acts as an important player in the 
Jak1/Stat6 signaling cascade involved in the activation through IL-4.  
Accordingly, PKCζ can be a potentially relevant target in treatment of asthma. In Th2 
cells with PKCζ deficiency, IL-4 is significantly reduced in addition to the synthesis of three 
other Th2 cytokines namely IL-5, IL-10, and IL-13.27 Moreover, loss of PKCζ inhibited allergic 
airway disease in ovalbumin (OVA) mouse model and reduced allergic response to the OVA 
challenge, where mucus production was not observed in lung sections. In addition, IL-4, IL-5, 
IL-13 and eotaxin supernatant levels, which were dramatically increased in OVA-challenged WT 
mice, were severely reduced in similarly treated PKCζ deficient mice.27  
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In a previous study using a mouse model, blockade of PKCζ signals by instillation of 
pseudosubstrate inhibitor (PPI) showed that PPI alleviates allergen-specific Th2 response and 
asthmatic manifestations. Inhibition of PKCζ was shown to decrease IL-5 and IL-13 levels in 
bronchoalveolar lavage fluid to approximately 20% of the control levels and also caused a 
marked drop in the level of TNF-α. In addition, serum OVA-specific IgE level and ex vivo IL-4, 
IL-5 and IL-13 production by peribronchial lymph node cells were also considerably lower in 
PPI-treated mice.32  
Morin et al. recently studied the role of PKCζ in airway hyper responsiveness using an in 
vitro model of TNFα-treated human bronchi and an in vivo guinea pig model of chronic asthma. 
PKCζ-specific inhibition produced a significant increase in isoproterenol sensitivity in TNFα-
treated bronchi and OVA-sensitized guinea pig bronchi. An enhanced expression of PKCζ was 
ascertained in the in vivo model of allergic asthma and was delineated in TNFα-treated bronchi 
when compared with an untreated control, where there was an observed increase in bronchi Ca2+ 
sensitivity which was reversed upon treatment with the Myr-PKCζ-peptide inhibitor.33 PKCζ is 
also found to be largely involved in eosinophil migration in asthma, although its specific 
intracellular targets remain undefined.34 Additionally, some studies reported  PKCζ to mediate 
lung inflammation in response to cigarette smoking.35 Altogether, these data can validate PKCζ 
as therapeutic target in asthma and lung inflammation. 
However, the validity of using PPI to study PKCζ should be studied due to the possible 
reactivity with PKCι or other PKCs which also have essential roles in Th2 function. 
Nevertheless, the PPI results are consistent with the findings from PKCζ-knockout mice studies.  
Furthermore, the evidence that PKCζ is heavily expressed in lung extracts under resting 
conditions is consistent with this kinase’s putative role in other pulmonary diseases, including 
chronic obstructive pulmonary disease (COPD) and lung cancer.36 
1.2.1.5 PKCζ and Liver Inflammation  
T cell-mediated immune responses play important roles in the pathogenesis of a variety 
of human liver disorders including autoimmune liver disease, viral hepatitis, and alcoholic liver 
disease (37 and references there in). 
In T-cell-mediated hepatitis, T cells release IL-4 which targets NKT cells and 
hepatocytes leading to the production of IL-5 and eotaxin-1 respectively, both of which are 
important mediators in the control of eosinophil infiltration and liver injury in ConA-induced 
hepatitis, a well-established model to study T cell-mediated hepatitis (Figure 6). 
Based on its previously mentioned role in IL-4 signaling, PKCζ is also important player 
in T-cell-induced hepatitis, therefore in PKCζ-KO mice with ConA-induced hepatitis, synthesis 
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of IL-5 and eotaxin-1 was reduced with a consequent reduction in liver injury.28 Moreover, the 
loss of Par-4 (a  –ve regulator for PKCζ) in Par-4-KO mice injected with ConA exacerbates the 
appearance of liver necrosis.28 
 
Figure 6: Mechanism of liver injury activated by IL-4. IL-4 activates Jak1/Stat6 in hepatocytes to produce eotaxin, 
and triggers IL-5 production by natural killer T cells (NKT). Both mediators promote liver eosinophil recruitment 
and damage. (Copied from 36). 
1.2.2 PKCζ in Cancer 
PKCζ was reported to mediate several key steps in tumor progression including cell 
proliferation, survival, cell migration and angiogenesis. In cancer-specific cell models, PKCζ is 
required for EGF (epidermal growth factor)-induced migration of human breast and lung cancer 
cells.38,39 PKCζ is involved in the control of glioblastoma cell migration and invasion by 
regulating the cytoskeleton rearrangement, cell adhesion and matrix metalloprotease-9 
expression.40  
PKCζ was shown to be highly expressed in head and neck tumors. Inhibition of PKCζ 
was shown to reduce proliferation and viability of squamous cell carcinomas of the head and 
neck (SCCHN) as it reduced EGFR-mediated MAPK signaling and DNA synthesis. In addition, 
PKCζ inhibition was found to potentiate the action of other growth inhibitors in SCCHN.41 PKCζ 
may also have an important role in angiogenesis in renal cell carcinoma.42 A recent report 
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suggested a role for the nuclear PKCζ fraction in sustaining intracellular tumor pathways that 
allow cancer cells to become drug-resistant, which suggests that selective inhibition of nuclear 
PKCζ can restore the effectiveness of chemotherapeutic agents in chemo-resistant cancer cells.43 
Inhibition of  PKCζ activity in U937 human leukemic cells in vitro and in vivo (in nude 
mice) was found to sensitize tumor cells to chemotherapeutic  drug-induced cytotoxic activity.44 
Moreover, PKCζ was found to be highly expressed in follicular B cell lymphoma and other 
lymphoma cells compared to normal B cells. It was reported to be a target for the anticancer 
antibody rituximab in follicular B cell lymphoma.45 In addition, PKCζ may be a possible 
therapeutic target in Mantle cell lymphoma.46 
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1.3 Protein Kinases as Drug Targets 
Since protein phosphorylation controls a diverse range of cellular and pathogenic 
processes, even subtle changes in protein kinase activity can lead to a wide variety of diseases 
including cancer, inflammatory disorders, diabetes, neurodegeneration and central nervous 
system diseases. This pivotal role has made protein kinases an important and tractable 
therapeutic class for drug discovery.47  
Currently, there are 12 US Food and Drug Administration-approved protein kinase 
inhibitors for various cancer indications,48 whereas other therapeutic areas are yet strongly 
under-represented. One reason for this focus on cancer, although not the only one, is that many 
kinase inhibitors exhibit off-target effects because of poor selectivity. While multi-targeted 
agents (also called “group selective”) are often considered more efficient than selective inhibitors 
for oncology patients with possibly acceptable adverse effects,49, 50 an accumulation of side-
effects due to unwanted off-target inhibition must be avoided in non-life-threatening diseases. 
The major reason for the difficulty in optimizing the selectivity of kinase inhibitors is that they 
are mainly directed to the ATP-binding pocket, which is highly conserved in all 518 kinases of 
the human kinome.47   
These off-target side effects of protein kinase inhibitors have diverted efforts from 
targeting the ATP-binding pocket in order to produce inhibitors that have the potential to be 
more kinase specific. The specificity in targeting particular protein kinases may be achieved 
more readily by targeting more remote sites away from the highly conserved ATP binding 
pocket.47  
1.3.1 Classification of Kinase Inhibitors  
1) Type I inhibitors: bind to the highly conserved ATP binding pocket in the kinase’s active 
conformation.51 These compounds represent the vast majority of ATP-competitive 
inhibitors. It is also to be noted that these inhibitors must ultimately target the kinase with 
high affinity to compete with the high intracellular concentrations of ATP, however they 
sometimes do not discriminate between the ATP-binding sites conserved in protein kinases 
and other ATP-binding proteins.52 
2) Type II inhibitors: bind to an inactive conformation occurring in certain kinases thus 
prevent kinase activation. They use the ATP binding cleft and an adjacent hydrophobic 
pocket created by the activation loop which is accessible only when the Phe side-chain of 
the conserved DFG motif moves out of the hydrophobic pocket.  
3) Type III inhibitors: allosteric inhibitors which target allosteric or regulatory sites in the 
protein kinase. This class of inhibitors is more promising to achieve selectivity because 
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such inhibitors exploit binding sites and regulatory mechanisms that are unique to a 
particular kinase.5  It is worth mentioning that the typical allosteric effectors are those that 
regulate the catalytic activity by binding to a region distant from the active site. This, 
however, should not be confused with modulators that can partly bind to the active site like 
type II inhbitors.53 
1.3.1.1 Advantages of Allosteric Inhibitors 
1) Higher selectivity, even permitting targeting kinases which were not previously considered 
as druggable. 
2) Escape from the crowded patent space around ATP-binding site-directed inhibitors due to 
novel chemical entities targeting new binding sites. 
3) No increase in IC50s in cellular compared to cell-free assays (in general, for kinases with 
relatively high ATP-binding affinities (Km = 1–20 µM), it was proven to be difficult to 
develop ATP-competitive inhibitors with sufficient selectivity and cellular activity).54 
4) Allosteric inhibitors may cause sustained inactivation for the target kinase in cellular 
environment even after the washout of the inhibitor as some allosteric inhibitors can 
promote activation loop dephosphorylation.53 This finding is verified by our allosteric 
inhibitors as will be discussed later in this thesis. ATP competitive inhibitors can rather 
stabilize the active conformation by protecting the phosphorylated residues from 
phosphatase action, as exemplified by an ATP-competitive inhibitor of PKC,55 or in some 
cases increase phosphorylation of the target kinase as in the case of PKB/AKT. It was 
found that treatment of cells with active site inhibitors increased the steady state levels of 
phosphorylated AKT.56 Such undesirable effects can make ATP competitive inhibitors 
completely ineffective in vivo, since the target kinase would respond with an increased 
activity after wash-out of the inhibitor.53 
1.3.2 PIF Pocket as an Allosteric Site to Modulate AGC 
Kinases Activity 
1.3.2.1 Discovery and Physiological Function  
The PIF-binding pocket is a conserved regulatory element located on the small lobe of 
the kinase domain and is present in all of the members of the AGC kinase family. It was first 
described in phosphoinositide-dependent kinase-1 (PDK1)13 based on the similarity to the 
intramolecular docking site of the C-terminal peptide FSEFCOOH in protein kinase A (PKA),57 
where in all X-ray-structures of active PKA, the PIF pocket is occupied by this C-terminal 
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hydrophobic motif (HM) peptide. The HM peptide FSEF-COOH at the C-terminal end of PKA is 
the shortest HM sequence found. In several other AGC kinases, the motif is extended to Phe-
Xaa-Xaa-Phe-Ser/Thr-Tyr/Phe, in which the Ser/Thr is the phosphorylated residue.13 PDK1 was 
found to lack the HM peptide; its PIF pocket serves as a transient intermolecular docking site for 
the C-terminal HM motifs of other substrate AGC kinases which need activation loop 
phosphorylation by PDK1 to be fully active (Figure 7). This interaction of HM peptides from 
various substrate kinases with PDK1 PIF pocket is essential for its complete catalytic activity. 
13,58
 An exception to this is the PKB family, which are activated by PDK1 via a different 
mechanism depending on the PH domains of both PDK1 and PKB. Based on this finding, the 
PIF pocket was characterized as an allosteric site on PDK1 catalytic domain which transduces 
signals from interacting ligands to the active site. 
 
Figure 7:  Physiological role of the PIF pocket in PDK1. Recognition and phosphorylation of the substrate AGC 
kinases (except PKB) depend on a transient intermolecular docking interaction involving the HM of substrate AGC 
kinase and PIF pocket of PDK1.(Adapted from 53). 
The HM peptide derived from the PKC-related protein kinase 2 (PRK2) , the PRK2-
Interacting Fragment peptide  “PIFtide”, was found to have the strongest affinity and activating 
potency on PDK1, hence the name of the receptor site – the PIF pocket- on PDK1.59  
In most HM peptides, there is a serine or threonine residue C-terminal to the FXXF motif 
which is phosphorylated by another kinase (mostly mTORC2). This HM phosphorylation turns 
the inactive AGC kinase into a PDK1 substrate as the negatively charged phosphate exhibits an 
essential docking interaction with the PIF pocket. 59 However, in some AGC kinases like PKCζ, ι 
and PRK, an aspartate or glutamate residue is found instead of the phospho Ser/Thr residue 
which is able to mimic its interaction with the PIF pocket, thus abolishing the need for a 
“priming” kinase for the HM motif phosphorylation. The binding of HM and the HM-phosphate 
to the PIF pocket acts in concert to stabilize the active structure of the kinase.60, 61 
+
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After binding to PDK1, the substrate kinase is phosphorylated by PDK1 at the activation 
loop which triggers the release of the substrate kinase, causing the free the HM peptide to fold 
back and bind intramolecularly to its own PIF pocket. This interaction is probably enforced 
because the prior T-loop phosphorylation promotes the formation of a functioning PIF pocket 
through the stabilization of the αC-helix, as will be mentioned later. Thus, the active enzyme 
conformation is fully stabilized and ready to phosphorylate downstream substrates  dependent on 
further regulatory mechanisms (Figure 7).59  
1.3.2.2 Molecular Interactions of the Natural HM Peptide Ligands 
There are two major forces which drive the affinity of the natural ligand HM peptides 
towards the PIF pocket: hydrophobic and Van der Waals interactions by the two phenyl rings 
from the FXXF motif, and ionic and hydrogen-bond interactions mediated by a negatively 
charged residue C-terminal to the FXXF motif and by the peptide backbone respectively.53 The 
intramolecular interactions by the HM peptide with the PIF pocket of PKC βII is shown in 
Figure 8.  
 
Figure 8: The intramolecular binding of HM peptide to the PIF pocket in PKCβII (PDB 2I0E). The hydrophobic 
motif FEGFSF in PKCβII is comprised of residues 656-661, shown in golden yellow. The hydrophobic motif is 
phosphorylated at Ser660. The three aromatic side chains of the hydrophobic motif, Phe656, Phe659, and Phe661, 
form lipophilic interactions with helices αB and αC, and strands β4 and β5, shown in purple (the framing elements 
of the PIF pocket). Several hydrogen bonds are anchoring the hydrophobic motif to helix αC and strand β4. For 
example, the backbone carbonyl of Phe659 is hydrogen bonded to the side chain of Lys391 of helix αC, while the 
phosphate of Ser660 is hydrogen bonded to the conserved Gln411 on strand β4 (from the crystal structure of PKCβII 
bound to a competitive inhibitor of ATP).62 The Figure is copied from 6. 
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1.3.2.3 Allosteric Mechanism by the PIF Pocket  
The PIF pocket is considered as an allosteric site that can modulate the kinase catalytic 
activity. It has been previously shown that the binding of the PIF pocket ligand activators in 
PDK1 produces local changes at the PIF binding pocket, as well as allosteric changes at the ATP 
binding site and the activation loop.63 Furthermore, the activity states of PIF pocket and ATP-
binding site are intimately coupled as has been shown by the co-crystal structure of the type II 
inhibitor MP7 with PDK1 (PDB ID: 3NAX).64 As a result of this conformational linkage, the 
allosteric interaction between the two sites is mutual. So, it can be reasoned that compounds 
stabilizing such non active PIF pocket shapes will also induce catalytically inactive 
conformations in the ATP-binding site of PDK1.53  
1.3.2.3.1 Role of the αC-helix in Allosteric Control through the PIF Pocket  
The crystal structure of PDK1 revealed the PIF pocket as a shallow, 5Å deep surface 
pocket with a hydrophobic center and polar surrounding residues. The most important secondary 
elements framing the PIF pocket are the β-sheets 4 and 5, a short αB-helix and the αC-helix (the 
same elements are shown for PKCβII PIF pocket in Figure 8).60   
The αC-helix plays the most crucial role in allosteric regulation of AGC kinase activity as 
it provides a structural link between the PIF pocket and the phosphorylated T-loop Ser/Thr 
residue.61,65 The binding of the HM peptide to the PIF pocket induces a disordered-to-ordered 
transition of the αC-helix, which promotes the interaction of a basic αC-helix residue with the 
activation loop phosphate in some AGC kinases for example Arg129 in PDK1, as shown in 
Figure 9-A. Vice versa, T-loop phosphorylation favors the formation and stabilization of an 
intact αC-helix and hence the formation of the PIF pocket, which has been demonstrated in the 
case of PKB.65 In this way, both formation of the αC-helix and T-loop phosphorylation mutually 
stabilize the kinase in its active state, mediated by electrostatic interaction of the two elements.  
However in the crystal structure of some AGC kinases like PKCβII (PDB 2I0E), this 
direct interaction between the activation loop phosphate and the αC helix basic residue is 
missing. Instead, the activation loop phosphate on Thr500 (PKCβII numbering) forms an ion pair 
with Arg465 of the catalytic loop and Lys489 of the activation loop. This correctly orients 
Glu490 of the activation loop for hydrogen bonding to Arg392 of the αC-helix. In turn, this 
rearrangement orients the αC-helix in an optimum position to aid the catalysis (Figure 9-B) .62   
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Figure 9: Interactions mediated by the αC-helix. (A) The PIF pocket and its link to the kinase’s active site: the figure 
shows the allosteric activator PS48 bound to PIF pocket of PDK1. There are two important interactions mediated by 
PIF pocket through the αC-helix to affect the structural elements that regulate kinase activity. The first interaction is 
made by Arg129 from the αC-helix with activation loop phosphate, while the second one is through Glu130 with 
Lys111, which directly interacts with ATP phosphates.  Both interactions are promoted by binding of  the natural 
HM peptide or ligand activators to the  PIF pocket.63 (B) From the crystal structure of PKCβII bound to a 
competitive inhibitor of ATP: intramolecular docking of HM peptide to PIF pocket is shown, where the activation 
loop phosphate is not in direct interaction with the αC-helix.  However, Glu490 from the activation loop interacts 
with  Arg392 from the αC-helix.62 
Additionally, the αC-helix can form a highly conserved salt bridge between a glutamate 
residue from the αC-helix (Glu130 in PDK1) and a lysine residue (Lys111 in PDK1) in the 
active site (also shown in Figure 9-A).60,63 This Lys can directly interact with and correctly 
positions the phosphates from ATP for catalysis. Based on its crucial role, disturbance of the αC-
helix is inevitably accompanied by inhibition of the kinase catalytic activity. Considerably, 
inactive structures of the AGC kinases PKB/AKT,65,66 MSK1,67 and RSK268 exhibit a completely 
disturbed PIF pocket; two of its lining walls, the conserved αC- and αB-helices, are either 
disordered or replaced by an unusual β-sheet. Thus, changes in the HM/PIF pocket are 
accompanied by inactive conformations of key residues in the ATP-binding pocket and of the T-
loop.53 Some of the putative effects expected from PIF pocket-directed allosteric inhibitors are 
shown in Figure 10. 
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Figure 10: Proposed mechanism of action of allosteric inhibitors binding to the PIF pocket of AGC kinases e.g. 
PKCζ. Intramolecular binding of the HM peptide to the PIF pocket stabilizes the kinase active conformation. The 
allosteric inhibitor binds to the PIF pocket leading to displacement of the HM peptide. Allosteric inhibitors can 
promote dephosphorylation at the activation loop and thus sustained inactivation of PKC. In addition, displaced 
peptide extension might be recognized as a misfolded element by ubiquitin ligases, promoting increased degradation 
by the proteasome. (Adapted from 53). 
1.3.2.4 Targeting the PIF Pocket with Small Molecule Ligands to 
Inhibit the Activity of AGC Kinases 
Being an allosteric site which can regulate the kinase activity, the PIF-binding pocket 
may offer a great advantage over the ATP pocket as a drug target, where the PIF-binding pocket 
shows a lower degree of sequence conservation in comparison to the highly conserved ATP-
binding site. In particular, the amino acids surrounding the hydrophobic groove, being within 
reach of small molecules, are only moderately conserved thus offering the possibility to develop 
more selective compounds compared to the possibility using ATP-competitive strategies. 
Targeting the PIF pocket could be an option even in case of closely related kinase isoforms such 
as the PKC family, which was considered not druggable by the currently available design 
strategies targeting the ATP binding pocket since no isoform-selective kinase inhibitors have 
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been obtained so far. It is important to note that a sequence alignment of the PKC isoforms 
reveals a much lower degree of conservation in the regulatory PIF pocket. This difference can 
even be shown in case of the most closely related aPKC isoforms ζ and ι, which enabled us to 
develop potent and highly selective isoform inhibitors towards PKCζ, as will be presented later 
in this thesis. 
Through continuous research work, the PIF pocket was shown to transduce activation or 
inhibition by small molecule modulators. The first efforts to develop PIF pocket ligands were 
directed to PDK1 PIF pocket, yielding the discovery and development of compounds that are 
PDK1 activators and protein-protein interaction inhbitors.58,63,69,70 These ligands prevent the 
docking of the HM peptide to the PIF pocket of PDK1, thus inhibiting the phosphorylation and 
activation of all substrate AGC kinases except PKB/AKT. On the other hand, targeting the PIF 
pocket by small molecule inhibitors was only successful towards the atypical PKCζ,71, 72 the 
target of interest in this thesis.  
1.3.2.4.1 Discovery of First Allosteric PKCζ Inhibitors 
The development of the first allosteric PKCζ inhibitors started when two 3-phenylglutaric 
acid monoanilides, which are weak inhibitors of the atypical PKCζ, were discovered during 
routine screening of hits previously identified as weak PDK1 activators against a panel of related 
AGC kinases (compounds A and B, Figure 11).72 Potency optimization was achieved via 
bioisosteric replacement of the amide function involving cyclization to the benzimidazole 
analogs to yield 4-benzimidazolyl-3-phenylbutanoic acid analogues. The new scaffold showed 
increased potency as inhibitors of full-length PKCζ, highlighting that these more drug-like aryl 
moieties such as benzoheterocycles can be tolerated by subregions of the mostly hydrophobic 
PIF pocket.  
Several 4-benzimidazolyl-3-phenylbutanoic acid analogues were synthesized and tested 
for their inhibitory activity against full-length PKCζ. The results showed that the benzimidazole 
ring can have large substituents such as 5-iodine and 5-phenyl with increase in potency, thus 
demonstrating the high structural plasticity of the PIF pocket (cf. compounds 1q and 1y in Figure 
11). Furthermore, a potential halogen bond of the iodine in the 5-iodobenzimidazole derivatives 
(as in 1q) was indicated by the SARs. This halogen bond is probably engaging the 5-iodo 
substituent with the backbone carbonyls and/or the His289 imino nitrogen. Thus, 1q was 
identified to be the most potent compound of the series, shown in Figure 11 (IC50 of the racemate 
= 18 µM). 
The enhancing effect of halogen substitutions at the aryl rings was coherent with SARs 
observed with PDK1 activators69, 73 and in agreement with our results for the triarylpyrazolines 
which will be shown later in this thesis. In addition, the PIF pocket in PKCζ can tolerate even 
longer alkyl chains at the phenyl ring (cf. compound 1x in Figure 11). 
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Figure 11: Allosteric inhibitors targeting the PIF pocket of PKCζ. 
    Targeting the PIF pocket was confirmed by several lines of experimental evidence:  
(i) Several compounds of the series which are active PKCζ inhibitors (e.g. 1x and 1y) 
were able to show moderate activation of PDK1 by about 3 fold at 50 µM. 
(ii) Binding of 1n (PS171 in 71) to the PDK1-PIF pocket was confirmed by co-
crystallography (PDB ID: 4A07). 71 
(iii) When compounds 1n and 1y (PS168 in 71) were tested against PKCζ mutated at 
residues central to the PIF pocket (PKCζ-Val297Leu and PKCζ-Leu328Phe), they 
totally lost their inhibitory potency.71  
Selectivity testing showed that, unlike the more potent compound 1q, compounds 1x, 1n 
and 1y were highly selective inhibitors of PKCζ, without affecting PKCι (the most closely 
related isoform). Further testing with PKCζ mutants suggested that the natural replacement of 
Phe321 in PKCι by Leu328 in PKCζ was responsible for the PKCζ specificity of 1n (PS171) and 
1y (PS168).71  Luciferase reporter gene assay, which monitors the PKCζ-mediated coactivation 
of NF-ĸB in U937 cells, confirmed the cellular inhibitory activity toward PKCζ since many 4-
benzimidazolyl-3-phenylbutanoic acid analogs efficiently suppressed the activity of NF-ĸB after 
induction by TNF-α.   
  
PKCζ % inhibition
at 200 µM 98%74%
PKCζ inhibition
IC50 (µM) 18 33 38 25
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Two important observations were made:  
(i) There was a close correlation between the cell-free and cellular inhibition potencies, 
indicating that PKCζ was targeted in both cases.  
(ii) No loss of potency occurred in the cell compared with that of the cell-free assay.72 
Beside the greater selectivity, another advantage over ATP-competitive compounds is 
being unaffected by the high intracellular ATP concentration that can cause up to a 
100-fold increase of IC50s in case of ATP-competitive compounds.74 
Another important result of this study was the fact that the same compounds that caused 
activation of PDK1 by binding to the PIF pocket triggered inhibition of another AGC kinase.  
1.3.2.4.2 Other Reported Inhibitors for PKCζ   
A limited number of compounds were reported as PKCζ inhibitors, all of which have 
limited selectivity in particular towards the most closely related isoform, PKCι, for instance, 
hydroxyphenyl-1-benzopyran-4-ones, represented by compounds 1, 2 and 3 in ref 75. A second 
example is PKCzI257.3 (N-(4-((dimethylamino)methyl)benzyl)-1H-pyrrole-2-carboxamide) with 
an IC50 of 28 µM against PKCζ.76 In addition, the 2-(6-phenylindazolyl)-benzimidazole 
derivative (compound 9 in ref.77) was reported by Trujillo et al. as a potent PKCζ inhibitor with 
an IC50 of 5.2 nM. It also showed good selectivity versus other PKC isoforms but with less than 
10-fold selectivity towards PKCι. Moreover, several kinases from less related families were 
significantly inhibited.77  
Another inhibitor is CRT0066854, a thieno[2,3-d]pyrimidine-based chemical inhibitor of 
aPKCs. The compound is about 4-fold more potent against PKCι than PKCζ, where the 
measured IC50 values for full-length PKCζ and PKCι were 639 nM and 132 nM respectively. 
The compound showed significant cross reactivity with PRK2 and CDK5.78 Another recent  
report describeed a series of 2-amino-3-carboxy-4-phenylthiophenes as non-competitive  aPKCs 
inhibitors, where the most potent compound showed an IC50 of 0.8 and 0.9 µM  vs. PKCζ and 
PKCι respectively (compound 30 in ref79 ). Although the compounds lacked aPKC isoform 
selectivity and showed moderate activity in the cell free assay, the compounds showed high 
activity in cellular  assays approaching a single digit nM range which suggests the need for 
further biological testing to exclude off-target interactions.79,80 All the structures of the 
aforementioned inhibitors are shown in Figure 12.  
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Figure 12 : Other PKCζ inhibitors. Compounds 1-3 are the hydroxyphenyl-1-benzopyran-4-ones in ref75. Compound 
9 is a 2-(6-phenylindazolyl)-benzimidazole derivative (ref.77). Compound 30 is a 2-amino-3-carboxy-4-
phenylthiophene derivative, the most potent compound in ref.79. 
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1.4 Exploration of the Pyrazoline Scaffold in Other 
Protein-Protein Interaction Targets as Exemplified by 
the p53-Mdm2 Interaction 
1.4.1 The Tumor Suppressor p53 
The tumor suppressor p53, known as “the guardian of the genome”, is a transcription 
factor that plays a crucial role in the regulation of DNA repair, cell cycle and apoptosis.81-83 Its 
activity is important to the health and survival of tissues, as it suppresses the growth of defective 
cells such as tumor cells and prevents damaged cells from multiplying and passing their mutated 
genes to the next generation. Accordingly, p53 is found to be functionally inactivated by 
mutation or deletion in about 50% of human cancers.84 The murine double minute 2 (Mdm2; 
Hdm2 in humans) oncoprotein is a cellular inhibitor of p53 that can bind the trans-activation 
domain of p53 and down regulate its ability to activate transcription.  
Mdm2 inhibits the activity of p53 through several ways; it prevents p53 from interaction 
with other proteins, exports p53 out of the nucleus away from nuclear DNA, and promotes p53 
proteasomal degradation through its E3 ubiquitin ligase activity.85, 86 
In cancers with wild type p53, its function was found to be effectively inhibited by Mdm2. 
The imbalance of the Mdm2/p53 activities can lead to malignant transformation of normal cells, 
where over-expression of Mdm2 promotes cells  growth and tumorigenesis.87 Mdm2 was found 
to be  amplified in 7% of human cancers when 28 different types of human cancers in nearly 
4,000 human tumor samples were analyzed.88  
1.4.2 p53-Mdm2 Interactions  
The high-resolution crystal structures of human Mdm2 complexed with the 
transactivation domain of p53, residues 15–29 (PDB code 1YCR),89 showed that the p53-Mdm2 
interaction is mediated by a well-defined hydrophobic surface pocket in Mdm2 and three key 
hydrophobic residues in p53, namely Phe19, Trp23, and Leu26 (Figure 13). All the three amino 
acids undergo multiple van der Waals contacts with the surrounding Mdm2 receptor amino acids, 
while Trp23 forms an additional hydrogen-bond with the backbone carbonyl of Leu54 in Mdm2. 
These three amino acid residues can be imagined to act as three fingers which insert themselves 
into three complementary pockets on the Mdm2 surface. The relative  compactness  of Mdm2 
binding pocket made it appear possible to design non-peptide, drug-like small-molecule 
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inhibitors to prevent this interaction and act as a tool to reactivate p53 in cells with wild type 
p53.90 
 
Figure 13: The p53–Mdm2 interaction.  (A) The hotspot triad made up of Leu26, Trp23 and Phe19 in P53, these 
three amino acid residues are acting as three fingers which insert into three complementary pockets on the Mdm2 
surface (copied from 91). (B) p53 (blue) bound to Mdm2, p53’s hot spots (Leu26, Trp23 and Phe19) can be seen as 
sticks buried deep in the Mdm2 pocket. The hydrogen-bond formed between Trp23 and Mdm2’s backbone carbonyl 
of Leu54 can be seen as an orange dashed line. (Copied from 90). 
1.4.3 Some Small Molecule Non-peptide Inhibitors of p53-
Mdm2 Interaction 
Owing to the critical inhibitory function of Mdm2 on p53, blocking the interaction 
between Mdm2 and p53 has been anticipated to be a potential cancer therapeutic approach. It 
was proposed that by mimicking the three key hydrophobic residues in p53, non-peptide small-
molecule inhibitors can achieve high affinities to Mdm2 and displace p53 from its complex with 
Mdm2. 
Nutlins are among the first potent and specific Mdm2 inhibitors. They were discovered 
by Vassilev and co-workers at Hoffman-La Roche.92 Nutlins were discovered by high-
throughput screening of a diverse library of synthetic compounds. They have a cis-imidazoline 
core structure; both nutlin-1 and nutlin-2 were tested as racemate while nutlin-3a is an active 
enantiomer (Figure 15). Nutlins 1, 2 and 3a are able to disrupt the p53-Mdm2 interaction with 
IC50 values of 0.26, 0.14 and 0.09 µM, respectively. 
The crystal structure of Mdm2 complexed with nutlin-2 (PDB code: 1RV1) shows that 
nutlin-2 is able to mimic the interactions of the p53 peptide (Figure 14). In nutlin-2, one of the 
bromophenyl groups interacts with the Trp23 pocket, the other interacts with the Leu26 pocket, 
and the ethoxy side chain targets the Phe19 pocket. The backbone of the imidazoline scaffold 
HN
Phe19
Leu26
Trp23
p53 ProteinA B
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mimics the α-helix of p53. It is to be noted that, nutlin-2 does not make a H-bond similar to the 
one between Trp23 indole NH in p53 and the backbone carbonyl group of Leu54 in Mdm2. 
 
Figure 14:  Interactions of Nutlin-2 with Mdm2. (A) The three lipophilic parts in nutlin-2 which mimic the hotspot 
triad of p53 are highlighted in red. (B) The overlay of nutlin-2 (PDB code: 1RV1) and p53 trans-activation domain 
peptide (PDB code: 1YCR) on the Mdm2 surface. Nutlin-2 and p53 peptide are colored in magenta and yellow 
respectively.(Copied from 93) 
Grasberger et al. discovered benzodiazepinedione-based Mdm2 inhibitors using high 
throughput screening of combinatorial libraries.94 The benzodiazepinedione compound 1 (in 
reference 94) showed  a Ki of 80 nM in the fluorescent peptide displacement (FP) assay (structure 
is shown in Figure 15).  Extensive modifications have been made on spirooxindoles by Ding et 
al. employing a structure-based de novo design strategy.95, 96 MI-147 was reported as one of the 
most potent of this class of compounds, with a Ki of 0.6 nM in an FP-based competitive binding 
assay.97 All the structures are shown in Figure 15. 
 
Nutlin 2
A B
Introduction 
29 
 
 
 
Figure 15: Small molecule inhibitors of p53-Mdm2 interaction. 
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2 Scientific goal  
The aPKCζ was reported to play an important role in NF-ĸB signaling, B cell 
development and Th2 cell differentiation. In addition, PKCζ was found to be abundantly 
expressed in lung and liver tissues. These findings suggested that PKCζ is a possible target in the 
treatment of bronchial asthma, liver inflammation and autoimmune diseases. Moreover, several 
reports suggested PKCζ inhibition as a strategy to suppress some types of cancers like B cell 
lymphoma.   
However, no potent isoform selective inhibitors for PKCζ vs. its closely related isoform 
PKCɩ have been discovered to date. In our study, we aimed at developing a selective class of 
PKCζ inhibitors that can offer a pharmacological tool for further cellular and disease model 
studies to validate PKCζ as a possible therapeutic target. Selective inhibitors are also required to 
address the possible adverse effects resulting from PKCζ inhibition especially on glucose uptake 
following to insulin action. 
The use of ATP-competitive type I inhibitors is a less promising approach due to the 
highly conserved sequence of the ATP binding pocket in PKC family and generally in all protein 
kinases. To overcome this, we directed our efforts to the PIF pocket which was previously 
reported as an allosteric site to modulate kinase activity in AGC kinases. In normal physiological 
conditions, the PIF pocket is bound to the C-terminal HM peptide contributing to the 
stabilization of the kinase in its fully active conformation. Therefore, disrupting this protein–
protein interaction by small molecule non-peptide inhibitors was the major aim behind our 
efforts to achieve the required inhibition.  
We decided to start the modifications based on the previously reported 4-benzimidazolyl-
3-phenylbutanoic acids, PIF pocket directed allosteric PKCζ inhibitors to finally reach more 
potent and selective inhibitors having pyrazoline scaffold as will be illustrated in chapter 3.1.  
Furthermore, we aimed at testing the pyrazoline scaffold as a possible inhibitor for the 
p53-Mdm2 interaction as another type of protein-protein interaction since p53 binding pocket on 
Mdm2/Hdm2 partially resembles the PIF pocket regarding shape and physicochemical 
properties. The displacement of the p53 from its binding to Mdm2 using small molecule non-
peptide inhibitors is a proven strategy to induce apoptosis in cancer cells with wild type p53.  
The pyrazoline scaffold is a rigid scaffold with favorable synthetic tractability. 
Consequently, it seemed reasonable that we introduce it into such type of protein-protein 
interaction pockets which need a highly modifiable synthetic scaffold to reach the desired 
activity and selectivity, since many “hot spots” in protein-protein interaction sites are 
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characterized by a hydrophobic groove. We proposed that the pyrazoline core can mimic the α-
helix of p53’s trans-activation domain and can furnish versatile 1-, 3- and 5- lipophilic 
substituents to mimic the hot spot triad of p53 (Leu26, Trp23 and Phe19) which interact with 
Mdm2. This proposal was supported by structural overlay of the planned tri- and tetra-substituted 
pyrazolines (energy minimized form) with the closely similar, previously reported cis-imidzoline 
inhibitor, nutlin-2, as appearing in its crystal structure with Mdm2 (as will be shown in chapter 
3.2).   
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3 Results 
3.1 Discovery and Optimization of 1,3,5-trisubstituted 
Pyrazolines as Potent and Highly Selective Allosteric 
Inhibitors of PKCζ 
A major part of this chapter is submitted to the Journal of Medicinal Chemistry  
ABSTRACT 
There is increasing evidence that the atypical protein kinase C (PKC) ζ might be a 
therapeutic target in pulmonary and hepatic inflammatory diseases. However, targeting the 
highly conserved ATP-binding pocket in the catalytic domain held little promise to achieve 
selective inhibition. In the present study, we introduce 1,3,5-trisubstituted pyrazolines as potent 
and selective allosteric PKCζ inhibitors. The rigid scaffold offered many sites for modification, 
all acting as hot spots for improving activity and displaying sharp structure-activity relationships. 
Targeting of PKCζ in cells was confirmed by reporter gene and transfection assays. The strongly 
reduced cell-free and cellular activities towards a PIF-pocket mutant of PKCζ suggested that the 
inhibitors most likely bound to the PIF-pocket on the kinase catalytic domain. Thus, using a 
rigidification strategy and by establishing and optimizing multiple molecular interactions with 
the binding site, we were able to significantly improve the potency of the previously reported 
PKCζ inhibitors. 
INTRODUCTION 
The Protein kinase C (PKC) family comprises the classical (cPKCα, βI, βII, and γ), novel 
(nPKCδ, ε, η, and θ), and atypical (aPKCζ and λ/ι) isoenzymes, based on their biochemical 
requirements for activation. Only cPKCs respond to calcium, whereas both cPKCs and nPKCs 
are sensitive to phorbol esters and the lipid second messenger diacylglycerol (DAG). Finally, 
PKCζ and PKCι (termed λ in the mouse) were named atypical because they do not respond to the 
above agents but might be activated by some lipids, such as phosphatidylinositols and ceramide 
(reviewed in 1). In addition, aPKC activity is regulated by protein interaction partners that also 
provide the required temporal and spatial specificity, including the inhibitory protein Par-4 and 
the adapter protein p62.2, 3 
Both atypical PKCs share a high degree of identity (84%) in the catalytic domain, and are 
less conserved in the N-terminal regulatory PB1 and C1 domains (53% identical). Although both 
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enzymes are similarly regulated and activated, not all of their biological functions are redundant 
(see3 for a recent review). PKCζ knockout mice appeared grossly normal; only the formation and 
maturation of secondary lymphoid organs was altered during the first weeks after birth, however, 
most of these defects were overcome in adult animals.4 These findings suggested that targeting 
PKCζ with specific inhibitors might not cause harmful toxic effects. On the other hand, knockout 
of the PKCι gene was lethal in early embryonic development.5 With respect to the PKCζ 
biological function, knockout studies revealed that PKCζ was essential for the development and 
differentiation of B cells and Th2 cells.6 As a consequence, PKCζ-deficient mice developed only 
a mild form of concanavalin A-induced hepatitis,7 with a dramatic decrease in leukocyte 
infiltration and liver apoptosis.8 Since Th2 responses critically mediate humoral immunity 
against extracellular pathogens and in allergic reactions, OVA-induced allergic airway 
inflammation was also strongly reduced in PKCζ-deficient mice.6 
On the molecular level, PKCζ mediates B cell proliferation and survival by activation of 
the extracellular signal-regulated kinase (ERK) pathway.9-11 Even more importantly, after B cell 
receptor stimulation, PKCζ induces the transcription of IκB and other NF-κB-dependent genes, 
such as IL-6 or Bcl-XL.4, 11 The activation of the transcriptional activity of NF-κB is one of the 
key functions of PKCζ in autoimmune and chronic inflammatory diseases because it can lead to 
exacerbated lymphocyte activities.12 PKCζ phosphorylates Ser311 on the RelA subunit of NF-
κB,13 which has been shown to be required for full NF-κB transcriptional activity in vivo and in 
cell culture experiments.4 Numerous transfection experiments using kinase-defective dominant-
negative mutants, overexpression studies and anti-sense experiments further supported a role for 
the PKCζ in the control of NF-κB activation.14-19 Another important consequence of the Ser311 
phosphorylation by PKCζ was demonstrated by Levy et al.: it triggered displacement of the 
histone methyltransferase GLP from RelA, which abrogated the GLP-mediated methylation of 
histone H3, thus finally enabling NF-κB to become transcriptionally active.20 In addition, a rather 
cell type specific function as an IKK kinase was demonstrated for PKCζ in the lung, exerting 
additional control on the NF-κB activation in these tissues, but not in fibroblasts or T cells.4,6,8,13  
In the lung tissue where the kinase is abundantly expressed, PKCζ was required for both 
IKK and NF-κB activation in response to TNFα, IL-1b, or LPS.4 Contrastingly, in naïve T cells, 
PKCζ was not involved in NF-κB activation but was rather found to be essential for the efficient 
activation of Jak1 and the subsequent phosphorylation and nuclear translocation of Stat6.6  As a 
consequence, PKCζ-deficient naïve CD4+ T cells were not able to differentiate into Th2 cells 
and secreted low levels of the Th2-related cytokines, IL-4, IL-5, IL-10, and IL-13.6 Similarly, 
PKCζ interacted with and phosphorylated Jak1 in the mouse liver and in IL-4-stimulated 
fibroblasts, and PKCζ activity was required for Stat6 activation.8 Altogether, these studies 
established a central role of PKCζ in the IL-4/Stat6 pathway. 
The identified function of PKCζ in the IL-4 signaling might also be relevant in the T-cell-
mediated fulminant hepatitis, which had been discovered using the concanavalin A (ConA) 
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model.21 In this model, PKCζ-deficient mice showed impaired NF-κB activation in the liver, 
which should have resulted in impaired survival. Nevertheless, the mice showed reduced damage 
to the liver and a healthier state than their wild type littermates.8 It was found that some major 
effects brought about by the loss of PKCζ was the reduced induction of serum IL-5 and liver 
eotaxin which are two important mediators of liver damage.8 
Besides its direct implication in the control of transcription factors such as NF-κB and 
Stat6, PKCζ was recently reported to be involved in the regulation of gene expression at the 
epigenetic level as well; it was found to physically interact with and phosphorylate DNA 
methyltransferase 1, resulting in a reduced activity of this enzyme.22 In agreement with this 
observation, down-regulation of PKCζ signalling was identified as a potential mechanism by 
which very low density lipoproteins might silence pro-inflammatory genes in macrophage-like 
THP-1 cells, an effect which is known to be mediated by de novo DNA methylation.23 
The other atypical PKC, PKCι, was demonstrated to act as an oncogene in lung cancer, 
colon carcinoma and other types of solid tumors (reviewed in24). In a recent study, specific 
inhibition of PKCι in the liver led to normalization of glucose and triglyceride levels in vivo,25 
thus potentially expanding the scope for selective PKCι inhibitors to the metabolic syndrome and 
to insulin-resistant states of obesity. 
As a potential adverse side effect of PKCζ inhibitors, impairment of the insulin-
dependent glucose uptake might be considered, because PKCζ was also demonstrated to play an 
important role in the phosphorylation and activation of the glucose transporter GLUT-4.26, 27 
However, all of these findings were derived from experiments in rats or mice, whereas in 
humans, PKCι and not -ζ appears to be the major aPKC expressed in skeletal muscle.28 Thus, 
PKCζ–selective inhibitors might not suppress glucose uptake in human muscle tissue. 
Alternatively, tissue–specific drug delivery might be a viable approach to reduce potential side 
effects. 
In summary, an increasing body of evidence suggests that PKCζ might be suited as a 
pharmacological target in allergic asthma of the lung and in liver inflammation. Up to now, drug 
development efforts towards this target were rather limited. Given the high similarity of the ten 
PKC isoforms in their ATP-binding sites, traditional approaches using ATP-competitive 
inhibitor strategies did not appear very promising because of the difficulty of obtaining selective 
inhibitors.29  Hence, only a few small molecule compounds were reported as PKCζ inhibitors, but 
all with limited selectivity in particular against the most closely related isoform, PKCι, including 
hydroxyphenyl-1-benzopyran-4-ones30 and PKCzI257.3 (N-(4-((dimethylamino)methyl)benzyl)-
1H-pyrrole-2-carboxamide).31 A 2-(6-phenylindazolyl)-benzimidazole derivative was reported as 
a potent PKCζ inhibitor which was less active toward PKCι, however, several kinases from less 
related families were significantly inhibited.32 Most recently, CRT0066854, a thieno[2,3-
d]pyrimidine-based chemical inhibitor of aPKCs was reported. However, the compound was 
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about four-fold more potent against PKCι than PKCζ. In addition, it showed significant cross 
reactivity with   PRK2 and CDK5.33 Titchenell et al. reported a series of non-ATP competitive 
aPKC inhibitors with an unidentified binding site, exhibiting IC50s in the low µM range.34, 35 
While these 2-amino-3-carboxy-4-phenylthiophenes showed remarkable selectivity against other 
PKC families, they inhibited both aPKCι and -ζ with equal potency. However, it remains to be 
shown whether the more than three orders of magnitude higher activity of the compound series 
in cell-based vs. cell-free assays is due to inhibition of intracellular aPKCs or other 
mechanisms.35 
Inhibitors with a true allosteric mode of action are generally believed to be more 
selective, because they are targeting less conserved, often subtype-specific regulatory sites. 
However, they often display only moderate affinities.36 Recently, the first allosteric inhibitors of 
a PKC isoenzyme which bind to the so-called PIF-pocket (also named the hydrophobic motif 
(HM) pocket) of PKCζ were reported.37 These 4-benzimidazolyl-3-phenylbutanoic acids 
exhibited a remarkable selectivity even against the most closely related isoform, PKCι, however 
the potency (IC50 = 18 µM for compound A, Figure 1) required optimization. Of note, the first 
efforts to develop PIF pocket ligands were directed to PDK1 PIF pocket, yielding the discovery 
and development of compounds that are PDK1 activators and protein-protein interaction 
inhbitors.38-42 
In the present study, we describe the design, synthesis and optimization of tri- and tetra-
substituted pyrazoline derivatives as novel allosteric inhibitors of PKCζ. Several compounds 
potently inhibited the purified, recombinant enzyme and blocked PKCζ-dependent signalling in 
U937 cells. Furthermore, we demonstrate that the pyrazoline core is a versatile scaffold which 
allows independent fine-tuning of all substituents to optimize potency, physicochemical 
properties and stability. 
RESULTS AND DISCUSSION 
CHEMISTRY 
Design concept. The previously published allosteric inhibitors of PKCζ contained three 
flexible bonds connecting the essential aromatic rings (Figure 1), which were thought to bind to 
the two hydrophobic grooves of the PIF-pocket.37 Therefore, rigidification of the molecule 
offered great potential to enhance the binding affinity. Since the presence of a carboxyl function 
was another potential shortcoming with respect to cell permeability, we also envisaged its 
replacement by a H-bond acceptor function, which would potentially interact with Lys301 of  
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Figure 1. Structures of the previously published allosteric inhibitors of PKCζ. (The original codes in ref.37 were A, 
1q; B, 1a; C, 1n). 
PKCζ instead of the carboxylate. Interestingly, some of the published allosteric PKCζ inhibitors 
(e.g. those depicted in Figure 1, B and C) were found to be allosteric activators of PDK1 as well, 
suggesting that the shapes of the PIF-pockets in active PDK1 and inactive PKCζ may share some 
similarities. Moreover, since the binding modes of B and C in the PIF-pocket of PDK1 were 
elucidated after cocrystallography (superimposed in Figure 2A, PDB codes 4A06 and 4A07, 
respectively), we reasoned that the bound conformations of the small molecules could serve as 
templates for the design of rigidified analogues. Thus our preferred strategy was to fix the 
relative positions of the two aromatic moieties of B and C as observed in the cocrystal with 
PDK1. Such a conformation was compatible as well with binding to the PIF-pocket of the active 
PKCι catalytic domain (PDB code: 3A8X), which displayed a very similar shape. 
 
Figure 2 (A) Superimposed binding modes of B (orange) and C (cyan) (cf. Figure 1) in the PIF-pocket of PDK1 
(PDB codes 4A06 and 4A07, respectively). For compound C, ionic interactions with two PIF-pocket residues were 
identified (distances are given in angstrom), whereas the carboxyl side chain of B was not resolved. The 
conformation of the less substituted compound B was used as a template for ligand design.  
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The defined requirements were met by utilizing pyrazoline ring as a central core 
furnished with two aromatic rings in the 1- and 5-positions (see superimposition in Figure 2B). 
The presence of an sp3 hybridized atom at one of the connection positions seemed important to 
conserve the dihedral angle enclosed by the single bonds linked to the aromatic rings in the PIF-
pocket-bound B. Furthermore, the pyrazoline system was synthetically accessible by a three 
component reaction, allowing introduction of three different substituents at positions 1, 3 and 5. 
This flexible synthetic approach provided the possibility to optimize all three positions 
independently using a diverse range of substituted phenyls or other moieties. 
 
Figure 2 (B) Pyrazoline prototype compound 1a superimposed with the 3D structure of B in the cocrystal–bound 
conformation (taken from PDB entry 4A06) (C) Two carbonyl functions are available for H-bonding in the PIF-
pocket of atypical PKCι. The cocrystal structure of PDK1 with compound B (orange) bound in the PIF-pocket (PDB 
code: 4A06, yellow residues) was superimposed with the crystal structure of the atypical PKCι (PDB code: 3A8X, 
grey residues), the most closely related isoform of PKCζ. The benzimidazole ring (orange) denotes the putative 
position of B in the superimposed PIF-subpocket of PKCι. Two backbone carbonyl groups derived from PKCι 
Lys278 and Val281, respectively (circled), are sequestered into the PIF-subpocket, and would be in a close distance 
(indicated in angstrom) to the 5´-chlorine of the benzimidazole if a similar binding mode was assumed. In contrast, 
the carbonyl equivalent to that of Lys278 in PDK1 is less available (upper circle, yellow residue). 
Synthesis. The synthesis of the target compounds was carried out in two steps. In the first 
step, a Claisen-Schmidt condensation was carried out between aromatic aldehydes and 
pinacolone or acetophenone analogues, using 10% aq. KOH as a catalyst in methanol, in order to 
afford the required enones. In the second step, these enones were reacted to give the desired 
pyrazolines using the previously reported regioselective synthesis of 1,3,5-triarylpyrazolines.43 
This was accomplished via enone-arylhydrazine hydrochloride condensation reaction under an 
inert atmosphere using DMF as solvent while heating for 5 hours at 85oC (Schemes 1,2 and 3). 
 
K278
V281
B C
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In our early trials, p-hydroxybenzaldehyde was used in an attempt to obtain the essential p-
hydroxy group on the phenyl enone derivatives. Unfortunately, the phenoxide anion, which was 
generated due to the strong alkaline reaction conditions, both hindered the reaction and reduced 
the yield dramatically. Hence, we decided to use methoxy or ethoxybenzaldehyde derivatives, 
which afforded the respective enones in a very high yield; the final compounds were then 
obtained after deprotection using BBr3 in dichloromethane at -78 oC (Scheme 2, step iii). 
In an attempt to test the effect of other substituents at the 5-phenyl, t-butoxybenzaldehyde 
was used to get the enone E1 (Figure 3), which was then reacted with 4-chlorophenylhydrazine 
hydrochloride to yield compound D. Surprisingly, compound 1a was the major product obtained 
while compound D was obtained in a very low yield. This clearly suggested that the t-butyl ether 
group was spontaneously cleaved to give the corresponding p-hydroxyl group under the reaction 
conditions used. This fact was confirmed by comparing 1H-NMR and 13C-NMR spectra of both 
E1 and 1a. The concomitant cleavage was observed throughout the 33 reactions shown in 
Scheme 1, thus providing a short and facile pathway for obtaining 5-(4-hydroxy phenyl) 
pyrazolines in a good yield, eliminating the need for deprotection and ether cleavage by BBr3. 
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Figure 3. Structure of the enone intermediate E1 which yielded 1a after reacting with p-chlorophenyl hydrazine, via 
a spontaneous ether cleavage of D. 
The aniline derivatives were obtained in a very good yield by synthesizing the respective 
nitro derivatives followed by reduction using SnCl2•2H2O in refluxing methanol (Scheme 3). To 
introduce a methyl group at position 4 of the pyrazoline derivative 3h, deprotonation of the 
acidic methylene group with LDA at -78oC was done to give the respective anion which was 
instantly trapped with methyl iodide to afford the methyl-substituted pyrazoline derivative 8.43 
This compound was then deprotected using BBr3 to give compound 9 (Scheme 4). Oxidation of 
the pyrazoline ring in 3e to the corresponding pyrazole 10 was achieved using DDQ in refluxing 
benzene followed by deprotection using BBr3 to afford compound 11 (Scheme 5). 
It is worth mentioning that the use of the arylhydazine as hydrochloride salt rather than the 
free base was of great importance to increase the yield of the cyclization reaction and to reduce 
the reaction side products. In addition to this, one equivalent amount of HCl was added to the 
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reaction medium in order to improve the yield especially when enones containing basic moieties, 
like pyridine or aniline as in E8 and E10, respectively, were used. 
Scheme 1 
 
Reagents and conditions: (i) 10% KOH, MeOH, ice cooling then room temperature, overnight; 
(ii) 1.5 equiv Ar-NH-NH2·HCl, DMF, 85 oC, 5h. 
No. E R1 R2 No. E R1 R2 
1a 1 t-Bu 4-Cl 1r 1 t-Bu 3-chlro-4-fluoro 
1b 1 t-Bu 4-F 1s 1 t-Bu 3,4-difluoro 
1c 1 t-Bu 4-Br 1t 1 t-Bu 2,3,4-trifluoro 
1d 1 t-Bu 4-CF3 1u 1 t-Bu 4-H 
1e 1 t-Bu 4-CH3 2a 2 phenyl 4-Cl 
1f 1 t-Bu 4-isopropyl 2b 2 phenyl 3-Cl 
1g 1 t-Bu 4-COOH 2c 3 2-hydroxyphenyl 4-Cl 
1h 1 t-Bu 3-Cl 2d 4 2-methoxyphenyl 4-Cl 
1i 1 t-Bu 3-F 2e 5 2-ethoxyphenyl 4-Cl 
1j 1 t-Bu 3-CF3 2f 6 2-chlorophenyl 4-Cl 
1k 1 t-Bu 3-CH3 2g 7 thiophen-2-yl 4-Cl 
1l 1 t-Bu 2-Cl 2h 7 thiophen-2-yl 4-Br 
1m 1 t-Bu 2-F 2i 7 thiophen-2-yl 4-CF3 
1n 1 t-Bu 2,4-dichloro 2j 8 pyridin-2-yl 3-Cl 
1o 1 t-Bu 2,4-difluoro 2k 9 pyrrol-2-yl 3-Cl 
1p 1 t-Bu 2,4-dimethyl 2l 10 4-aminophenyl 4-Cl 
1q 1 t-Bu 2,6-dichloro     
 
Scheme 2 
 
Reagents and conditions: (i) 10% KOH, MeOH, ice cooling then room temperature, overnight; 
(ii) 1.5 equiv Ar-NH-NH2·HCl, DMF, 85 oC, 5h; (iii) 3-9 equiv BBr3, CH2Cl2, -78 oC then room 
temperature, 20h. 
3/4 E R1 R2 R3 R4 R5 R6 
a 11 3-OMe t-Bu 4-Cl 3-OH t-Bu 4-Cl 
b 12 4-OMe t-Bu 4-OMe 4-OH t-Bu 4-OH 
c 13 4-Cl t-Bu 4-OMe 4-Cl t-Bu 4-OH 
d 14 3-F,4-OMe t-Bu 4-Cl 3-F,4-OH t-Bu 4-Cl 
Results 
40 
 
e 15 3-Cl,4-OMe t-Bu 4-Cl 3-Cl,4-OH t-Bu 4-Cl 
f 16 4-F,3-OMe t-Bu 3-Cl 4-F,3-OH t-Bu 3-Cl 
g 17 3,4-dimethoxy 2-methoxyphenyl 4-Cl 3,4-dihydroxy 2-hydroxyphenyl 4-Cl 
h 18 3-F,4-OMe 2-methoxyphenyl 3-Cl 3-F,4-OH 2-hydroxyphenyl 3-Cl 
i 19 3,5-difuoro-4-OEt 2-methoxyphenyl 3-Cl 3,5-difuoro-4-OH 2-hydroxyphenyl 3-Cl 
j 20 2,3-difuoro-4-OMe 2-methoxyphenyl 3-Cl 2,3-difuoro-4-OH 2-hydroxyphenyl 3-Cl 
k 21 3-F,4-OMe 2,4-dimethoxyphenyl 3-Cl 3-F,4-OH 2,4-dihydroxyphenyl 3-Cl 
l 22 4-F t-Bu 4-Cl - - - 
m 13 4-Cl t-Bu 4-Cl - - - 
n 23 4-Br t-Bu 4-Cl - - - 
o 24 4-CN t-Bu 4-Cl - - - 
p 25 4-OMe phenyl 4-Cl - - - 
q - 4-OH Me 4-Cl - - - 
Scheme 3 
 
Reagents and conditions: (i) 10% KOH, MeOH, ice cooling then room temperature, overnight; 
(ii) 1.5 equiv Ar-NH-NH2·HCl, DMF, 85 oC, 5h; (iii) 5 equiv SnCl2·2H2O, MeOH, reflux, 2h; 
(iv) 1.5 equiv CH3COCl, acetone, ice cooling , 2h. 
5/6 E NO2/NH2 position R1 R2 
a 26 4 t-Bu 4-Cl 
b 26 4 t-Bu 2,4-difluoro 
c 26 4 t-Bu 3-Cl 
d 27 3 t-Bu 4-Cl 
e 28 4 cyclopropyl 3-Cl 
f 29 4 1-methylcyclopropyl 3-Cl 
g 30 4 cyclohexyl 4-Cl 
h 31 4 thiophen-2-yl 3-Cl 
i 32 4 furan-2-yl 3-Cl 
j 33 4 2-chloropheyl 3-Cl 
K 34 4 2-trifluoromethylphenyl 3-Cl 
l 35 4 2-methylphenyl 3-Cl 
m 36 4 2-methoxyphenyl 3-Cl 
n 37 4 benzo[d][1,3]dioxol-5-yl 3-Cl 
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Scheme 4 
 
Reagents and conditions: (i) 1.5 equiv LDA, 1.5 equiv MeI, THF, -78 oC then room 
temperature, 20h; (ii) 6 equiv BBr3, CH2Cl2, -78 oC then room temperature, 20h. 
Scheme 5 
 
 
Reagents and conditions: (i) 1.5 equiv DDQ, benzene, reflux, 5h; (ii) 3 equiv BBr3, CH2Cl2, -
78 oC then room temperature, 20h. 
BIOLOGICAL ACTIVITY 
Structure-Activity Relationships (SARs) in the Cell-Free Assay 
 To test the suitability of the scaffold, some initial pyrazoline compounds were 
synthesized containing, on the one hand, p-halogen-substituted phenyl rings like in the previous 
PIF-pocket–directed compounds. On the other hand, a phenol was introduced to potentially 
exploit specific features identified in the PIF-pocket of PKCι, which were potentially conserved 
in PKCζ as well. The PKCι PIF-pocket exposed two backbone carbonyl groups that could be 
targeted by H-bonds, derived from Val281 and Lys278 (Figure 2C). Given the high structural 
similarity among the atypical PKCs in the catalytic domain, it was expected that the 
corresponding carbonyl functions are also present in PKCζ. On the contrary, both carbonyls in 
the equivalent PDK1 PIF-subpocket are considerably less or not accessible. 
All the initially synthesized compounds were screened against recombinant, full length 
PKCζ at a concentration of 62.5 µM; for compounds showing more than 75% inhibition, the IC50 
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was determined (Table 1). Then at a later stage, favorable features identified with the first 
compound series were combined. With respect to the determined IC50s, it should be noted that 
the inhibition at compound concentrations lower than 0.2 µM could not be accurately measured, 
because this was equal to the concentration of the PKCζ protein in the assay. 
Table 1. Inhibition of recombinant PKCζ and the NF-κB pathway in cells 
 
Cpd 
No. 
R1 R2 R3 R4 
Cell free assay NF-κB reporter gene 
assay (U937 cells) 
% inhibition 
at 62.5 µMa 
IC50 
(µM)a 
% 
inhibition  
at 5 µMa 
IC50 
(µM)a 
1a 4-OH t-Bu 4-Cl H 91.5 10.7 75.1 3.2 
1b 4-OH t-Bu 4-F H 95.5 9.4 63.8 NDa 
1c 4-OH t-Bu 4-Br H 93.2 11.4 58.4 ND 
1d 4-OH t-Bu 4-CF3 H 94.2 8.8 NDb ND 
1e 4-OH t-Bu 4-CH3 H 88.8 12.6 62.9 ND 
1f 4-OH t-Bu 4-isopropyl H 54.9 ND NDb ND 
1g 4-OH t-Bu 4-COOH H 47.9 ND 40.7 ND 
1h 4-OH t-Bu 3-Cl H 96.8 5.2 64.6 ND 
1i 4-OH t-Bu 3-F H 98.1 2.2 73.5 ND 
1j 4-OH t-Bu 3-CF3 H 96.1 2.7 89.7 2.7 
1k 4-OH t-Bu 3-CH3 H 91.7 3.5 73.7 ND 
1l 4-OH t-Bu 2-Cl H 57.1 ND 23.5 ND 
1m 4-OH t-Bu 2-F H 57.6 ND 48.7 ND 
1n 4-OH t-Bu 2,4-dichloro H 71.0 ND 50.2 ND 
1o 4-OH t-Bu 2,4-difluoro H 68.0 ND 51.8 ND 
1p 4-OH t-Bu 2,4-dimethyl H 59.9 ND 41.5 ND 
1q 4-OH t-Bu 2,6-dichloro H 65.5 ND 12.3 ND 
1r 4-OH t-Bu 3-chloro-4-fluoro H 98.8 0.9 92.0 1.9 
1s 4-OH t-Bu 3,4-difluoro H 97.8 0.5 90.1 0.9 
1t 4-OH t-Bu 2,3,4-trifluoro H 91.7 0.7 84.2 3.1 
1u 4-OH t-Bu 4-H H 84.3 28.8 38.5 ND 
2a 4-OH phenyl 4-Cl H 95.6 3.5 50.8 ND 
2b 4-OH phenyl 3-Cl H 90.5 2.1 42.2 ND 
2c 4-OH 2-hydroxyphenyl 4-Cl H 92.0 1.5 68.2 ND 
2d 4-OH 2-methoxyphenyl 4-Cl H 68.4 ND 26.5 ND 
2e 4-OH 2-ethoxyphenyl 4-Cl H 42.8 ND 48.2 ND 
2f 4-OH 2-chlorophenyl 4-Cl H 90.8 12.7 38.7 ND 
2g 4-OH thiophen-2-yl 4-Cl H 97.0 0.6 52.8 ND 
2h 4-OH thiophen-2-yl 4-Br H 95.2 0.5 64.2 ND 
2i 4-OH thiophen-2-yl 4-CF3 H 99.4 0.4 76.3 2.9 
2j 4-OH pyridin-2-yl 3-Cl H 82.2 6.2 70.2 ND 
2k 4-OH pyrrol-2-yl 3-Cl H 63.0c 0.5 54.1 ND 
2l 4-OH 4-aminophenyl 4-Cl H 98.0 5.4 42.3 ND 
3l 4-F t-Bu 4-Cl H 0 ND 3.7 ND 
3m 4-Cl t-Bu 4-Cl H 11.8 ND 5.5 ND 
3n 4-Br t-Bu 4-Cl H 39.0 ND 9.3 ND 
3o 4-CN t-Bu 4-Cl H 20.7 ND 20.1 ND 
3p 4-OMe phenyl 4-Cl H 21.1 ND 2.9 ND 
3q 4-OH Me 4-Cl H 58.8 ND 50.8 ND 
4a 3-OH t-Bu 4-Cl H 95.6 5.3 89.9 2.0 
4b 4-OH t-Bu 4-OH H 40.9 ND 35.0 ND 
4c 4-Cl t-Bu 4-OH H 72.2 ND 37.3 ND 
4d 3-F,4-OH t-Bu 4-Cl H 98.5 3.8 95 3.7 
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4e 3-Cl,4-OH t-Bu 4-Cl H 94.5 0.7 85 2.9 
4f 4-F,3-OH t-Bu 3-Cl H 75.0c 0.3 92.8 2.5 
4g 3,4-dihydroxy 2-hydroxyphenyl 4-Cl H 89.7c <0.1 62.0 ND 
4h 3-F,4-OH 2-hydroxyphenyl 3-Cl H 64.7c 2.9 71.7 ND 
4i 3,5-difluoro-4-OH 2-hydroxyphenyl 3-Cl H 62.0d 11.1 75.1 2.5 
4j 2,3-difluoro-4-OH 2-hydroxyphenyl 3-Cl H 69.4d 6.6 81.7 1.4 
4k 3-F,4-OH 2,4-dihydroxyphenyl 3-Cl H 89.0c <0.1 87.4 1.1 
5a 4-NO2 t-Bu 4-Cl H 0 ND 5.9 ND 
6a 4-NH2 t-Bu 4-Cl H 19.0 ND 22.7 ND 
6b 4-NH2 t-Bu 2,4-difluoro H 52.3 ND 23.5 ND 
6C 4-NH2 t-Bu 3-Cl H 53.6 ND 42.3 ND 
6d 3-NH2 t-Bu 4-Cl H 18.7 ND 21.9 ND 
6e 4-NH2 cyclopropyl 3-Cl H 57.4 ND 24.5 ND 
6f 4-NH2 1-methylcyclopropyl 3-Cl H 55.6 ND 47.7 ND 
6g 4-NH2 cyclohexyl 4-Cl H 9.1 ND 30.9 ND 
6h 4-NH2 thiophen-2-yl 3-Cl H 33.0 ND 44.9 ND 
6i 4-NH2 furan-2-yl 3-Cl H 48.1 ND 26.1 ND 
6j 4-NH2 2-chlorophenyl 3-Cl H 1.3 ND 24.4 ND 
6K 4-NH2 2-trifluoromethylphenyl 3-Cl H 24.0 ND 50.8 ND 
6l 4-NH2 2-methylphenyl 3-Cl H 30.0 ND 31.3 ND 
6m 4-NH2 2-methoxyphenyl 3-Cl H 28.3 ND 28.2 ND 
6n 4-NH2 benzo[d][1,3]dioxol-5-yl 3-Cl H 38.0 ND 22.2 ND 
7a 4-NHCOCH3 t-Bu 4-Cl H 45.1 ND 25.5 ND 
9 3-F,4-OH 2-hydroxyphenyl 3-Cl CH3 81.8c 0.72 73.0 ND 
11 - - - - 54.0d 17.4 93.0 3.0 
A - - - - 54.6d 15.9 6.4 ND 
aValues are mean values of at least two experiments; standard deviation <15%; bcompounds were toxic in the MTT assay (Supplementary Table 
S3); c% inhibition is shown at 10 µM; d% inhibition is shown at 20 µM; ND: not determined 
While the p-halogen-substituted prototype compounds (at both the 1- and 5-phenyl) 
showed only little activity towards the purified enzyme (3m-n), 1a inhibited PKCζ by more than 
90% (Table 1). The IC50 was determined to be 10.7 µM, thus showing somewhat higher activity 
than the most potent compound from the previous series of allosteric PKCζ inhibitors, compound 
A (named 1q in 37), for which we determined an IC50 of 15.9 µM. This value was close to the 
previously reported IC50 for this compound (18 µM).37 
Using the hit compound 1a as a template, numerous sites of modification around the 
pyrazoline ring system were explored, as described in the following. 
The 5-phenyl 
As observed already in the initial screening, the phenolic OH at the para-position of 1a 
was found to be essential for activity; like chlorine and bromine, fluorine could not successfully 
replace this OH either (compound 3l). Next, we tested several H-bond acceptor (HBA) functions, 
including the lipophilic and electron–withdrawing nitro function as well as the more hydrophilic 
cyano group (compounds 5a and 3o respectively), which, however, completely abolished the 
inhibitory activity. Replacing the phenolic OH in compound 2a by a methoxy function 
(compound 3p) resulted in an almost inactive compound as well. Altogether, these findings 
indicated that the crucial role of the hydroxyl function came from its H-bond donating ability. In 
the light of these results, the amino group was conceivable as a possible bioisostere. Therefore, 
we synthesized a series of aniline derivatives including compounds 6a-n. Surprisingly, none of 
these aromatic amine compounds showed an activity comparable to that of the hit 1a, giving 
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clear indication that the primary amine function cannot replace the hydroxyl in its interaction 
with the target amino acid(s). Shifting the amino function to the meta-position (compound 6c) 
did not recover the potency either. The largely reduced activity might be attributed to the lower 
δ+ character of the amine hydrogen atoms or to the slightly different spatial orientation of the 
aromatic amine. To increase the H-bond donor (HBD) capacity of the amino function, the amino 
group in compound 6a was acetylated to yield the acetamido analogue of 1a (compound 7a). 
This modification recovered some of the activity compared with 6a, but the potency was still 
considerably lower than that of 1a, suggesting that the acetyl moiety was not well tolerated by 
the PIF-subpocket.  
 Compound 4a, a positional isomer of 1a, in which the hydroxyl group is shifted to the 
meta-position, was synthesized to investigate the optimal position of the hydroxyl group. This 
modification led to a modest increase of activity by roughly 2 fold, suggesting that a more 
efficient hydrogen bonding might occur from the meta-position. In compounds synthesized later, 
after optimization at other positions, it was therefore logic to include a compound with a 3,4-
dihydroxy function (catechol derivative) to test if this might further improve the potency by 
establishing a bidentate H-bond interaction with the putative carbonyl oxygen, or by targeting 
even two different carbonyl functions. Indeed, compound 4g showed a more than 15 fold 
increase in activity when compared to the 4-hydroxy congener 2c. 
To further increase the potency through fine-tuning at the phenol ring, we decided to 
synthesize compounds 4d and 4e bearing an additional m-fluoro or m-chloro substituent adjacent 
to the essential 4-hydroxyl group. Both halogens triggered superior activity; while the additional 
m-fluoro increased the potency about 3 fold, the m-chloro led to a dramatic increase in activity 
by more than 15 fold. This beneficial effect of the neighboring halogen substitution can be 
attributed to two major effects: firstly, the electron withdrawing effect, particularly of the 
fluorine, increased the partial positive charge on the hydroxyl hydrogen, thus enhancing the 
strength of the hydrogen bond. Secondly, the presence of the halogen at the aromatic ring 
restored its lipophilicity, thus increasing the entropy of binding to the rather hydrophobic pocket. 
Obviously, the second effect prevailed as indicated by the larger impact of the chlorine. As 
another potential benefit, this meta-halogen substitution was also expected to improve the 
stability of the hydroxyl group towards metabolic phase II conjugation reactions which might be 
important for in vivo activity.44, 45 
The 1-phenyl 
 To test the importance of the halogen substitution, we synthesized compound 1u which 
lacked the 4-chloro of 1a. The higher IC50 showed that the 4-chloro is important for activity, 
which was consistent with the previous observation with PIF-pocket-directed PKCζ inhibitors, in 
which ring substitutions with halogens or alkyl had a large impact on the potency and possibly 
also on the selectivity.37 Several compounds bearing various lipophilic electron withdrawing 
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substituents, comprising 4-fluoro, 4-bromo and 4-trifluoromethyl, were prepared (compounds 
1b-d, respectively). All of them showed inhibitory activity comparable with that of the 4-chloro 
analogue, and this finding was consistent with the result obtained for compounds 2g-i also 
substituted with 4-chloro, 4-bromo and 4-trifluoromethyl at the 1-phenyl ring, respectively 
(further discussed below). Interestingly, replacing the 4-chloro in 1a by 4-methyl (compound 1e) 
kept the activity at a similar level, suggesting that mainly the lipophilic character of the 4-
substituent rather than its electronegativity is the important factor for the improvement of the 
activity. This was confirmed by synthesizing compounds 1g and 4b with polar hydrophilic 
substituents (4-carboxy and 4-hydroxy, respectively). The presence of such polar groups was 
obviously deleterious to the activity, in agreement with their putative binding to the entirely 
hydrophobic subpocket 2 lacking any accessible HBD/HBA function (Figure 4, binding model). 
However, sensitivity to steric hindrance at the 4-position of this aromatic ring with regard to 
potency was found, as replacing the 4-methyl in compound 1e by a bulkier branched alkyl like 
isopropyl (compound 1f) significantly decreased the activity.  
Moving the lipophilic substituent from para- to the meta-position brought this group in 
an even better position for interaction with the pocket; this was evident from compounds 1h-k, 
substituted by m-chloro, m-fluoro, m-trifluoromethyl and m-methyl, respectively, which showed 
about two- to four times higher potencies than the corresponding p–substituted analogues (1a-b 
and 1d-e). The finding that both the para- and the meta-substitution had a boosting effect 
prompted us to synthesize some hybrid compounds with 3,4-disubstitutions. Interestingly, 
compounds 1r with 3-chloro-4-fluoro, and 1s with 3,4-difluoro substituents were among the 
most active compounds with submicromolar IC50s, indicating at least additive effects of the 
lipophilic substituents at these two positions. On the other hand, lipophilic substitution of the 
ortho-position as in the case of compounds 1l (o-chloro) and 1m (o-fluoro) dramatically reduced 
the activity when compared to the corresponding meta-substituted analogues. This unfavorable 
effect of the ortho-substitution was also confirmed by the di-substituted analogues 1n (2,4-
dichloro), 1o (2,4-difluoro), 1p (2,4-dimethyl), and 1q (2,6-dichloro). This was unexpected since 
it was assumed that the ortho effect would actually stabilize the biologically active conformation 
and hence increase the binding affinity. It could be speculated that a steric clash of the ortho-
substituent with the border of the hydrophobic subpocket might hinder binding of the 
compounds, or might push away the helix alpha-C, thus impairing the putative H-bond 
interaction of the pyrazoline imine with the helix residue Lys301 (cf. Figure 2A; Arg131 is 
equivalent to Lys301 in PKCζ). 
However, in compound 1t with 2,3,4-trifluoro substitution, the effect of the ortho-fluoro 
on activity was minimal, maintaining a submicromolar IC50 similar to the potent 3,4-difluoro 
analogue (compound 1s). In 1t, favorable synergistic effects of the para- and meta-fluorine 
substitution seemed to outbalance the adverse effect observed with the isolated ortho-
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substitution. Such favorable interaction could potentially be explained by dipole–dipole 
interactions with the peptide backbone from Leu328 of the β-sheet bordering subpocket 2.  
Substituent at position 3 
 To explore the relative importance of the bulky t-butyl substituent in hit compound 1a, 
we started the modifications by contracting it to a methyl group (compound 3q). Rather 
unexpectedly, this modification caused a considerable drop of activity. This result was not 
anticipated because the third substituent of the pyrazoline core was not expected to bind to the 
PIF-pocket, rather the binding model predicted that it would point outside the pocket. 
Nevertheless, the favorable effect of the t-butyl group on the affinity could be explained based on 
the binding model. Firstly, the strong positive inductive effect of the t-butyl might be propagated 
via the conjugated double bond, thus increasing the electron density and hence the H-bond 
acceptor strength of the pyrazoline nitrogen. However, an even more important, parallel effect of 
the bulky t-butyl group might be the shielding of this potential H-bond with the pyrazoline 
nitrogen from water molecules. This might be particularly relevant here in the case of a highly 
water accessible surface pocket, where H-bonds are strongly competed and weakened by water 
molecules. Schmidtke et al. showed that shielding such a H-bond by an ethyl “lid” provided by 
the ligand created a more lipophilic binding groove which significantly stabilized and enhanced 
the H-bond interaction.46 In the future, this concept might receive broad attention especially in 
the growing field of protein-protein interaction inhibitors, even though it might not seem logic at 
first sight to introduce a (bulky) lipophilic residue at a water exposed position. 
Replacing the t-butyl by unsubstituted phenyl increased the activity about 3 times 
(compounds 2a-b), which might be explained by additional interactions exerted by the aromatic 
π-electrons, such as CH-π or cation-π interactions. Interestingly, it was previously reported that 
such a cation-π interaction effectively enhanced the binding affinity of a ligand by up to 8 kJ/mol 
at a fully solvent exposed binding site, proving that such an interaction is not attenuated by 
hydration effects.47 It might thus successfully substitute H-bond interactions in cases where the 
binding site cannot be protected from water molecules. 
A further two fold increase in activity was achieved by substituting this phenyl with a 
hydroxyl group at the o-position (compound 2c) which might be at least partially attributed to the 
mesomeric enhancement of the π-electron system. In addition, calculations of the lowest energy 
conformer of 2c (Supplementary Figure S1) suggested that the hydroxyl group forms an 
intramolecular H-bond with the pyrazoline nitrogen, thus fixing the phenyl ring in a favorable 
position, also resulting in a smaller entropic penalty upon ligand binding. Furthermore, the 
hydroxyl oxygen is potentially available as an alternative HBA for Lys301 (see Figure 4, binding 
model).  In contrast, the loss of this conformational constraint in the methoxy– and ethoxy–
substituted analogues (2d and 2e, respectively) was accompanied by a gradual decrease of the 
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potency. As could be confirmed by ab initio calculations, the ether oxygen in these compounds 
was preferably pointing to the opposite side due to electrostatic repulsion with the pyrazoline 
nitrogen. 
Substitution of the 4-position with an amino group (2l) did not increase the activity 
compared to the unsubstituted phenyl, apparently contradicting the presumed cation–π 
interaction. However, a closer inspection of the calculated electrostatic potential surface 
(Supplementary Figure S1) revealed that the strong electron donating effect of the amino 
function slightly increased the electron density even at the p-hydroxy on the 5-phenyl, thus 
negatively affecting the H-bond donor strength. The same effect was also observed in the case of 
the 2-methoxy and ethoxy substituents, but not with the 2-hydroxyl analogue 2c or the 
unsubstituted analogue 2a, providing another explanation for the substantially decreased activity 
of the two alkoxy derivatives. 
Replacing this 2-hydroxyl by a lipophilic, electron-withdrawing group like chlorine led to 
more than eight fold reduction in potency (compound 2f), also corroborating that a higher 
electron density was favorable for the activity.  
Next, some heteroaryl rings were introduced instead of the phenyl in compounds 2a-b, 
starting with a mildly basic heterocycle like 2-pyridyl (compound 2j) which would improve the 
physicochemical properties and could potentially offer its nitrogen as HBA. However, the 
activity was reduced by about three fold compared with that of 2b, indicating that an electron–
poor heterocycle was inferior to phenyl. Moreover, the pyridine nitrogen apparently could not 
replace the pyrazoline imine as HBA, which might be due to electrostatic repulsion between the 
lone pairs of the nitrogen atoms, forcing the pyridine nitrogen to rotate to a position opposite to 
the imine (Supplementary Figure S1). On the other hand, the thiophene ring in compounds 2g-i 
caused remarkable increase in activity by more than six fold when compared with the 
unsubstituted phenyl analogue (compare 2g with 2a). A similar improvement was observed with 
the pyrrole analogue 2k. The higher potency conferred by the five-membered heterocycles 
compared with the phenyl might be attributed to the higher electron polarizability of these ring 
systems, enabling superior Van der Waals and π-electron–dependent interactions.  
In summary, the SARs were fully consistent with a cation–π interaction, as the π-electron 
density highly correlated with the potency – with the only exception of 2l, as discussed above. 
As can be concluded from the SARs, the electronic properties and bulkiness of the 
substituents in position 3 allow the adjustment of the electron density and water accessibility of 
the pyrazoline nitrogen, respectively, but can also slightly influence the H-bond donor capacity 
of the essential hydroxyl function. Aromatic systems could serve as π-electron donors to Lys301 
in addition. Furthermore, since the 3-position of the pyrazoline ring tended to be very tolerant 
with respect to a variety of substituents like bulky alkyls, hydroxylated phenyl, and heteroaryl 
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rings, it was identified as a key position for the optimization of the physicochemical properties 
such as water solubility and logP. 
 
 
Figure 4. Model for the hypothetical interaction of the triphenylpyrazoline analogues based on the SAR. Given the 
high homology to the crystallized PKCι isoform, the PIF-pocket of PKCζ can be assumed to feature two mostly 
hydrophobic subpockets which accommodate the two phenyl rings (1-phenyl and 5-phenyl). The essential hydroxyl 
function is thought to interact with the backbone carbonyl of Lys285 or Val288 (Lys278 and Val281, respectively, 
in PKCι, cf. Figure 2C), thus determining the binding orientation. The 1-phenyl ring binds to the merely 
hydrophobic subpocket 2. For the potential interaction with Lys301, both the imine nitrogen and the phenyl π-
electrons are within appropriate distances. 
Finally, the proposed binding model (Figure 4) also was confirmed by synthesizing the 
inverted analogue of 1a in which the substituents of the two aromatic rings were reversed 
(compound 4c). This inversion resulted in a less active compound, suggesting that the imine 
nitrogen interaction might be lost if the phenol ring still binds to the same position as with 1a, 
thus accounting for the drop of potency. In contrast, the alternative binding mode with the phenol 
ring docking to the other subpocket was unlikely bearing in mind the huge loss of activity 
observed with the bisphenol compound 4b. 
  
Lys301
PIF pocket
Hydrophobic 
subpocket 2 
Hydrophobic 
subpocket 1
Lys285
Val288
Val297
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Some combined favorable features and further modifications.  
In order to further enhance the binding affinity, it was straightforward to combine some 
of the favorable modifications identified in the compounds described above. For instance, while 
the t-butyl was kept at position 3 of the pyrazoline, the essential phenolic OH was shifted to m-
position, combined with an adjacent p-fluoro substituent, and a 3-chloro substituent was placed 
at the 1-phenyl. The resulting compound 4f proved to be one of the most potent compounds, with 
an IC50 of 0.3 µM. In addition, four compounds were prepared (4h-k) in which we employed the 
2-hydroxyphenyl at position 3 of the pyrazoline as it had augmented the activity before 
(compound 2c). As another beneficial effect, we expected a reduction of the logP, while the 
ortho-hydroxyl should be rather protected from phase II conjugation.48 We first combined this 
moiety with the 3-fluoro-4-hydroxyphenyl at the 5-position of pyrazoline (4h). However, in this 
case the fluorine did not increase the activity like it was observed before with the 3-t-butyl 
analogue 4d. In compounds 4i-j, we added a second fluorine compared with compound 4h, to 
yield a difluoro-substitution adjacent to the essential p-hydroxyl group at the 4-phenyl residue. 
Unexpectedly, in compound 4i this second fluorine in 5-position of the phenyl caused a more 
than 4 fold decrease in activity compared with 4h, while in 4j the second fluorine in o-position 
still reduced the activity by half. Although this di-fluoro substitution in the vicinity of the 
essential phenolic OH was expected to increase its HBD ability, it decreases at the same time the 
electron density on the aromatic ring, which might have attenuated putative Van der Waals and 
CH–π interactions with the aliphatic PIF-pocket residues. 
In compound 4k, an additional 4-hydroxyl group was introduced to the 3-phenyl. 
Compared with 4h, this additional OH caused a dramatic increase in activity by more than 29-
fold, yielding one of the most potent compounds of the present series. This order of magnitude 
corresponded to an affinity gain of more than 8.5 kJ/mol as estimated based on the IC50s, 
suggesting that the p-hydroxyl could be involved in a potential H-bond with the target site, too.  
Introduction of a fourth alkyl substituent at position 4 of the pyrazoline 
Afterwards we decided to test the effect of introducing a fourth small alkyl substituent 
like methyl at position 4 of the pyrazoline core. Hence, we prepared compound 9 as the 4-methyl 
analogue of compound 4h. Interestingly, this 4-methyl led to more than four fold increase in 
activity compared with compound 4h, which could be explained either by additional 
hydrophobic interactions or by the effect of this 4-substitution on the relative orientation of the 
neighboring groups arising from the pyrazoline core, or by a combination of both effects. It is 
worth mentioning that alkylation of 1,3,5-trisubstituted pyrazolines at position 4 was reported to 
increase the chemical stability of the ring towards oxidation to the corresponding pyrazole.43 
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Core ring planarity 
To test the effect of core planarity (pyrazoline vs. pyrazole), the pyrazole derivative 
compound 11 was prepared by oxidation of compound 4e. Switching to the planar pyrazole 
system caused more than 24 fold drop in activity confirming the importance of the tetrahedral sp3 
hybridized atom (C5) to conserve the dihedral angle enclosed by 1- and 5-phenyl for the 
biologically active conformation. Moreover, this finding was in agreement with a non ATP-
competitive binding mechanism of the pyrazolines, because if the ATP-binding pocket was the 
target site, conversion to the flat pyrazole ring system should have rather increased the binding 
affinity. Indeed, trisubstituted pyrazole compounds were reported to be potent ATP-competitive 
inhibitors of several serine/threonine kinases.49-52 
Selectivity and proof of the allosteric mechanism 
We screened 1a and most of the active compounds which showed IC50s below 10 µM for 
their ability to inhibit the most closely related isoform, PKCι (Table 2).  
Table 2. Inhibition of PKCι at 20 µMa 
Cpd  No. PKCι % inhibition   
at 20 µM Cpd No. 
PKCι % inhibition  
at 20 µM Cpd No. 
PKCι % inhibition  
at 20 µM 
1a 0 2a 31.6 4a 17.4 
1h 43.5 2b 45.5 4d 29.7 
1i 19.3 2c 13.4 4e 0 
1j 17.0 2h 21.4 4g 44.1 
1k 13.9 2i 45.9 4h 25.2 
1r 31.6 2j 24.1 4i 45.2 
1s 23.7 2k 20.3 4j 39.2 
1t 7.8 2l 38.7 9 23.1 
aValues are mean values of at least two experiments; standard deviation <15%. 
Remarkably, 1a did not show any inhibition even at 40 µM, and all the compounds which 
had shown submicromolar IC50s towards PKCζ did not exhibit appreciable inhibition of PKCι at 
20 µM, indicating that these compounds were highly selective for PKCζ. In addition, this finding 
strongly argued for a non-ATP-competitive mechanism, since the ATP binding sites of both 
atypical PKCs are lined by almost identical residues, rendering such a degree of selectivity for 
ATP-pocket-directed compounds rather unlikely. On the other hand, the PIF-pocket in PKCι can 
be regarded as a kind of PKCζ PIF-pocket mutant which differs in only two amino acid residues 
(Leu328 is Phe and His289 is Asn in PKCι, respectively).53 This difference in the PIF-pocket 
might account for the lack of activity against PKCι, suggesting that our compounds were 
targeting the PIF-pocket in PKCζ. It is worth mentioning that even single mutation of Leu328 in 
PKCζ into Phe was enough to abolish the inhibitory activity of the previously published inhibitor 
compound C (PS171 in ref53). Furthermore, compound 4f, the most potent compound among the 
t-Bu analogues was screened against all PKC isoforms and some of the related AGC kinases. 
Interestingly, 4f did not show inhibition for all of the tested kinases and only gave weak 
inhibition for SGK1 by about 20% (Supplementary Table S4). Again, this selectivity for PKCζ 
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vs. other PKC isoform can be explained by the bulkier Phe residue present in the PIF pocket of 
all PKCs which is replaced by smaller Leu in PKCζ.       
Consistent with this assumption, a more direct evidence for the allosteric mechanism and 
targeting of the PIF-pocket was obtained by testing the inhibitory potency of 1a and three of the 
more potent congeners (2c, 2h and 4e) towards PKCζ mutated at a residue central to the PIF-
pocket (PKCζ[Val297Leu]) (Table 3). The inhibitory potencies of compounds 1a, 2c, and 2h 
were reduced by a factor of more than two, while for compound 4e, we noticed a more than 20 
fold increase of the IC50 against the mutant. The latter finding might be explained by a steric 
clash of the m-chloro with the larger Leu297 residue in the mutated PIF-pocket, and was in 
agreement with the proposed binding model (cf. Figure 4). 
Table 3.Inhibition of PKCζ [Val297Leu] vs. PKCζ [wt]a 
Cpd No. IC50(µM),PKCζ [Val297Leu] IC50(µM),PKCζ [wt] Relative potency (wt vs. mutant) 
1a 26.7 10.7 2.5 
2c 3.1 1.5 2.1 
2h 1.0 0.5 2.0 
4e 14.8 0.7 20.8 
aValues are mean values of at least two experiments; standard deviation <15%. 
To further investigate the non-ATP competitive mechanism, we performed reporter dye 
assays using SYPRO Orange, a dye that is known to change fluorescence dramatically when it 
binds to hydrophobic patches of proteins, thus being applicable as a conformational sensor 
(Figure 5).54 Our results suggested that compounds 1a, 2i and 4f as well as the previously 
published allosteric inhibitor A could induce the exposure of hydrophobic regions in the protein, 
to which the dye bound, thereby increasing its fluorescence. In contrast, the ATP-competitive 
PKC inhibitor Ro31-822055 did not trigger this effect. It is likely that the allosteric inhibitors 
stabilize an inactive protein conformation which renders hydrophobic residues accessible for the 
reporter dye. 
In addition, HEK293 cell transfection experiments using PKCζ wild type and [Val297Leu] 
mutant expression plasmids were performed, to investigate whether the compounds would cause 
a persistent inactivation of the target kinase. After transfection, the cells were treated with the 
allosteric inhibitor 4f and the ATP-competitive compound Ro31-8220, respectively, in serum-
free medium. After stimulation of the PI3/PDK1 signaling pathway by IGF-I, the recombinant 
proteins were isolated from the cells and the enzymatic activity was measured after extensive 
washing. We found that treatment of the cells with 4f reduced the specific activity of the isolated 
wild type PKCζ in a concentration–dependent manner (Figure 6). This suggested that the 
conformational change for which we provided evidence in the SYPRO Orange binding 
experiment was also induced in the cellular environment, which might have triggered persistent 
deactivation by cellular regulatory mechanisms, e.g. dephosphorylation.  
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Figure 5. Allosteric inhibitors of PKCζ increase the exposure of hydrophobic patches. The fluorescence of the 
indicator dye SYPRO Orange was measured in the presence of recombinant PKCζ (0.5 µM) and different 
concentrations of some pyrazoline compounds (1a, 2i, 4f), the previously published allosteric inhibitor A, the ATP-
competitive inhibitor Ro31-8220 (IX), or DMSO as a control. From each plotted value, the respective fluorescence 
intensity obtained with the identical mixture but in the absence of PKCζ protein was subtracted. All reaction 
mixtures were incubated for 4 min at 37°C before measurement. The data shown are representative for a set of three 
independent experiments which gave essentially the same results. Indicated are the relative fluorescence units with 
standard deviations. 
Such a mechanism was observed earlier with allosteric inhibitors and type II inhibitors 
which shift the intracellular equilibrium toward inactive conformations of the target kinases, 
thereby promoting dephosphorylation, as exemplified for a type II inhibitor of PDK1.56 In 
contrast, the enzymatic activity of the PKCζ protein isolated from the Ro31-8220–treated cells 
was not significantly altered compared to the DMSO-treated control. Ro31-8220 was chosen for 
this transfection experiment because it is more selective for PKCs than staurosporine and does 
not inhibit PI3-kinase/PDK1-dependent signaling,57 which might have artificially blocked the 
potential intracellular re-phosphorylation and activation of the recombinant enzyme by PDK1 
during IGF-I stimulation. In addition, Ro31-8220 was reported to effectively inhibit PKCζ and –ι 
in transfected cells at concentrations of 2-3 µM.58, 59 
In order to prove that the sustained reduction of the PKCζ activity was specifically 
dependent on the PIF-pocket, the same experiment was performed in parallel using the 
PKCζ[Val297Leu] mutant expression plasmid. Indeed, treatment of the transfected cells with 4f 
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did not affect the specific activity of the mutant PKCζ relative to the DMSO–treated control 
samples, demonstrating that deactivation of the kinase required an intact PIF-pocket. 
 
Figure 6. Compound 4f induces deactivation of PKCζ in cells. HEK293 cells were transfected with GST-PKCζ wild 
type and [Val297Leu] mutant expression plasmids, and incubated with 4f, the bisindolylmaleimide Ro31-8220 or 
DMSO, respectively, for 6h in serum-free medium. After stimulation with IGF-I for 30 min, the cells were lysed and 
the recombinant proteins pulled down using glutathione agarose. The purified PKCζ was eluted from the beads 
using glutathione and the enzymatic activity was measured in a phosphorylation assay. All treatments were done in 
triplicates; shown are the representative values of two independently performed experiments. 
In summary, this experiment showed that the allosteric inhibitors of PKCζ might offer an 
additional advantage over ATP-competitive inhibitors under in vivo conditions which might have 
implications on the efficacy, future studies will show whether there is even a persistent 
inactivation caused by allosteric inhibitors of PKCζ, because deactivation of PKCζ is likely to 
persist after washout of the inhibitor in the conditions of the experiment. Altogether, our 
experimental data strongly corroborated that the binding site of the allosteric PKCζ inhibitors 
was the PIF-pocket. 
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Cellular Effects on the NF-κB Signaling Pathway 
To analyze cellular effects on the NF-κB signaling pathway, the U937 cell line was 
chosen, where PKCζ is strongly expressed and is essential for the NF-κB activation.15,60  
Transfections were performed using a reporter gene plasmid expressing luciferase under control 
of NF-κB response elements to monitor PKCζ-induced effects on NF-κB activation (the principle 
of assay is illustrated in Figure 7). All the compounds were tested in the reporter gene assay at a 
5 µM concentration, and the IC50 was determined for compounds showing 75% inhibition or 
higher (Table 1). 
 
Figure 7: Reporter gene assay in U937 cells. Inhibition of PKCζ in U937 cells transfected with a reporter gene 
plasmid expressing luciferase under control of NF-κB response elements is correlated with the inhibition of the 
produced luminescence in response to TNFα.  
From the very beginning, we verified that the hit compound 1a was effective in this cell-
based assay. We found that 1a was able to disrupt the NF-κB activation cascade as monitored by 
the reporter enzyme with an IC50 of 3.2 µM (Table 1). Initially, we checked whether the 
inhibition of another kinase known to participate in the activation of NF-κB could have been 
responsible for the observed effect. Hence, 1a was tested towards all kinases associated with the 
TNF Receptor-1 signaling complex, whose composition in U937 cells had been elucidated.61 It 
was found that 1a did not inhibit any of the purified kinases at a concentration of 10 µM (Table 
S1, Supporting information). 
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We then analyzed whether there was a correlation between the compounds´ potencies in 
cellular and cell-free conditions. To this end, the compounds were grouped into high, moderate 
and low activity categories according to their potencies to inhibit purified PKCζ (see Table S2, 
Supporting Information). Then the Wilcoxon´s signed rank test was applied by pair-wise 
comparison of the corresponding cellular potencies. It was found that compounds with low 
potency towards the purified PKCζ also displayed a significantly lower inhibition of the NF-κB 
activation than compounds showing a moderate (P=0.002) or a strong inhibition (P=0.00017) of 
the purified PKCζ. The degree of significance was somewhat lower when comparing the groups 
with moderate and high inhibition of PKCζ in the cell free assay (P=0.0273). However, the latter 
significance was obtained only after excluding the compounds with plain 3-aryl and hetero aryl 
moieties from the analysis, all of which had uniformely impaired the cellular activity of the 
compounds when compared to the 3-t-butyl analogues (see below). Altogether, the statistical 
significance corroborated that PKCζ was also the intracellular target of the pyrazoline 
compounds, consistent with our data from the HEK293 cell transfection experiment. 
As already anticipated by the statistical analysis, many structural modifications caused the 
same trend both for the cell-free and the cellular potencies (Table 1). In particular, the phenolic 
OH at the 1-phenyl was essential for PKCζ cellular inhibitory activity as well, since all 
compounds lacking the phenolic OH were inactive (cf. compounds 3l-p and 5a). Similarly, the 
aniline derivatives 6a-d and 6h were all less active than their respective phenolic analogues. 
 Compound 1s with 3,4-difluoro-substitution at the 1-phenyl was the most active 
compound in cells with an IC50 of 0.9 µM. It could be noticed that introduction of multiple 
fluorine atoms at the 1-phenyl was an effective means to enhance the cellular potency 
(compounds 1s, 1j, 2i and 1t). 
Unlike in the cell-free assay, it was clearly observed that the plain aryl and heteroaryls at 
position 3 of the pyrazoline were not a superior replacement for the t-Bu group of 1a, since 
compounds 2a-b, 2g-h and 2j-k showed equal or worse inhibition of the reporter gene activity 
when compared with their t-butyl analogues 1a and 1g. This could be possibly explained by an 
increased non-specific binding of the multi-aryl ring system to other cellular proteins. However, 
increasing the polarity of the 3-phenyl, e.g. by ortho-hydroxylation, resulted in higher cellular 
potency when compared to the plain phenyl (compounds 2c, 4h-j), with the best activity 
achieved by a 2,4-dihydroxy-substitution in 4k. This compound was among the two most potent 
compounds in the cell free assay and displayed the second highest cellular activity with an IC50 
of 1.1 µM. 
Unexpectedly, the pyrazole analogue 11 was equally active to its respective pyrazoline 4e, 
which might be attributed to off-target interactions as the cell-free assay data showed a huge 
reduction of PKCζ inhibition. In addition, the methyl-substitution at position 4 of the pyrazoline 
(compound 9) did not add to the activity in cells. The higher lipophilicity of compound 9 might 
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have decreased the cellular availability due to reduced solubility in the assay medium and/or 
increased non-specific interaction (the additional methyl group in compound 9 raised the 
calculated logP by 0.35 to 0.57 units, depending on the calculation method used). Probably for 
the same reason, we noted that for the more potent compounds, the cellular assay conditions 
seemed to level the potencies. However, the two most active compounds in cells were found 
among the most potent submicromolar inhibitors in the cell free assay (compounds 1s and 4k). 
Importantly, we were able to improve the cellular potency of the previously reported allosteric 
PKCζ inhibitors by more than one order of magnitude. 
Inhibition of NO formation in RAW 264.7 macrophage cells. 
PKCζ was reported to be essential for the NF-ĸB pathway activation in RAW cells.62 In 
the same cell line NF-ĸB activation was required to induce transcription of inducible nitric oxide 
synthase (iNOS) after LPS stimulation.63 Hence, iNOS is one of the enzymes that are 
transcriptionally co-regulated by PKCζ signaling pathway; accordingly, our allosteric PKCζ 
inhibitors were expected to suppress the induction of iNOS and to reduce the release of its 
specific enzymatic product, nitric oxide (NO), in the cell culture medium (the principle of the 
assay is shown in Figure 8). Indeed, we found that several of our most potent compounds (4f, 2h 
and 2i, see Table 4) but not two analogues which were inactive or less active against purified 
PKCζ (1l and 1u) were effectively suppressing the production of NO after LPS stimulation 
(Table 4) in the low µM range. Furthermore, the hit compound 1a also triggered iNOS 
suppression but at a somewhat lower extent than 4f, 2h and 2i, consistent with its less potent 
inhibition of PKCζ. Curcumin, a known inhibitor of iNOS induction64 was tested in parallel as a 
positive control (Table 4). 
Table 4. Inhibition of iNOS induction in RAW 264.7 macrophage cells 
 
 
Cpd No. % inhibition  at 7.5 µMa IC50 (µM)a 
1l 26 ND 
1u 32 ND 
1a 50 7.5 
4f 74 4.6 
2h 65 3.4 
2i 69 2.4 
Curcumin 97 0.8 
aValues are mean values of at least four experiments; standard deviation ≤10%. 
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Figure 8: Inhibition of PKCζ in RAW cells stimulated with LPS leads to inhibition of iNOS expression and NO 
production. 
Conclusions  
In summary, we have discovered 1,3,5-trisubstituted and 1,3,4,5-tetrasubstituted 
pyrazolines as a potent and selective class of allosteric PKCζ inhibitors. As suggested by the 
strongly reduced in vitro and cellular activities towards a PIF-pocket mutant of PKCζ, the 
compounds were most likely targeting the PIF-pocket on the kinase catalytic domain. Cellular 
reporter gene and transfection assays confirmed that PKCζ was also targeted in the cells. For the 
first time we could provide evidence that the putative PIF-pocket-directed compounds triggered a 
persistent deactivation of the target kinase by cellular regulatory mechanisms. 
Our novel PKCζ inhibitor scaffold proved to be rich in many modifiable positions, all 
acting as hot spots for improving binding characteristics and displaying sharp SARs. The 
phenolic group on the 5-phenyl was essential for the inhibitory activity, with a catechol 
providing the best activity. The presence of a lipophilic (halogen or alkyl) substituent on the 1-
phenyl proved to be essential for the generation of high potency, with the meta-position being the 
most preferable for mono-substitution, and the 3,4-positions for di-substitution. There was a 
substantial flexibility with respect to the functionality tolerated at the 3-position of the 
pyrazoline, with the 2,4-dihydroxy phenyl identified as one of the most favorable motifs for 
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activity. Furthermore, an additional methyl-substitution at the 4-postion of the pyrazoline had a 
profound effect on potency, in addition to its potential role in stabilizing the pyrazoline ring 
against oxidation. 
EXPERIMENTAL SECTION 
Chemistry 
Solvents and reagents were obtained from commercial suppliers and used as received. A 
Bruker DRX 500 spectrometer was used to obtain 1H NMR and 13C NMR spectra, in very few 
cases Varian Mercury VX 300 spectrometer was used for recoding the spectra of some enones. 
The chemical shifts are referenced to the residual protonated solvent signals and occasionally 
TMS was used as a reference. At least 95% purity in all the tested compounds (Table 1) was 
could be verified by means of HPLC coupled with mass spectrometry.  Mass spectra (HPLC-
ESI-MS) were obtained using a TSQ quantum (Thermo Electron Corporation) instrument 
prepared with a triple quadrupole mass detector (Thermo Finnigan) and an ESI source. All 
samples were inserted using an autosampler (Surveyor, Thermo Finnigan) by an injection 
volume of 10 µL. The MS detection was determined using a  source CID of 10 V and carried out 
at a spray voltage of 4.2 kV, a nitrogen sheath gas pressure of 4.0·105Pa, a capillary temperature 
of 400 oC , a capillary voltage of 35 V and an auxiliary gas pressure of 1.0·105 Pa.  The 
stationary phase used was an RP C18 NUCLEODUR 100-3 (125 × 3 mm) column (Macherey 
&Nagel). The solvent system consisted of water containing 0.1% TFA (A) and 0.1% TFA in 
acetonitrile (B). HPLC-Method: flow rate 400 µL/min. The percentage of B started at an initial 
of 5%, was increased up to 100% during 16 min, kept at 100% for 2 min, and flushed back to 5% 
in 2 min. Melting points were determined using a Mettler FP1 melting point apparatus and are 
uncorrected. 
General synthetic methods and experimental details for some key compounds. 
General procedure for the enone synthesis. To a an ice-cooled solution of the 
appropriate ketone (10 mmol) in MeOH (50 mL), 10 % KOH aq. solution (30 ml) was added, 
followed by gradual addition of the corresponding aryl aldehyde (10 mmol). The mixture was 
left to attain room temperature and stirred overnight. The solid product was filtered and washed 
three times with MeOH/H2O mixture (5:3) and left to dry. In case of oily products the reaction 
mixture was extracted by CH2Cl2 (4 × 20 mL) and the combined organic layers were washed 
with water, filtered over anhydrous MgSO4, evaporated under reduced pressure and used without 
further purification. 
(E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-one (E1). Synthesized according to the 
procedure for the enone synthesis using pinacolone and 4-(tert-butoxy)benzaldehyde; yellow 
solid; yield: 2 g (77 %); mp 110-111 °C; 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 15.6 Hz, 
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1H), 7.49 – 7.45 (m, 2H), 7.00 – 6.95 (m, 3H), 1.36 (s, 9H), 1.20 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 204.22, 157.72, 142.55, 129.75, 129.21, 123.75, 119.28, 79.27, 43.16, 28.85, 26.38. 
General procedure for the pyrazoline synthesis. A mixture of the enone derivative (2 
mmol) and the corresponding phenylhydrazine hydrochloride (3 mmol) in 15 mL of anhydrous 
DMF was heated to 85 °C for 5 h under argon atmosphere. The reaction solution was cooled to 
room temperature and partitioned between 50 mL of diethyl ether and 20 mL of water. The 
organic layer was separated and washed with three 20 mL-portions of water. The aqueous layers 
were combined and extracted with three 20 mL-portions of diethyl ether. The organic layers 
were combined, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The 
residue was purified using column chromatography or used in the next step without further 
purification. 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1a). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for the 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); beige solid; yield: 
0.28 g (44%); mp111-112oC; 1H NMR (500 MHz, DMSO-d6) δ 9.35 (s, 1H), 7.24 – 7.19 (m, 
2H), 7.03 – 6.98 (m, 2H), 6.79 – 6.75 (m, 2H), 6.71 – 6.67 (m, 2H), 5.06 (dd, J = 11.6, 6.3 Hz, 
1H), 3.48 (dd, J = 17.5, 11.6 Hz, 1H), 2.66 (dd, J = 17.5, 6.4 Hz, 1H), 1.17 (s, 9H); 13C NMR 
(125 MHz, DMSO-d6) δ 159.87, 156.53, 144.57, 132.56, 131.18, 126.87, 115.58, 114.47, 108.65, 
62.71, 42.70,33.43, 27.88; MS (ESI): m/z= 329.18 (M+H)+. 
4-(3-(tert-butyl)-1-(3,4-difluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1s). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 3,4-difluorophenylphenylhydrazine hydrochloride according to the general 
procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light 
brown solid;  yield: 0.37 g (57%); mp 95.8 oC;1H NMR (500 MHz, DMSO-d6) δ 9.38 (s, 1H), 
7.13 (dt, J = 10.6, 9.2 Hz, 1H), 7.07 – 7.00 (m, 2H), 6.80 – 6.73 (m, 1H), 6.73 – 6.68 (m, 2H), 
6.55 – 6.50 (m, 1H), 5.04 (dd, J = 11.5, 6.7 Hz, 1H), 3.48 (dd, J = 17.5, 11.5 Hz, 1H), 2.67 (dd, J 
= 17.5, 6.7 Hz, 1H), 1.17 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ 160.32, 156.61, 149.47 (dd, 
1JC-F = 241.8, 2JC-F = 13.2 Hz), 143.01 (dd, 3JC-F = 8.7, 4JC-F =1.2 Hz), 142.15 (dd, 1JC-F = 236.1, 
2JC-F =11.8 Hz), 132.40, 126.98, 117.28 (d, 2JC-F = 17.2 Hz), 115.63, 108.07 (dd, 3JC-F = 5.4, 4JC-F 
=2.7 Hz), 101.16 (d, 2JC-F = 21.8 Hz), 63.20, 42.86, 33.42, 27.84; MS (ESI):m/z= 330.91 (M+H)+. 
General procedure for the ether dealkylation. A 1 M BBr3 solution in CH2Cl2 (3-9 
equiv) was added dropwise via syringe under nitrogen to a stirred solution of the methyl/ethyl 
ether derivative (1 mmol, 1 equiv) in CH2Cl2 at -78 °C. Then the reaction was maintained at -78 
°C for 1 hour, after that allowed to reach room temperature and stirred for an additional 20 hours. 
The mixture was cooled to 0 °C and H2O was carefully added (15-25 mL). The product was then 
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repeatedly extracted with EtOAc and the organic layers were dried over anhydrous Na2SO4. 
Upon solvent removal the residue was purified by column chromatography. 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-chlorophenol (4e). The 
title compound was prepared by demethylation of 3-(tert-butyl)-5-(3-chloro-4-methoxyphenyl)-
1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (3e) using BBr3 (3 equiv) according to the general 
procedure for ether dealkylation. The product was purified by CC (CH2Cl2/hexane 4:1); off-
white solid;  yield: 0.18 g (51%); mp 134-136oC; 1H NMR (500 MHz, DMSO-d6) δ 10.14 (s, 
1H), 7.18 (d, J = 2.1 Hz, 1H), 7.15 – 7.11 (m, 2H), 6.96 (dt, J = 6.7, 3.4 Hz, 1H), 6.92 – 6.88 (m, 
1H), 6.85 – 6.80 (m, 2H), 5.10 (dd, J = 11.5, 6.4 Hz, 1H), 3.48 (dd, J = 17.6, 11.6 Hz, 1H), 2.69 
(dd, J = 17.6, 6.4 Hz, 1H), 1.16 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.99, 152.21, 
144.12, 134.11, 128.48, 127.17, 125.36, 121.37, 119.74, 117.08, 114.03, 62.25, 42.58, 33.42, 
27.85; MS (ESI): m/z = 362.65 (M+H)+. 
 
5-(3-(tert-butyl)-1-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-fluorophenol (4f). The 
title compound was prepared by demethylation of 3-(tert-butyl)-1-(3-chlorophenyl)-5-(4-fluoro-
3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3f) using BBr3 (3 equiv) according to the general 
procedure for ether dealkylation. The product was purified by CC (CH2Cl2/hexane 4:1); buff 
solid; yield: 0.23 g (66%); mp 101-102.5oC; 1H NMR (500 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.12 
– 7.05 (m, 2H), 6.88 (t, J = 2.1 Hz, 1H), 6.78 (dd, J = 8.5, 2.1 Hz, 1H), 6.71 – 6.63 (m, 3H), 5.15 
(dd, J = 11.7, 6.0 Hz, 1H), 3.51 (dd, J = 17.6, 11.7 Hz, 1H), 2.69 (dd, J = 17.6, 6.0 Hz, 1H), 1.17 
(s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.47, 150.18 (d, 1JC-F = 240.5 Hz), 146.33, 145.22 
(d, 2JC-F = 12.4 Hz), 138.88, 133.38, 130.33, 117.09, 116.59 (d, 3JC-F = 6.6 Hz), 116.38 (d, 2JC-F = 
18.4 Hz), 114.52, 111.81, 110.82,  62.23, 42.53, 33.45, 27.84; MS (ESI): m/z = 346.89 (M+H)+. 
4-(1-(4-chlorophenyl)-3-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzene-1,2-diol 
(4g). The title compound was prepared by demethylation of 1-(4-chlorophenyl)-5-(3,4-
dimethoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3g) using BBr3 (9 equiv) 
according to the general procedure for ether the dealkylation. The product was purified by CC 
(CH2Cl2/MeOH 99:1); beige solid; yield: 0.31 g (82%); mp163-164oC; 1H NMR (500 MHz, 
DMSO-d6) δ 10.20 (s, 1H), 8.74 (s, 1H), 8.67 (s, 1H), 7.21 (dd, J = 7.8, 1.5 Hz, 1H), 7.05 (dt, J = 
16.9, 4.9 Hz, 1H), 7.02 – 6.98 (m, 2H), 6.75 (dd, J = 8.2, 0.8 Hz, 1H), 6.72 – 6.66 (m, 3H), 6.46 
(d, J = 8.0 Hz, 1H), 6.42 – 6.33 (m, 2H), 5.04 (dd, J = 12.0, 6.3 Hz, 1H), 3.75 (dd, J = 17.8, 12.1 
Hz, 1H), 3.01 (dd, J = 17.8, 6.3 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.17, 150.59, 
145.72, 144.85, 142.48, 132.49, 130.50, 128.76, 128.16, 122.51, 119.56, 116.91, 116.58, 116.09, 
115.87, 114.30, 112.69, 61.85, 44.08; MS (ESI): m/z= 380.74 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-fluorophenol 
(4h). The title compound was prepared by demethylation of 1-(3-chlorophenyl)-5-(3-fluoro-4-
methoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3h) using BBr3 (6 equiv) 
Results 
61 
 
according to the general procedure for the ether dealkylation. The product was purified by CC 
(CH2Cl2); beige solid; yield: 0.18 g (49%) ; mp165-167oC; 1H NMR (500 MHz, DMSO-d6) δ 
10.32 (s, 1H), 9.89 (s, 1H), 7.48 (dd, J = 7.8, 1.6 Hz, 1H), 7.29 (ddd, J = 8.3, 7.3, 1.6 Hz, 1H), 
7.21 (dd, J = 11.0, 5.3 Hz, 1H), 7.12 – 7.07 (m, 1H), 7.00 – 6.89 (m, 5H), 6.85 (ddd, J = 8.4, 2.2, 
0.8 Hz, 1H), 6.79 (ddd, J = 7.9, 2.0, 0.8 Hz, 1H), 5.41 (dd, J = 12.0, 6.2 Hz, 1H), 4.01 (dd, J = 
17.9, 12.0 Hz, 1H),  3.29 (dd, J = 17.8, 6.2 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.21, 
151.01 (d, 1JC-F = 241.9 Hz), 150.98, 144.79, 144.28 (d, 2JC-F = 12.0 Hz), 133.62, 132.86 (d, 3JC-F 
= 5.0 Hz), 130.70 (d, 3JC-F = 6.3 Hz), 128.33,124, 122.05 (d, 4JC-F = 3.0 Hz), 119.55, 118.47, 
118.30, 116.61, 116.18, 113.83 (d, 2JC-F = 18.8 Hz), 112.28, 111.47, 61.12, 44.12; MS (ESI): 
m/z= 382.67 (M+H) +. 
4-(1-(3-chlorophenyl)-5-(3-fluoro-4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)benzene-
1,3-diol (4k). The title compound was prepared by demethylation of 1-(3-chlorophenyl)-3-(2,4-
dimethoxyphenyl)-5-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3k) using BBr3 (9 
equiv) according to the general procedure for the ether dealkylation. The product was purified by 
CC (CH2Cl2/MeOH 99:1); beige solid; yield: 0.22 g (55%); mp183-184oC; 1H NMR (500 MHz, 
DMSO-d6) δ 10.41 (s, 1H), 9.89 (d, J = 17.4 Hz, 2H), 7.28 – 7.23 (m, 1H), 7.21 – 7.15 (m, 1H), 
7.07 (dd, J = 9.9, 3.1 Hz, 1H), 6.93 – 6.86 (m, 3H), 6.79 (ddd, J = 8.4, 2.2, 0.8 Hz, 1H),6.75 
(ddd, J = 7.9, 2.0, 0.8 Hz, 1H), 6.37 (dt, J = 8.3, 2.2 Hz, 2H), 5.32 (dd, J = 11.8, 6.1 Hz, 1H), 
3.94 (dd, J = 17.7, 11.8 Hz, 1H), 3.21 (dd, J = 17.7, 6.1 Hz, 1H). 13C NMR (125 MHz, DMSO-
d6) δ 160.14, 158.05, 151.73, 150.99 (d, 1JC-F = 241.8 Hz), 145.12, 144.22 (d, 2JC-F = 12.1 Hz), 
133.59, 132.99 (d, 3JC-F = 5.0 Hz), 130.62, 129.58, 122.02 (d, 4JC-F = 2.9 Hz), 118.28, 118.02, 
113.80 (d, 2JC-F = 18.9 Hz), 111.99, 111.22, 108.27, 107.71, 102.55, 60.78, 44.07; MS (ESI):m/z= 
398.62 (M+H) +. 
General reduction procedure. A suspension of the nitro derivative (1 mmol) and 
SnCl2·2H2O (5 mmol, 1.12 g) in MeOH (40 mL) was heated to reflux for 2 h under argon 
atmosphere. Then MeOH was evaporated under reduced pressure and the residue was dissolved 
in EtOAc (100 mL) and alkalinized with 100 mL aqueous NaHCO3 solution. The resulting 
mixture was filtered under vacuum followed by separation of organic and water layers. The 
aqueous layer was extracted with two 20 mL-portions of EtOAc, the organic fractions were 
combined, dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue 
was purified using column chromatography. 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6a). The title 
compound was prepared by reduction of 3-(tert-butyl)-1-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-
dihydro-1H-pyrazole according to the general reduction procedure. The product was purified by 
CC (CH2Cl2); buff solid; yield: 0.28 g (87%); mp 131-132oC; 1H NMR (500 MHz, DMSO-d6) δ 
7.13 – 7.07 (m, 2H), 6.89 – 6.85 (m, 2H), 6.85 – 6.80 (m, 2H), 6.51 – 6.46 (m, 2H), 5.00 (s, 2H), 
4.95 (dd, J = 11.5, 6.5 Hz, 1H), 3.44 (dd, J = 17.5, 11.6 Hz, 1H), 2.64 (dd, J = 17.5, 6.6 Hz, 1H), 
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1.17 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.73, 147.86, 144.42, 129.27, 128.28, 126.43, 
120.94, 114.14, 113.97, 63.16, 42.73, 33.42, 27.90 ; MS (ESI): m/z= 327.77 (M+H) +. 
N-(4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenyl)acetamide (7a). 
Acetylchloride (0.14 mL, 2 mmol) was added gradually to a stirred solution of 6a (0.33 g, 1 
mmol) and Na2CO3 (0.16 g, 1.5 mmol) in acetone (40 mL) under ice cooling. The mixture was 
stirred at room temperature under a nitrogen atmosphere for 2h. After pouring to 100 mL of 
water ice mixture, the solid obtained was separated by filtration followed by CC purification 
(CH2Cl2/MeOH 98:2) to give the title compound as an off-white solid; yield: 0.30 g (81%), 
mp119-120°C; 1H NMR (500 MHz, DMSO-d6) δ 9.91 (s, 1H), 7.53 – 7.49 (m, 2H), 7.17 – 7.07 
(m, 4H), 6.83 – 6.79 (m, 2H), 5.11 (dd, J = 11.6, 6.6 Hz, 1H), 3.51 (dd, J = 17.5, 11.7 Hz, 1H), 
2.68 (dd, J = 17.5, 6.6 Hz, 1H), 2.01 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 168.16, 159.85, 
144.25, 138.42, 136.88, 128.41, 126.10, 121.24, 119.50, 113.98, 62.92, 42.64, 33.43, 27.87, 
20.73; MS (ESI): m/z= 369.75 (M+H) +. 
1-(3-chlorophenyl)-5-(3-fluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4-methyl-4,5-
dihydro-1H-pyrazole (8). To a three-necked flask containing 20 mL of dry THF 0.6 mL of a 
lithium diisopropylamide (LDA) solution (2M in THF/n-heptane/ethylbenzene) was added under 
argon atmosphere, followed by a solution of 411 mg (1 mmol) of 1-(3-chlorophenyl)-5-(3-
fluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3h) in 10 mL of THF 
via syringe at -78 °C. The mixture was stirred for 1h. Afterward iodomethane (0.093 mL, 1.5 
mmol) was added to the solution, the resulting mixture was stirred at -78 °C for 30 min, then left 
to attain room temperature and stirred for 20h. The reaction was quenched with 10 mL of brine, 
the aqueous layer was separated and extracted with two10 mL-portions of CH2Cl2, the combined 
organic layer was dried over MgSO4 and concentrated under reduced pressure. The residue was 
purified by CC (CH2Cl2/hexane, 1:3) to afford (8); off-white solid; yield : 0.26 g (61%); mp 170-
171 °C; 1H NMR (500 MHz, CDCl3) δ 7.95 – 7.91 (m, 1H), 7.45 – 7.39 (m, 1H), 7.25 – 7.22 (m, 
1H), 7.17 – 7.14 (m, 1H), 7.14 – 7.07 (m, 3H), 7.02 – 6.97 (m, 2H), 6.88 – 6.84 (m, 1H), 6.83 – 
6.78 (m, 1H), 4.68 (d, J = 7.2 Hz, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 3.83 – 3.76 (m, 1H), 1.34 (d, J 
= 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 157.15, 152.98, 152.77 (d, 1JC-F = 247.0 Hz), 
147.09 (d, 2JC-F = 10.8 Hz), 146.06, 134.88 (d, 3JC-F = 5.3 Hz), 134.73, 131.74, 130.36, 130.05, 
129.79, 126.24, 121.39 (d, 4JC-F = 3.5 Hz), 120.97, 118.80, 113.89, 113.61 (d, 2JC-F = 18.9 Hz) , 
113.58, 111.28 (d, 3JC-F = 9.8 Hz), 71.81, 56.26, 55.44, 53.58, 18.19;  m/z= 424.81 (M+H) +. 
3-(tert-butyl)-5-(3-chloro-4-methoxyphenyl)-1-(4-chlorophenyl)-1H-pyrazole (10). A mixture 
of 0.37 g (1 mmol) of 3-(tert-butyl)-5-(3-chloro-4-methoxyphenyl)-1-(4-chlorophenyl)-4,5-
dihydro-1H-pyrazole (3e) and 0.34 g (1.5 mmol) of dichlorodicyanoquinone (DDQ) in 10 mL of 
benzene was heated to reflux for 5h. The mixture was cooled to room temperature and filtered 
through a plug of silica gel wetted with diethyl ether. The filtrate was concentrated under 
reduced  pressure and the residue was purified by CC (CH2Cl2/hexane 1:3) to give the title 
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compound as a white solid (95%, 0.35 g), mp 182-183 °C; 1H NMR (500 MHz, CDCl3) δ 7.34 – 
7.31 (m, 1H), 7.30 – 7.21 (m, 4H), 6.97 (dd, J = 8.5, 2.2 Hz, 1H), 6.84 – 6.81 (m, 1H), 6.31 (s, 
1H), 3.90 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 162.89, 154.85, 141.56, 138.68, 132.57, 
130.38, 129.00, 128.17, 126.19, 124.11, 122.55, 111.77, 104.97, 56.14, 32.23, 30.46; MS (ESI): 
m/z = 374.67 (M+H) +. 
BIOLOGICAL ASSAYS  
Fluorescence probing of compound–induced conformational changes  
Potential effects of the compounds on the protein conformation were probed using the 
SYPRO Orange dye, which strongly increases its fluorescence intensity upon binding to solvent 
exposed hydrophobic areas of proteins.54 Assays were performed in a final reaction volume of 25 
µL, containing 50 mM Tris-HCl, pH 7.4, 140 mM NaCl, 1 mM DTT, 0.8 times concentrated 
SYPRO Orange (Molecular Probes), 0.5 µM PKCζ, and compounds in the indicated 
concentrations. Control experiments were set up in the same manner except that PKCζ was 
omitted. Measurements were done in black 384 well plates (485 nm excitation/585 nm emission) 
after heating of the samples for 4 min at 37°C  in a PolarStar plate reader (BMG Labtech, 
Germany). To correct for fluorescence emission triggered by direct interaction between the 
compounds and the dye, the control values obtained in the absence of PKCζ protein were 
subtracted from the fluorescence units generated in the presence of PKCζ. 
Protein Kinases and Kinase Assays  
PKCζ was prepared and purified as described before.37 The cell-free assay was done 
basically as previously described except that reaction samples were incubated for 4 min at 37°C 
before the phosphorylation reactions were started by the addition of γ32P-ATP/Mg2+
.
37,38
 Similar 
conditions were used for the PKCι and mutant PKCζ assays. 
HEK293 cells transfection experiments  
To investigate the effect of 4f on the activity of cellular PKCζ, HEK293 cells were seeded 
in 6-well plates and, at 80% confluency, transfected using GST-PKCζ wt and GST-
PKCζ[V297L] mutant expression plasmids essentially as described.37 The next day, the medium 
was exchanged to DMEM containing 0.1% FCS, and the test compounds were added in different 
concentrations as indicated. After 6h in the incubator, cells were stimulated by the addition of 
IGF-I (50 ng/ml final concentration) for 30 min at 37°C. The cells were then lysed, and the 
recombinant PKCζ was isolated and purified using glutathione sepharose beads as previously 
described.37 Equal amounts of eluted GST-PKCζ (50 ng per reaction) were assayed for 
enzymatic activity as described using myelin basic protein as a substrate.38 
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Reporter Gene Assay 
The human histocytic lymphoma cell line U937 was transfected with a NF-κB reporter 
gene plasmid and the assay performed exactly as previously described.37 
Nitrite assay (Griess assay)  
RAW 264.7 cells were seeded in 96-well plates (8•104 cells/200µL DMEM supplemented 
with 10% FBS and 1% antibiotics), cultured for two days under 5% CO2 at 37°, and then 
incubated with or without LPS in the absence or presence of the test compounds or DMSO 
control for 20h. As a parameter of NO synthesis, nitrite the stable oxidation product was 
quantified photometrically after its reaction to an azo-dye in the supernatant according to Green 
et al.65 Briefly, 100 µL of cell culture supernatant were removed and combined with each 90µL 
of 1 % sulfanilamide in 5% phosphoric acid, and 90µL 0.1 % N-(1-naphthyl)ethylenediamine 
dihydrochloride in water in a 96-well plate. Samples were then measured at 550 nm using a in a 
PolarStar plate reader (BMG Labtech, Germany). In addition, a background measurement was 
done at 620 nm and the values obtained were subtracted. Nitrite concentrations in the 
supernatants were determined by comparison with a sodium nitrite standard curve. Experiments 
were performed at least four times in triplicates. 
To correct for any potential effects on the cell vitality, an MTT assay was performed in 
parallel each time using the same cell line (cf. Supplementary Table S3). 
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SUPPORTING INFORMATION  
1) Experimental procedures and Analytical data 
4-(3-(tert-butyl)-1-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1b). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 4-fluorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yellowish white 
solid; yield: 0.34 g (55%); mp 111-112 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 7.08 
– 7.03 (m, 2H), 6.96 – 6.89 (m, 2H), 6.85 – 6.79 (m, 2H), 6.72 – 6.68 (m, 2H), 4.96 (dd, J = 
11.5, 7.5 Hz, 1H), 3.46 (dd, J = 17.4, 11.5 Hz, 1H), 2.64 (dd, J = 17.4, 7.6 Hz, 1H), 1.17 (s, 9H); 
13C NMR (125 MHz, DMSO-d6) δ 159.18, 156.48, 155.41 (d, 1JC-F = 233.8 Hz), 142.76, 132.88, 
127.02, 115.55, 115.03 (d, 2JC-F = 22.1 Hz), 113.86 (d, 3JC-F = 7.4 Hz), 63.85, 42.81, 33.37, 
27.91; MS (ESI): m/z = 311.01 (M-1)+. 
4-(1-(4-bromophenyl)-3-(tert-butyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1c). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 4-bromophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); off-white solid; 
yield: 0.45 g (61%); mp 125-126 oC; 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.28 (m, 2H), 7.27 – 
7.23 (m, 2H), 7.07 – 7.02 (m, 2H), 6.99 – 6.94 (m, 2H), 5.08 (dd, J = 11.6, 7.7 Hz, 1H), 3.61 (dd, 
J = 17.2, 11.7 Hz, 1H), 2.91 (dd, J = 17.2, 7.7 Hz, 1H), 1.40 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 159.44, 154.93, 144.82, 134.78, 128.58, 127.18, 123.18, 115.91, 114.40, 64.47, 43.27, 
33.82, 28.21; MS (ESI): m/z = 372.71 (M+H)+. 
4-(3-(tert-butyl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1d). 
The title compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-
1-en-3-one (E1) and 4-(trifluoromethyl)phenylhydrazine hydrochloride according to the general 
procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light 
brown solid; yield: 0.35 g (48%); mp 121-122 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.38 (s, 
1H), 7.39 (d, J = 8.5 Hz, 2H), 7.03 – 6.98 (m, 2H), 6.93 (d, J = 8.6 Hz, 2H), 6.75 – 6.65 (m, 2H), 
5.21 (dd, J = 11.6, 5.4 Hz, 1H), 3.53 (dd, J = 17.7, 11.7 Hz, 1H), 2.71 (dd, J = 17.7, 5.5 Hz, 1H), 
1.18 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 161.32, 156.62, 147.43, 132.26, 126.76, 125.96, 
125.07 (q, 1JC-F = 270.2 Hz), 116.96 (q, 2JC-F = 31.8 Hz), 115.66, 111.79, 61.97, 42.65, 33.51, 
27.83; MS (ESI): m/z = 362.74 (M+H)+. 
4-(3-(tert-butyl)-1-(p-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1e). The title compound was 
prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-one (E1) and p-
tolylhydrazine hydrochloride according to the general procedure for pyrazoline synthesis. The 
product was purified by CC (CH2Cl2/hexane 4: 1); tan solid; yield: 0.24 g (40%); mp 125.9 oC; 
1H NMR (500 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.06 – 7.00 (m, 2H), 6.88 (d, J = 8.2 Hz, 2H), 
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6.78 – 6.72 (m, 2H), 6.71 – 6.65 (m, 2H), 4.95 (dd, J = 11.5, 7.4 Hz, 1H), 3.43 (dd, J = 17.3, 11.6 
Hz, 1H), 2.61 (dd, J = 17.3, 7.4 Hz, 1H), 2.12 (s, 3H), 1.16 (s, 9H); 13C NMR (125 MHz, 
DMSO-d6) δ 158.34, 156.36, 143.76, 133.24, 128.97, 126.97, 126.25, 115.45, 112.95, 63.55, 
42.59, 33.34, 27.96, 20.03; MS (ESI): m/z = 308.74 (M+H)+. 
4-(3-(tert-butyl)-1-(4-(isopropyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1f). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 4-isopropylphenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); beige solid; yield: 
0.19 g (28%); mp 162-163  oC; 1H NMR (500 MHz, DMSO-d6) δ 9.32 (s, 1H), 7.10 – 7.04 (m, 
2H), 6.97 – 6.90 (m, 2H), 6.81 – 6.74 (m, 2H), 6.72 – 6.67 (m, 2H), 4.91 (dt, J = 22.8, 11.4 Hz, 
1H), 3.43 (dd, J = 17.3, 11.5 Hz, 1H), 2.70 (hept, J = 6.9 Hz, 1H), 2.60 (dd, J = 17.3, 7.9 Hz, 
1H), 1.16 (s, 9H), 1.10 (d, J = 6.9 Hz, 6H); 13C NMR (125 MHz, DMSO-d6) δ 158.39, 156.40, 
144.17, 137.77, 133.37, 126.98, 126.26, 115.49, 112.90, 63.75, 42.68, 33.34, 32.46, 27.96, 24.09, 
24.06; MS (ESI): m/z = 337.08 (M+H)+. 
4-(3-(tert-butyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid (1g). The 
title compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-
en-3-one (E1) and 4-hydrazinobenzoicacid  hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/MeOH 98:2); white solid; yield: 
0.26 g (39%) ; mp 259.1-261 oC; 1H NMR (500 MHz, DMSO-d6) δ 12.14 (s, 1H), 9.37 (s, 1H), 
7.66 (d, J = 9.1 Hz, 2H), 7.02 – 6.97 (m, 2H), 6.89 – 6.81 (m, 2H), 6.72 – 6.67 (m, 2H), 5.23 (dd, 
J = 11.6, 5.1 Hz, 1H), 3.53 (dd, J = 17.7, 11.7 Hz, 1H), 2.70 (dd, J = 17.7, 5.1 Hz, 1H), 1.18 (s, 
9H); 13C NMR (125 MHz, DMSO-d6) δ 167.28, 161.45, 156.59, 147.88, 132.43, 130.67, 126.74, 
118.72, 115.63, 111.30, 61.80, 42.58, 33.53, 27.84; MS (ESI): m/z = 338.87 (M+H)+. 
4-(3-(tert-butyl)-1-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1h). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yellowish white 
solid; yield: 0.2 g (31%); mp 143.3-145.2 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.37 (s, 1H), 
7.09 – 7.04 (m, 1H), 7.04 – 7.00 (m, 2H), 6.88 (t, J = 2.1 Hz, 1H), 6.73 – 6.68 (m, 3H), 6.63 
(ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 5.10 (dd, J = 11.6, 6.1 Hz, 1H), 3.49 (dd, J = 17.6, 11.6 Hz, 1H), 
2.67 (dd, J = 17.6, 6.2 Hz, 1H), 1.17 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.34, 156.57, 
146.53, 133.29, 132.54, 130.20, 126.85, 116.88, 115.64, 111.85, 110.91, 62.55, 42.67, 33.46, 
27.86; MS (ESI): m/z = 328.86 (M+H)+. 
4-(3-(tert-butyl)-1-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1i). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 3-fluoropheylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light brown solid;  
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yield: 0.21 g (35%) ; mp  140.4 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.36 (s, 1H), 7.12 – 6.96 
(m, 3H), 6.74 – 6.66 (m, 2H), 6.62 – 6.55 (m, 2H), 6.44 – 6.34 (m, 1H), 5.08 (dd, J = 11.6, 6.3 
Hz, 1H), 3.49 (dd, J = 17.6, 11.7 Hz, 1H), 2.67 (dd, J = 17.6, 6.3 Hz, 1H), 1.17 (s, 9H); 13C 
NMR (125 MHz, DMSO-d6) δ 162.81 (d, 1JC-F = 239.7 Hz), 160.10, 156.56, 147.11 (d, 3JC-F = 
11.1 Hz), 132.69, 130.14 (d, 3JC-F = 10.1 Hz), 126.86, 115.61, 108.43, 103.61 (d, 2JC-F = 21.3 
Hz), 99.14 (d, 2JC-F = 26.5 Hz), 62.72, 42.69, 33.43, 27.86; MS (ESI): m/z = 312.10 (M+). 
4-(3-(tert-butyl)-1-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1j). The 
title compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-
en-3-one (E1) and 3-(trifluoromethyl)pheylhydrazine hydrochloride according to the general 
procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); 
yellow solid;  yield: 0.35 g (49%); mp 130.5 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.37 (s, 1H), 
7.27 (t, J = 7.9 Hz, 1H), 7.16 (s, 1H), 7.06 – 7.02 (m, 2H), 6.98 (dd, J = 8.3, 2.1 Hz, 1H), 6.93 – 
6.89 (m, 1H), 6.73 – 6.68 (m, 2H), 5.16 (dd, J = 11.6, 6.2 Hz, 1H), 3.52 (dd, J = 17.6, 11.6 Hz, 
1H), 2.71 (dd, J = 17.6, 6.2 Hz, 1H), 1.19 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.70, 
156.60, 145.54, 132.33, 129.89, 129.49 (q, 2JC-F = 31.2 Hz), 126.91, 124.33 (q, 1JC-F = 272.3 Hz), 
115.66, 115.45, 113.37, 108.38 , 62.53, 42.69, 33.48, 27.84; MS (ESI): m/z = 362.84 (M+H)+. 
4-(3-(tert-butyl)-1-(m-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1k). The title compound 
was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-one (E1) and 
m-tolylhydrazine hydrochloride according to the general procedure for pyrazoline synthesis. The 
product was purified by CC (CH2Cl2/hexane 4:1); yellowish white solid; yield: 0.25 g (41%); mp 
119.3-121.2 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.06 – 7.00 (m, 2H), 6.95 – 6.89 
(m, 1H), 6.75 (s, 1H), 6.71 – 6.67 (m, 2H), 6.56 (dd, J = 8.2, 2.1 Hz, 1H), 6.46 – 6.42 (m, 1H), 
5.00 (dd, J = 11.6, 6.8 Hz, 1H), 3.45 (dd, J = 17.4, 11.7 Hz, 1H), 2.62 (dd, J = 17.4, 6.8 Hz, 1H), 
2.15 (s, 3H), 1.17 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 158.59, 156.36, 145.66, 137.50, 
133.34, 128.39, 126.87, 118.52, 115.49, 113.36, 109.84, 63.01, 42.56, 33.36, 27.96, 21.42; MS 
(ESI): m/z = 308.94 (M+H)+. 
4-(3-(tert-butyl)-1-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1l). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light brown solid;  
yield: 0.33 g (51%); mp 162-163 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.25 (s, 1H), 7.28 (dd, J 
= 8.1, 1.5 Hz, 1H), 7.19 (dd, J = 7.9, 1.4 Hz, 1H), 7.11 – 7.05 (m, 1H), 6.90 (d, J = 8.5 Hz, 2H), 
6.83 (td, J = 7.8, 1.5 Hz, 1H), 6.53 (d, J = 8.5 Hz, 2H), 5.46 (dd, J = 10.9, 4.7 Hz, 1H), 3.43 – 
3.35 (m, 1H), 2.88 (dd, J = 17.2, 4.7 Hz, 1H), 1.22 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 
161.25, 156.47, 143.68, 131.40, 129.72, 127.51, 126.94, 123.63, 123.28, 122.66, 114.94, 65.06, 
41.50, 33.60, 27.93; MS (ESI): m/z = 328.86 (M+H)+. 
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4-(3-(tert-butyl)-1-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1m). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2-fluorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light brown solid;  
yield: 0.25 g (41%); mp 147.3 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.26 (s, 1H), 7.34 (td, J = 
8.3, 1.7 Hz, 1H), 6.98 – 6.88 (m, 4H), 6.73 (dddd, J = 8.1, 7.3, 4.6, 1.7 Hz, 1H), 6.59 – 6.54 (m, 
2H), 5.25 (dt, J = 11.0, 3.9 Hz, 1H), 3.40 (dd, J = 17.1, 11.0 Hz, 1H), 2.79 (dd, J = 17.2, 4.3 Hz, 
1H), 1.20 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.50, 156.45, 150.79 (d,1JC-F = 242.7 
Hz), 134.19 (d, 2JC-F = 9.3 Hz), 132.21, 127.12, 124.21 , 120.73, 119.22, 115.60 (d, 2JC-F = 20.0 
Hz), 115.06, 65.18, 41.91, 33.51, 27.86; MS (ESI): m/z = 312.93 (M+H)+. 
4-(3-(tert-butyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1n). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2,4-dichlorophenylhydrazine  hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); off-white solid; 
yield: 0.38 g (52%); mp 137.1-138.5 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 7.32 – 
7.27 (m, 2H), 7.15 (dt, J = 4.1, 2.1 Hz, 1H), 6.91 – 6.84 (m, 2H), 6.56 – 6.52 (m, 2H), 5.49 (dd, J 
= 10.9, 4.2 Hz, 1H), 3.41 (dd, J = 17.3, 10.9 Hz, 1H), 2.90 (dd, J = 17.3, 4.2 Hz, 1H), 1.22 (s, 
9H); 13C NMR (125 MHz, DMSO-d6) δ 162.08, 156.59, 142.94, 131.18, 128.96, 127.46, 127.03, 
125.92, 123.86, 123.59, 115.04, 64.93, 41.59, 33.64, 27.88; MS (ESI): m/z = 362.82 (M+H)+. 
4-(3-(tert-butyl)-1-(2,4-difluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1o), The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2,4-difluorophenylhydrazine  hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yellowish white 
solid;  yield: 0.22 g (33%); mp 163-164 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.29 (s, 1H), 7.29 
(td, J = 9.3, 6.1 Hz, 1H), 6.99 (ddd, J = 12.0, 9.0, 2.9 Hz, 1H), 6.93 – 6.88 (m, 2H), 6.88 – 6.82 
(m, 1H), 6.59 – 6.54 (m, 2H), 5.15 (ddd, J = 10.8, 4.7, 3.4 Hz, 1H), 3.38 (dd, J = 17.1, 10.9 Hz, 
1H), 2.81 (dd, J = 17.1, 4.9 Hz, 1H), 1.19 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 161.06, 
156.55, 156.21 (dd, 1JC-F = 239.3, 3JC-F =11.2 Hz), 150.95 (dd, 1JC-F = 246.7, 3JC-F =12.2 Hz), 
131.65, 131.32 (dd, 2JC-F = 9.7, 4JC-F= 3.1 Hz), 127.34, 120.21 (dd, 3JC-F = 9.0, 4.9 Hz), 115.07, 
110.71 (dd, 2JC-F  = 21.5, 4JC-F =3.3 Hz), 104.02 (dd, 2JC-F = 26.4, 24.4 Hz), 65.70, 41.80, 33.53, 
27.85; MS (ESI): m/z = 330.80 (M+H)+. 
4-(3-(tert-butyl)-1-(2,4-dimethylphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1p). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2,4-dimethylphenylhydrazine  hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); light brown solid; 
yield: 0.26 g (41%) ; mp 77-79 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.26 (s, 1H), 7.10 – 7.06 
(m, 2H), 6.86 – 6.83 (m, 1H), 6.78 – 6.76 (m, 2H), 6.63 – 6.59 (m, 2H), 4.87 (t, J = 10.6 Hz, 
1H), 3.24 (dd, J = 16.5, 10.1 Hz, 1H), 2.65 (dd, J = 16.5, 11.1 Hz, 1H), 2.18 (s, 3H), 2.13 (s, 3H), 
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1.16 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.41, 156.44, 142.97, 131.32,  131.18, 130.79, 
128.84, 127.91, 126.04, 118.81, 115.02, 66.78, 41.49, 33.46, 27.97, 20.20, 19.56; MS (ESI): m/z 
= 323.02 (M+H)+. 
4-(3-(tert-butyl)-1-(2,6-dichlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1q). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2,6-dichlorophenylhydrazine  hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); off-white solid; 
yield: 0.24 g (33%) ; mp 172-173 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.30 (s, 1H), 7.33 – 7.29 
(m, 2H), 7.15 – 7.10 (m, 1H), 7.09 – 7.04 (m, 2H), 6.62 – 6.57 (m, 2H), 5.15 (t, J = 10.6 Hz, 
1H), 3.35 (dd, J = 17.2, 11.1 Hz, 1H), 2.93 (dd, J = 17.2, 10.1 Hz, 1H), 1.20 (s, 9H); 13C NMR 
(125 MHz, DMSO-d6) δ 159.02, 156.83, 139.82, 134.06, 130.41, 129.34, 128.87, 127.86, 114.77, 
67.20, 40.73, 33.43, 27.87; MS (ESI): m/z =  362.79 (M+H)+. 
4-(3-(tert-butyl)-1-(3-chloro-4-fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1r). The 
title compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-
en-3-one (E1) and 3-chloro-4-fluorophenylhydrazine hydrochloride according to the general 
procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); brown 
solid; yield: 0.23 g (34%) ; mp 94.2 oC; 1H NMR (500 MHz, DMSO) δ 9.38 (s, 1H), 7.12 (t, J = 
9.2 Hz, 1H), 7.05 – 7.01 (m, 2H), 6.93 (dd, J = 6.5, 2.8 Hz, 1H), 6.73 – 6.67 (m, 3H), 5.06 (dd, J 
= 11.5, 6.6 Hz, 1H), 3.48 (dd, J = 17.5, 11.5 Hz, 1H), 2.68 (dd, J = 17.5, 6.7 Hz, 1H), 1.17 (s, 
9H); 13C NMR (125 MHz, DMSO-d6) δ 160.44, 156.61, 150.08 (d, 1JC-F = 236.4 Hz), 142.99 (d, 
4JC-F = 1.8 Hz), 132.31, 126.98, 119.21 (d, 2JC-F = 18.3 Hz), 116.75 (d, 2JC-F = 21.6 Hz), 115.65, 
113.30, 112.21 (d, 3JC-F = 6.3 Hz), 63.13, 42.84, 33.44, 27.85; MS (ESI): m/z = 346.91 (M+H)+. 
4-(3-(tert-butyl)-1-(2,3,4-trifluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (1t). The title 
compound was prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-
one (E1) and 2,3,4-trifluorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); yellow solid; 
yield: 0.22 g ( 32%); mp 159-161 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.34 (s, 1H), 7.11 – 7.02 
(m, 2H), 6.94 – 6.89 (m, 2H), 6.63 – 6.58 (m, 2H), 5.24 – 5.18 (m, 1H), 3.42 (dd, J = 17.3, 11.0 
Hz, 1H), 2.82 (dd, J = 17.3, 4.8 Hz, 1H), 1.19 (s, 9H); MS (ESI): m/z = 348.99 (M+H)+. 
 
4-(3-(tert-butyl)-1-phenyl-4,5-dihydro-1H-pyrazol-5-yl)phenol (1u) . The title compound was 
prepared by reaction of (E)-1-(4-(tert-butoxy)phenyl)-4,4-dimethylpent-1-en-3-one (E1) and 
phenylhydrazine  hydrochloride according to the general procedure for pyrazoline synthesis. The 
product was purified by CC (CH2Cl2/hexane 4:1); yellowish white solid; yield: 0.23 g (39%) ; 
mp 175-176 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.33 (s, 1H), 7.11 – 6.99 (m, 4H), 6.87 – 6.80 
(m, 2H), 6.73 – 6.66 (m, 2H), 6.62 (tt, J = 7.3, 1.1 Hz, 1H), 5.01 (dd, J = 11.6, 7.0 Hz, 1H), 3.46 
(dd, J = 17.4, 11.6 Hz, 1H), 2.63 (dd, J = 17.4, 7.0 Hz, 1H), 1.17 (s, 9H); 13C NMR (125 MHz, 
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DMSO-d6) δ 158.83, 156.42, 145.70, 133.21, 128.55, 126.91, 117.64, 115.52, 112.66, 63.13, 
42.63, 33.38, 27.94; MS (ESI): m/z = 294.91 (M+H)+. 
4-(1-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)phenol (2a). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-phenylprop-2-en-1-one 
(E2) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yellow solid; yield: 
0.19 g (28%) ; mp 164-165 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.40 (s, 1H), 7.74 (dt, J = 8.3, 
1.8 Hz, 2H), 7.47 – 7.31 (m, 3H), 7.21 – 7.14 (m, 2H), 7.09 – 7.03 (m, 2H), 7.02 – 6.95 (m, 2H), 
6.75 – 6.67 (m, 2H), 5.36 (dd, J = 12.1, 6.1 Hz, 1H), 3.87 (dd, J = 17.5, 12.1 Hz, 1H), 3.08 (dd, J 
= 17.5, 6.2 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.70, 147.99, 143.07, 132.19, 132.15, 
128.81, 128.63, 128.55, 127.03, 125.74, 121.98, 115.69, 114.37, 62.73, 43.12; MS (ESI): m/z = 
348.71 (M+H)+. 
4-(1-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)phenol (2b). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-phenylprop-2-en-1-one 
(E2) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yield: light brown 
solid; 0.23 g (33%); mp 161.2-163.3 oC;1H NMR (500 MHz, DMSO-d6) δ 9.41 (s, 1H), 7.78 – 
7.74 (m, 2H), 7.46 – 7.36 (m, 3H), 7.16 – 7.12 (m, 1H), 7.11 – 7.05 (m, 3H), 6.87 (ddd, J = 8.4, 
2.2, 0.9 Hz, 1H), 6.75 – 6.66 (m, 3H), 5.40 (dd, J = 12.1, 5.9 Hz, 1H), 3.88 (dd, J = 17.5, 12.1 
Hz, 1H), 3.10 (dd, J = 17.5, 6.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.73, 148.56, 
145.39, 133.48, 132.12, 132.01, 130.37, 128.98, 128.65, 127.01, 125.88, 117.75, 115.73, 112.32, 
111.35, 62.51, 43.10; MS (ESI): m/z = 348.74 (M+H)+. 
2-(1-(4-chlorophenyl)-5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenol (2c) . The 
title compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(2-
hydroxyphenyl)prop-2-en-1-one (E3) and 4-chlorophenylhydrazine  hydrochloride according to 
the general procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/MeOH 
99:1); beige solid;  yield: 0.27 g (38%); mp 214.2 oC; 1H NMR (500 MHz, DMSO-d6) δ 10.41 (s, 
1H), 9.42 (s, 1H), 7.44 (dd, J = 7.8, 1.5 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.25 – 7.19 (m, 2H), 7.12 – 
7.08 (m, 2H), 6.97 (ddd, J = 7.8, 6.9, 1.0 Hz, 1H), 6.95 – 6.88 (m, 3H), 6.74 – 6.69 (m, 2H), 5.35 
(dd, J = 12.0, 6.4 Hz, 1H), 4.00 (dd, J = 17.7, 12.0 Hz, 1H), 3.24 (dd, J = 17.8, 6.5 Hz, 1H); 13C 
NMR (125 MHz, DMSO-d6) δ 156.80, 156.19, 150.61, 142.51, 131.77, 130.51, 128.77, 128.17, 
127.15, 122.59, 119.54, 116.59, 116.10, 115.73, 114.41, 61.79, 44.11; MS (ESI): m/z = 364.34 
(M)+. 
4-(1-(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2d). The 
title compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(2-
methoxylphenyl)prop-2-en-1-one (E4) and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2); tan 
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solid; yield: 0.31 g (41%) ; mp 205-206 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.37 (s, 1H), 7.87 
(dd, J = 7.8, 1.7 Hz, 1H), 7.39 – 7.34 (m, 1H), 7.19 – 7.14 (m, 2H), 7.10 – 7.03 (m, 3H), 7.00 (td, 
J = 7.7, 1.0 Hz, 1H), 6.98 – 6.93 (m, 2H), 6.72 – 6.68 (m, 2H), 5.28 (dd, J = 12.0, 6.2 Hz, 1H), 
3.92 (dd, J = 18.1, 12.0 Hz, 1H), 3.79 (s, 3H), 3.15 (dd, J = 18.1, 6.3 Hz, 1H); 13C NMR (125 
MHz, DMSO-d6) δ 157.29, 156.62, 147.28, 143.26, 132.39, 130.37, 128.51, 128.14, 126.95, 
121.76, 121.08, 120.64, 115.65, 114.31, 112.31, 62.69, 55.61, 46.50; MS (ESI): m/z = 378.82 
(M+H)+. 
4-(1-(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2e). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(2-ethoxylphenyl)prop-
2-en-1-one (E5) and 4-chlorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); yellowish white 
solid; yield: 0.19 g (25%) ; mp 194-196 oC; 1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 7.6 Hz, 
1H), 7.60 – 7.51 (m, 2H), 7.45 – 7.30 (m, 4H), 7.25 (dd, J = 14.2, 7.7 Hz, 2H), 7.14 (d, J = 8.3 
Hz, 1H), 7.10 – 6.98 (m, 2H), 5.37 (dd, J = 12.0, 7.0 Hz, 1H), 4.43 (q, J = 6.8 Hz, 2H), 4.29 (dd, 
J = 17.8, 12.1 Hz, 1H), 3.55 (dd, J = 17.9, 7.0 Hz, 1H), 1.64 (t, J = 6.9 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 156.41, 156.21, 155.02, 143.69, 130.81, 129.06, 128.65, 126.60, 125.80, 
122.47,120.73, 115.90, 114.47, 112.32, 109.15, 66.11, 63.89, 46.97, 14.94; MS (ESI): m/z = 
393.11 (M+H)+. 
4-(1-(4-chlorophenyl)-3-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2f) . The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(2-chlorophenyl)prop-2-
en-1-one (E6) and 4-chlorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 4:1); off-white solid; 
yield: 0.35 g (46%) ; mp 124-125 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.42 (s, 1H), 7.78 – 7.72 
(m, 1H), 7.55 – 7.47 (m, 1H), 7.44 – 7.32 (m, 2H), 7.23 – 7.15 (m, 2H), 7.11 – 7.04 (m, 2H), 
7.03 – 6.94 (m, 2H), 6.75 – 6.66 (m, 2H), 5.39 (dd, J = 12.1, 6.1 Hz, 1H), 4.00 (dd, J = 17.5, 12.1 
Hz, 1H), 3.20 (dd, J = 17.5, 6.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.77, 146.30, 
142.89, 131.86, 130.99, 130.86, 130.74, 130.16, 129.90, 128.60, 127.30, 127.07, 122.44, 115.70, 
114.61, 62.78, 45.59; MS (ESI): m/z = 382.59 (M+H)+. 
4-(1-(4-chlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2g). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(thiophen-2-yl)prop-2-
en-1-one (E7) and 4-chlrorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); greenish yellow 
solid; yield: 0.14 g (20%); mp 169.9 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.41 (s, 1H), 7.61 
(dd, J = 5.1, 1.1 Hz, 1H), 7.26 (dd, J = 3.6, 1.1 Hz, 1H), 7.20 – 7.14 (m, 2H), 7.10 (dd, J = 5.1, 
3.6 Hz, 1H), 7.08 – 7.04 (m, 2H), 6.95 – 6.89 (m, 2H), 6.74 – 6.68 (m, 2H), 5.37 (dd, J = 12.0, 
6.1 Hz, 1H), 3.87 (dd, J = 17.3, 12.0 Hz, 1H), 3.09 (dd, J = 17.3, 6.1 Hz, 1H); 13C NMR (125 
MHz, DMSO-d6) δ 156.74, 144.42, 142.85, 135.51, 131.91, 128.58, 127.82, 127.70, 127.61, 
127.01, 122.00, 115.71, 114.33, 62.81, 43.88; MS (ESI): m/z = 354.47 (M+). 
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4-(1-(4-bromophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2h). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(thiophen-2-yl)prop-2-
en-1-one (E7) and 4-bromophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 3:1); greenish yellow 
solid;  yield: 0.15 g (19%); mp 162-164 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.40 (s, 1H), 7.62 
– 7.59 (m, 1H), 7.31 – 7.25 (m, 3H), 7.11 – 7.08 (m, 1H), 7.07 – 7.03 (m, 2H), 6.89 – 6.85 (m, 
2H), 6.74 – 6.69 (m, 2H), 5.37 (dd, J = 12.0, 6.0 Hz, 1H), 3.87 (dd, J = 17.3, 12.0 Hz, 1H), 3.09 
(dd, J = 17.3, 6.0 Hz, 1H).13C NMR (125 MHz, DMSO-d6) δ 156.74, 144.50, 143.15, 135.49, 
131.86, 131.41, 127.83, 127.75, 127.65, 126.99, 115.71, 114.82, 109.62, 62.70, 43.87; MS (ESI): 
m/z = 398.70 (M+H)+. 
4-(3-(thiophen-2-yl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2i). 
The title compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(thiophen-2-
yl)prop-2-en-1-one (E7) and 4-(trifluoromethyl)phenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 
3:1); yellowish white solid; yield: 0.25 g (33%) ; mp 162-163.6 oC; 1H NMR (500 MHz, DMSO-
d6) δ 9.43 (s, 1H), 7.65 (dd, J = 5.1, 1.1 Hz, 1H), 7.46 (dd, J = 9.0, 0.5 Hz, 2H), 7.32 (dd, J = 3.6, 
1.1 Hz, 1H), 7.12 (dt, J = 7.7, 3.8 Hz, 1H), 7.09 – 7.01 (m, 4H), 6.76 – 6.66 (m, 2H), 5.49 (dd, J 
= 11.9, 5.3 Hz, 1H), 3.92 (dd, J = 17.4, 12.0 Hz, 1H), 3.15 (dd, J = 17.4, 5.4 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6) δ 156.82, 146.28, 145.86, 135.16, 131.60, 128.39, 128.16, 127.90, 126.91, 
126.14, 124.96 (q, 1JC-F = 270.3 Hz), 117.90 (q, 2JC-F = 31.9 Hz), 115.78, 112.34, 62.19, 43.86; 
MS (ESI): m/z = 388.81 (M+1)+. 
4-(1-(3-chlorophenyl)-3-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2j). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(pyridin-2-yl)prop-2-en-
1-one (E8) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/MeOH 98:2 ); dark yellow solid; 
yield: 0.25 g (36%); mp 245.9-247 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.56 (ddd, 
J = 4.9, 1.8, 1.0 Hz, 1H), 8.11 (dt, J = 8.0, 1.1 Hz, 1H), 7.84 (ddd, J = 8.0, 7.5, 1.8 Hz, 1H), 7.35 
(ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 7.19 – 7.14 (m, 1H), 7.12 (t, J = 2.1 Hz, 1H), 7.10 – 7.05 (m, 2H), 
6.91 (ddd, J = 8.4, 2.2, 0.8 Hz, 1H), 6.76 (ddd, J = 7.9, 2.0, 0.8 Hz, 1H), 6.74 – 6.69 (m, 2H), 
5.47 (dd, J = 12.2, 5.8 Hz, 1H), 3.91 (dd, J = 18.1, 12.3 Hz, 1H), 3.14 (dd, J = 18.1, 5.8 Hz, 1H); 
13C NMR (125 MHz, DMSO-d6) δ 156.75, 151.05, 149.54, 149.25, 144.92, 136.45, 133.54, 
131.92, 130.44, 126.97, 123.39, 120.40, 118.34, 115.76, 112.63, 111.63, 62.65, 42.91; MS (ESI): 
m/z = 349.78 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(1H-pyrrol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2k). The title 
compound was prepared by reaction of (E)-3-(4-(tert-butoxy)phenyl)-1-(1H-pyrrol-2-yl)prop-2-
en-1-one (E9) and 3-chlorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2); grey solid; yield: 0.094 g 
(14%); mp 174.6-176.4 oC; 1H NMR (500 MHz, DMSO-d6) 10.12 (s, 1H), 9.39 (s, 1H), δ 7.78-
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7.71 (m, 1H), 7.15 – 7.09 (m, 1H), 6.99 (t, J = 2.1 Hz, 1H), 6.98 – 6.92 (m, 2H), 6.84 (ddd, J = 
8.4, 2.2, 0.9 Hz, 1H), 6.81 (dd, J = 3.4, 0.7 Hz, 1H), 6.72 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.68-
6.60 (m, 1H), 6.57 – 6.49 (m, 2H), 5.09 (dd, J = 11.5, 5.6 Hz, 1H), 3.69 (dd, J = 17.4, 11.6 Hz, 
1H), 2.89 (dd, J = 17.4, 5.6 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 151.28, 148.15, 146.21, 
142.65, 140.47, 134.40, 130.75, 128.46, 126.87, 117.75, 114.22, 113.60, 113.00, 112.93, 112.51, 
61.99, 42.03; MS (ESI): m/z = 337.76 (M+H)+. 
4-(3-(4-aminophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (2l). The title 
compound was prepared by reaction of  (E)-1-(4-aminophenyl)-3-(4-(tert-butoxy)phenyl)prop-2-
en-1-one (E10) and 4-chlorophenylhydrazine hydrochloride according to the general procedure 
for pyrazoline synthesis. The product was purified by CC (CH2Cl2/MeOH 98:2); yellow solid; 
yield: 0.33g (46%) ; mp 181.5 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.36 (s, 1H), 7.42 (d, J = 8.6 
Hz, 2H), 7.18 – 7.09 (m, 2H), 7.04 (d, J = 8.6 Hz, 2H), 6.95 – 6.87 (m, 2H), 6.74 – 6.66 (m, 2H), 
6.59 (t, J = 11.8 Hz, 2H), 5.49 (s, 2H), 5.21 (dd, J = 11.8, 6.0 Hz, 1H), 3.76 (dd, J = 17.2, 11.8 
Hz, 1H), 2.96 (dd, J = 17.2, 6.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.55, 149.91, 
149.04, 143.69, 132.56, 128.41, 127.19, 126.98, 120.94, 119.43, 115.61, 113.90, 113.47, 62.30, 
43.52; MS (ESI): m/z = 363.85 (M+H)+. 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3a). The 
title compound was prepared by reaction of (E)-1-(3-methoxyphenyl)-4,4-dimethylpent-1-en-3-
one (E11) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The residue obtained after solvent removal was used for the next step 
without further purification; yellow solid; yield: 0.45 g (66%); MS (ESI): m/z = 342.77 (M+H)+. 
3-(tert-butyl)-1,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3b). The title compound 
was prepared by reaction of 1-(4-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E12) and 4-
methoxyphenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The residue obtained after solvent removal was used for the next step without further 
purification; grey solid; yield: 0.40 g (59%); MS (ESI): m/z = 338.82 (M+H)+. 
3-(tert-butyl)-5-(4-chlorophenyl)-1-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3c). The 
title compound was prepared by reaction of 1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one 
(E13) and 4-methoxyphenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The residue obtained after solvent removal was used for the next step 
without further purification; brown solid; yield: 0.48 g (71 %); MS (ESI): m/z =  342.68 (M+H)+. 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-1H-pyrazole 
(3d). The title compound was prepared by reaction of (E)-1-(3-fluoro-4-methoxyphenyl)-4,4-
dimethylpent-1-en-3-one (E14) and 4-chlorophenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 
1:3); colorless oil; yield: 0.5 g (70%); 1H NMR (500 MHz, DMSO-d6) δ 7.48 – 7.42 (m, 2H), 
6.90 – 6.86 (m, 1H), 6.79 (dd, J = 12.2, 2.1 Hz, 1H), 6.74 – 6.70 (m, 1H), 6.66 – 6.59 (m, 2H), 
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5.10 (dd, J = 11.6, 5.0 Hz, 1H), 3.56 (s, 3H), 3.32 (dd, J = 17.7, 11.7 Hz, 1H), 2.52 (dd, J = 17.8, 
5.1 Hz, 1H), 1.12 (s, 9H); MS (ESI): m/z = 360.71 (M+H)+. 
3-(tert-butyl)-5-(3-chloro-4-methoxyphenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole 
(3e). The title compound was prepared by reaction of (E)-1-(3-chloro-4-methoxyphenyl)-4,4-
dimethylpent-1-en-3-one (E15) and 4-chlorophenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The product was purified by CC (CH2Cl2/ hexane 
1:4); yellowish white solid; yield: 0.43g (58%); mp 150-152 oC; 1H NMR (500 MHz, DMSO) δ 
7.18 (d, J = 2.1 Hz, 1H), 7.15 – 7.11 (m, 2H), 6.96 (dt, J = 6.7, 3.4 Hz, 1H), 6.90 – 6.85 (m, 1H), 
6.81 – 6.78 (m, 2H), 5.14 (dd, J = 11.7, 6.5 Hz, 1H), 3.82 (s, 3H), 3.48 (dd, J = 17.6, 11.6 Hz, 
1H), 2.76 (dt, J = 21.7, 10.9 Hz, 1H), 1.13 (s, 9H). MS (ESI): m/z = 376.78 (M+H)+. 
3-(tert-butyl)-1-(3-chlorophenyl)-5-(4-fluoro-3-methoxyphenyl)-4,5-dihydro-1H-pyrazole 
(3f). The title compound was prepared by reaction of (E)-1-(4-fluoro-3-methoxy phenyl)-4,4-
dimethylpent-1-en-3-one (E16) and 3-chlorophenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The residue obtained after solvent removal was used 
for the next step without further purification; yellow oil; yield: 56% (0.4 g); MS (ESI): m/z = 
360.74 (M+H)+. 
1-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole 
(3g). The title compound was prepared by reaction of 3-(3,4-dimethoxyphenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (E17) and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis. The residue obtained after solvent removal was 
used for the next step without further purification; brown solid; yield: 0.54 g (64%); MS (ESI): 
m/z = 422.81 (M+H)+. 
1-(3-chlorophenyl)-5-(3-fluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-
pyrazole (3h). The title compound was prepared by reaction of (E)-3-(3-fluoro-4-
methoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E18) and 3-chlorophenylhydrazine  
hydrochloride according to the general procedure for pyrazoline synthesis. The product was 
purified by CC (CH2Cl2/hexane 1:3); buff solid; yield: 0.43 g (53%); mp 182-184 oC; 1H NMR 
(500 MHz, CDCl3) δ 8.21 (dd, J = 16.5, 7.8 Hz, 1H), 7.57 – 7.47 (m, 2H), 7.39 (s, 1H), 7.31 – 
7.21 (m, 3H), 7.14 (t, J = 7.0 Hz, 2H), 6.98 (dd, J = 25.1, 8.0 Hz, 2H), 5.33 (dd, J = 12.2, 6.9 Hz, 
1H), 4.21 (dd, J = 20.3, 7.7 Hz, 1H), 4.08 (s, 3H), 4.03 (s, 3H), 3.50 (dd, J = 17.9, 6.8 Hz, 1H) ; 
MS (ESI): m/z = 410.76 (M+H)+. 
1-(3-chlorophenyl)-5-(4-ethoxy-3,5-difluorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-
pyrazole (3i). The title compound was prepared by reaction of (E)-3-(4-ethoxy-3,5-
difluorophenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E19) and 3-chlorophenylhydrazine 
hydrochloride according to the general procedure for pyrazoline synthesis. The product was 
purified by CC (CH2Cl2/hexane 1:4); buff solid; yield: 0.55 g (63%); mp 166-167 oC; 1H NMR 
(500 MHz, CDCl3) δ 8.00 (dd, J = 7.8, 1.8 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.15 (t, J = 2.1 Hz, 1H), 
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7.04 – 6.99 (m, 2H), 6.92 – 6.89 (m, 1H), 6.84 (ddd, J = 6.0, 3.4, 2.7 Hz, 2H), 6.77 – 6.73 (m, 
1H), 5.07 (dd, J = 12.2, 6.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 4.00 (dd, J = 20.1, 7.9 Hz, 1H), 
3.81 (s, 3H), 3.30 – 3.22 (m, 1H), 1.41 (t, J = 7.1 Hz, 3H) ; MS (ESI): m/z = 442.71 (M+H)+. 
1-(3-chlorophenyl)-5-(2,3-difluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-
pyrazole (3j). The title compound was prepared by reaction of (E)-3-(2,3-difluoro-4-
methoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E20) and 3-chlorophenylhydrazine 
hydrochloride according to the general procedure for pyrazoline synthesis. The product was 
purified by CC (CH2Cl2/hexane 1:4); yellowish white solid; yield: 0.62 g (73%); mp 209-210 oC; 
1H NMR (500 MHz, CDCl3) δ 8.16 (ddd, J = 7.7, 3.6, 1.8 Hz, 1H), 7.52 – 7.47 (m, 1H), 7.27 – 
7.25 (m, 1H), 7.24 – 7.22 (m, 1H), 7.19 – 7.16 (m, 1H), 7.09 – 7.05 (m, 1H), 6.99 (tt, J = 7.1, 3.5 
Hz, 1H), 6.91 (dddd, J = 8.3, 4.2, 2.1, 0.9 Hz, 2H), 6.79 (ddd, J = 13.3, 7.6, 3.9 Hz, 1H), 5.60 
(dd, J = 12.2, 6.1 Hz, 1H), 4.18 (dt, J = 16.5, 7.7 Hz, 1H), 4.02 (s, 3H), 3.99 (s, 3H), 3.45 (dd, J 
= 17.8, 6.1 Hz, 1H) ; MS (ESI): m/z = 429.26 (M+H)+. 
1-(3-chlorophenyl)-3-(2,4-dimethoxyphenyl)-5-(3-fluoro-4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole (3k). The title compound was prepared by reaction of (E)-3-(3-fluoro-4-
methoxyphenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (E21) and 3-chlorophenylhydrazine 
hydrochloride according to the general procedure for pyrazoline synthesis. The residue obtained 
after solvent removal was used for the next step without further purification; yellowish white 
solid; 0.51g (58%); MS (ESI): m/z = 440.69 (M+H)+. 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (3l). The title 
compound was prepared by reaction of 1-(4-fluorophenyl)-4,4-dimethylpent-1-en-3-one (E22) 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:3); yellow solid; yield: 0.18 g 
(28%); mp 71.2 oC; 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.39 (m, 2H), 7.27 – 7.22 (m, 2H), 
7.22 – 7.16 (m, 2H), 7.03 – 6.99 (m, 2H), 5.13 (dd, J = 11.7, 7.6 Hz, 1H), 3.63 (dd, J = 17.2, 11.7 
Hz, 1H), 2.89 (dd, J = 17.2, 7.6 Hz, 1H), 1.39 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 162.09 (d, 
1JC-F = 246.0 Hz), 159.25, 144.62, 138.29 (d, 4JC-F = 3.1 Hz), 128.65, 127.44 (d, 3JC-F = 8.1 Hz), 
123.41, 115.99 (d, 2JC-F = 21.5 Hz), 114.35, 64.26, 43.24, 33.82, 28.20;MS (ESI): m/z = 331.18 
(M+1)+. 
3-(tert-butyl)-1,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (3m). The title compound was 
prepared by reaction of 1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one (E13) and 4-
chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:5); white solid; yield: 0.34 g 
(49.5%); mp 85.3-87 oC; 1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.21 – 7.17 (m, 
2H), 7.10 – 7.05 (m, 2H), 6.85 – 6.80 (m, 2H), 4.94 (dd, J = 11.7, 7.6 Hz, 1H), 3.46 (dd, J = 
17.2, 11.7 Hz, 1H), 2.71 (dd, J = 17.2, 7.6 Hz, 1H), 1.21 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
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159.25, 144.53, 141.07, 133.26, 129.29, 128.68, 127.24, 123.48, 114.33, 64.28, 43.14, 33.82, 
28.20; MS (ESI): m/z = 347.16 (M+H)+. 
5-(4-bromophenyl)-3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (3n). The title 
compound was prepared by reaction of 1-(4-bromophenyl)-4,4-dimethylpent-1-en-3-one (E23) 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:5); off-white solid; yield: 0.4 g 
(52%); mp 108.8 oC; 1H NMR (500 MHz, CDCl3) δ 7.47 – 7.43 (m, 2H), 7.15 – 7.11 (m, 2H), 
7.10 – 7.05 (m, 2H), 6.85 – 6.79 (m, 2H), 4.92 (dd, J = 11.7, 7.6 Hz, 1H), 3.46 (dt, J = 17.2, 7.5 
Hz, 1H), 2.71 (dd, J = 17.2, 7.6 Hz, 1H), 1.21 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 159.50, 
144.76, 141.85, 132.49, 128.94, 127.84, 123.75, 121.57, 114.58, 64.57, 43.34, 34.07, 28.45; MS 
(ESI): m/z = 392.71 (M+H)+. 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)benzonitrile (3o). The title 
compound was prepared by reaction of 4-(4,4-dimethyl-3-oxopent-1-en-1-yl)benzonitrile (E24) 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:1); buff solid; yield: 0.44 g (66%) ; 
mp 109.5 oC; 1H NMR (500 MHz, DMSO-d6) δ 7.83 – 7.78 (m, 2H), 7.42 – 7.38 (m, 2H), 7.16 – 
7.10 (m, 2H), 6.83 – 6.77 (m, 2H), 5.33 (dd, J = 11.8, 6.3 Hz, 1H), 3.58 (dd, J = 17.6, 11.8 Hz, 
1H), 2.73 (dd, J = 17.6, 6.3 Hz, 1H), 1.16 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.05, 
147.90, 143.86, 132.95, 128.61, 126.91, 121.68, 118.58, 113.97, 110.21, 62.66, 42.33, 33.45, 
27.83; MS (ESI): m/z = 337.03 (M+). 
 
1-(4-chlorophenyl)-5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole (3p). The title 
compound was prepared by reaction of  3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one (E25) 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:3); yellow solid; yield: 0.43 g 
(59%) ; mp 173-175 oC; 1H NMR (500 MHz, CDCl3) δ 7.62 (ddd, J = 4.2, 3.5, 1.8 Hz, 2H), 7.38 
– 7.33 (m, 1H), 7.32 – 7.28 (m, 2H), 7.14 – 7.07 (m, 3H), 7.05 – 7.00 (m, 2H), 6.92 – 6.88 (m, 
1H), 6.79 – 6.74 (m, 2H), 5.10 (dd, J = 12.2, 7.1 Hz, 1H), 3.75 – 3.70 (m, 1H), 3.68 (s, 3H), 3.03 
(dd, J = 17.1, 7.1 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 159.08, 147.33, 143.37, 134.05, 
130.07, 129.09, 128.76, 127.00, 126.50, 125.75, 123.76, 114.54, 105.03, 63.97, 55.29, 43.6 9; 
MS (ESI): m/z = 362.33 (M+). 
4-(1-(4-chlorophenyl)-3-methyl-4,5-dihydro-1H-pyrazol-5-yl)phenol (3q). The title 
compound was prepared by reaction of the commercially available 4-hydroxybenzylideneacetone 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2); white solid; yield: 0.20 g (35%); mp 184-
186 oC;  1H NMR (500 MHz, DMSO-d6) δ 9.35 (s, 1H), 7.12 – 7.07 (m, 2H), 7.05 – 7.01 (m, 
2H), 6.82 – 6.77 (m, 2H), 6.72 – 6.68 (m, 2H), 5.02 (dd, J = 11.7, 6.9 Hz, 1H), 3.44 (ddd, J = 
17.7, 11.7, 1.1 Hz, 1H), 2.61 (ddd, J = 17.8, 6.9, 1.0 Hz, 1H), 2.00 (s, 3H); 13C NMR (125 MHz, 
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DMSO-d6) δ 156.52, 150.03, 144.28, 132.66, 128.37, 126.96, 121.06, 115.58, 113.84, 62.71, 
47.40, 15.54; MS (ESI): m/z = 286.89 (M+H)+. 
3-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)phenol (4a). The title 
compound was prepared by demethylation of 3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-
methoxyphenyl)-4,5-dihydro-1H-pyrazole (3a) using BBr3 (3 equiv) according to the general 
procedure for ether dealkylation. The product was purified by CC (CH2Cl2/hexane 4:1); beige 
solid;  yield: 0.21 g (64%); mp 131-133 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.39 (s, 1H), 7.15 
– 7.09 (m, 3H), 6.83 – 6.79 (m, 2H), 6.66 (ddd, J = 6.5, 3.8, 1.4 Hz, 1H), 6.64 – 6.59 (m, 2H), 
5.06 (dd, J = 11.7, 6.6 Hz, 1H), 3.52 (dd, J = 17.6, 11.8 Hz, 1H), 2.68 (dd, J = 17.6, 6.6 Hz, 1H), 
1.17 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.84, 157.81, 144.23, 144.05, 129.96, 128.43, 
121.18, 116.28, 114.34, 113.83, 112.10, 63.14, 42.65, 33.42, 27.89. MS (ESI): m/z = 328.91 
(M+H)+. 
4,4'-(3-(tert-butyl)-4,5-dihydro-1H-pyrazole-1,5-diyl)diphenol (4b). The title compound was 
prepared by demethylation of 3-(tert-butyl)-1,5-bis(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole 
(3b) using BBr3 (6 equiv) according to the general procedure for ether dealkylation. The product 
was purified by CC (CH2Cl2/MeOH 98:2); grey solid; yield: 0.22 g (73%); mp 104-106 oC; 1H 
NMR (500 MHz, DMSO-d6) δ 9.63 (s, 1H), 9.32 (s, 1H), 7.08 (d, J = 8.5 Hz, 2H), 7.04 – 6.98 
(m, 2H), 6.69 (ddd, J = 11.4, 7.7, 3.3 Hz, 2H), 6.55 – 6.50 (m, 2H), 4.77 (dd, J = 11.0, 9.2 Hz, 
1H), 3.52 (dd, J = 17.1, 11.1 Hz, 1H), 2.57 (dd, J = 17.1, 9.1 Hz, 1H), 1.15 (s, 9H); 13C NMR 
(125 MHz, DMSO-d6) δ 160.58, 157.95, 157, 139.68, 133.36, 132.05, 121.27, 115.14, 114.93, 
65.25, 42.73, 31.77,  27.99; MS (ESI): m/z = 311.10 (M+H)+. 
4-(3-(tert-butyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)phenol (4c). The title 
compound was prepared by demethylation of 3-(tert-butyl)-5-(4-chlorophenyl)-1-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole (3c) using BBr3 (3 equiv) according to the general 
procedure for ether dealkylation. The product was purified by CC (CH2Cl2/hexane 4:1); grey 
solid;  yield: 0.14 g (44%) ; mp 142-143 oC; 1H NMR (500 MHz, DMSO-d6) δ 8.68 (s, 1H), 7.41 
– 7.32 (m, 2H), 7.33 – 7.26 (m, 2H), 6.71 – 6.63 (m, 2H), 6.59 – 6.50 (m, 2H), 4.95 (dd, J = 
11.3, 8.7 Hz, 1H), 3.45 (dd, J = 17.2, 11.4 Hz, 1H), 2.61 (dd, J = 17.2, 8.7 Hz, 1H), 1.15 (s, 9H); 
13C NMR (125 MHz, DMSO-d6) δ 158.11, 150.35, 142.17, 139.24, 131.54, 128.69, 128.05, 
115.29, 114.87, 64.66, 42.51, 33.32, 27.96 ; MS (ESI): m/z = 328.71 (M+H)+. 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-fluorophenol (4d). The 
title compound was prepared by demethylation of 3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-fluoro-
4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3d) using BBr3 (3 equiv) according to the general 
procedure for ether dealkylation. The product was purified by CC (CH2Cl2/hexane 4:1); off-
white solid;  yield: 0.15 g (44%); mp 130-132 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.80 (s, 1H), 
7.15 – 7.10 (m, 2H), 6.95 (dd, J = 12.1, 2.0 Hz, 1H), 6.92 – 6.86 (m, 1H), 6.86 – 6.81 (m, 3H), 
5.09 (dd, J = 11.5, 6.4 Hz, 1H), 3.48 (dd, J = 17.5, 11.6 Hz, 1H), 2.69 (dd, J = 17.5, 6.4 Hz, 1H), 
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1.16 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.94, 150.94 (d, 1JC-F = 241.5 Hz),144.17, 
143.96 (d, 2JC-F = 12.1 Hz), 133.71 (d, 3JC-F = 5.0 Hz), 128.45, 121.84 (d, 4JC-F = 3.0 Hz), 121.35, 
118.17, 114.03, 113.52 (d, 2JC-F = 18.7 Hz), 62.40, 42.56, 33.42, 27.85.; MS (ESI): m/z = 347.37 
(M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2,6-
difluorophenol (4i). The title compound was prepared by deprotection of 1-(3-chlorophenyl)-5-
(4-ethoxy-3,5-difluorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3i) using BBr3 (6 
equiv) according to the general procedure for ether dealkylation. The product was purified by CC 
(CH2Cl2); off-white solid; yield: 0.30 g (77%); mp 179-181 oC; 1H NMR (500 MHz, DMSO-d6) 
δ 10.28 (s, 1H), 10.24 (s, 1H), 7.48 (dd, J = 7.8, 1.6 Hz, 1H), 7.29 (ddt, J = 11.1, 5.4, 2.7 Hz, 
1H), 7.24 – 7.19 (m, 1H), 7.00 – 6.96 (m, 4H), 6.92 (ddd, J = 7.8, 7.3, 1.2 Hz, 1H), 6.82 (dddd, J 
= 15.3, 7.9, 2.1, 0.8 Hz, 2H), 5.42 (dd, J = 12.0, 6.2 Hz, 1H), 4.02 (dd, J = 17.9, 12.0 Hz, 1H), 
3.31 (dd, J = 17.9, 6.2 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 156.21, 152.40 (dd, 1JC-F = 
243.0, 3JC-F =7.1 Hz), 150.99, 144.73, 133.68, 132.99 (t, 2JC-F = 16.1 Hz), 132.31 (t, 3JC-F = 6.9 
Hz), 130.78, 130.74, 128.37, 119.53, 118.65, 116.60, 116.21, 112.36, 111.46, 109.47 (dd, 2JC-F = 
16.1, 4JC-F = 6.4 Hz,), 60.89, 44.03; MS (ESI): m/z = 400.74 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2,3-
difluorophenol (4j). The title compound was prepared by demethylation of 1-(3-chlorophenyl)-
5-(2,3-difluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3j) using 
BBr3 (6 equiv) according to the general procedure for ether dealkylation. The product was 
purified by CC (CH2Cl2); off-white solid; yield: 0.27 g (69%); mp 196-197 oC; 1H NMR (500 
MHz, DMSO-d6) δ 10.48 (s, 1H), 10.30 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.29 (dd, J = 11.4, 4.0 
Hz, 1H), 7.25 – 7.18 (m, 1H), 7.01 – 6.94 (m, 2H), 6.94 – 6.89 (m, 1H), 6.87 – 6.78 (m, 3H), 
6.73 (t, J = 8.2 Hz, 1H), 5.61 (dd, J = 12.2, 5.5 Hz, 1H), 4.05 (dd, J = 17.8, 12.5 Hz, 1H), 3.40 
(dd, J = 18.0, 5.5 Hz, 1H).; 13C NMR (125 MHz, DMSO-d6) δ 156.17, 151.20, 148.50 (dd, 1JC-F 
= 245.8, 2JC-F = 10.8 Hz), 146.24, 144.51, 139.84 (dd, 1JC-F = 243.7, 2JC-F = 13.6 Hz), 133.72, 
130.78, 128.35, 121.67, 119.55, 119.46, 119.38, 118.56, 116.51, 116.19, 113.11, 112.13, 111.22, 
56.11, 42.83. ; MS (ESI): m/z = 400.81 (M+H)+. 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5a). The title 
compound was prepared by reaction of 4,4- dimethyl-1-(4-nitrophenyl)pent-1-en-3-one (E26) 
and 4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:2); orange solid;  yield: 0.50 g 
(71%) ; mp 146-147  oC; 1H NMR (500 MHz, CDCl3) δ 8.23 – 8.18 (m, 2H), 7.45 – 7.41 (m, 
2H), 7.11 – 7.04 (m, 2H), 6.81 – 6.77 (m, 2H), 5.07 (dd, J = 11.9, 7.6 Hz, 1H), 3.53 (dd, J = 
17.3, 11.9 Hz, 1H), 2.73 (dd, J = 17.3, 7.6 Hz, 1H), 1.22 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
159.23, 149.82, 147.43, 144.18, 128.82, 126.79, 124.50, 123.93, 114.32, 64.23, 42.96, 33.87, 
28.17; MS (ESI): m/z = 357.75 (M+). 
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3-(tert-butyl)-1-(2,4-difluorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5b). The 
title compound was prepared by reaction of 4,4-dimethyl-1-(4-nitrophenyl)pent-1-en-3-one 
(E26) and 2,4-difluorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 1:2); orange oil; yield: 
0.34 g (48%); 1H NMR (500 MHz, CDCl3) δ 8.03 – 7.98 (m, 2H), 7.32 (tt, J = 8.9, 4.4 Hz, 1H), 
7.26 – 7.20 (m, 2H), 6.64 (dddd, J = 9.1, 7.9, 2.8, 1.4 Hz, 1H), 6.56 – 6.49 (m, 1H), 5.26 (ddd, J 
= 11.3, 5.0, 3.3 Hz, 1H), 3.40 (dd, J = 17.1, 11.3 Hz, 1H), 2.76 (dd, J = 17.1, 5.0 Hz, 1H), 1.16 
(s, 9H); 13C NMR (125 MHz, CDCl3) δ 160.77, 157.40 (dd, 1JC-F = 242.7, 3JC-F =11.1 Hz), 
151.26 (dd, 1JC-F = 246.9, 3JC-F =11.7 Hz), 149.24, 147.29, 130.66 (dd, 2JC-F = 9.7, 4JC-F = 3.4 
Hz), 127.07, 123.92, 120.47 (dd, 3JC-F = 8.9, 4.6 Hz), 111.09 (dd, 2JC-F = 21.6, 4JC-F =3.4 Hz), 
104.27 (dd, 2JC-F = 26.3, 24.2 Hz), 66.25, 42.48, 33.93, 28.13; MS (ESI): m/z = 359.83 (M+H)+. 
3-(tert-butyl)-1-(3-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5c). The title 
compound was prepared by reaction of 4,4-dimethyl-1-(4-nitrophenyl)pent-1-en-3-one (E26) and 
3-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The residue obtained after solvent removal was used for the next step without further 
purification; orange solid; yield: 0.44 g (62%); MS (ESI): m/z = 357.92 (M+H)+. 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazole (5d). The title 
compound was prepared by reaction of 4,4-dimethyl-1-(3-nitrophenyl)pent-1-en-3-one (E27) and 
4-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The product was purified by CC (CH2Cl2/hexane 1:2); orange solid; yield: 0.40 g 
(57%) ; mp 115-116 oC; 1H NMR (500 MHz, CDCl3) δ 8.17 – 8.15 (m, 1H), 8.13 (ddd, J = 8.0, 
2.3, 1.2 Hz, 1H), 7.58 (dt, J = 7.7, 1.3 Hz, 1H), 7.53 – 7.49 (m, 1H), 7.10 – 7.06 (m, 2H), 6.84 – 
6.79 (m, 2H), 5.08 (dd, J = 11.8, 7.6 Hz, 1H), 3.54 (dd, J = 17.3, 11.8 Hz, 1H), 2.75 (dd, J = 
17.3, 7.6 Hz, 1H), 1.23 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 159.28, 148.80, 144.76, 144.21, 
131.92, 130.25, 128.80, 123.90, 122.70, 121.04, 114.37, 64.16, 43.07, 33.85, 28.16; MS (ESI): 
m/z = 357.80 (M+H)+. 
1-(3-chlorophenyl)-3-cyclopropyl-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5e). The title 
compound was prepared by reaction of  1-cyclopropyl-3-(4-nitrophenyl)prop-2-en-1-one (E28) 
and 3-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The residue obtained after solvent removal was used for the next step without further 
purification; orange solid; yield: 0.35g (51%); MS (ESI): m/z = 341.63 (M+H)+. 
1-(3-chlorophenyl)-3-(1-methylcyclopropyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole 
(5f). The title compound was prepared by reaction of (E)-1-(1-methylcyclopropyl)-3-(4-
nitrophenyl)prop-2-en-1-one (E29) and 3-chlorophenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The residue obtained after solvent removal was used 
for the next step without further purification; orange solid; yield: 0.57 g (81%); MS (ESI): m/z = 
355.75 (M+H)+. 
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1-(4-chlorophenyl)-3-cyclohexyl-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5g). The title 
compound was prepared by reaction of (E)-1-cyclohexyl-3-(4-nitrophenyl)prop-2-en-1-one 
(E30) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The product was purified by CC (CH2Cl2/hexane 1:2); orange solid; yield: 
0.49 g (64%); mp 112-113 oC; 1H NMR (500 MHz, CDCl3) δ 8.22 – 8.16 (m, 2H), 7.45 – 7.39 
(m, 2H), 7.10 – 7.05 (m, 2H), 6.80 – 6.74 (m, 2H), 5.05 (dd, J = 11.9, 7.5 Hz, 1H), 3.48 (ddd, J = 
17.4, 12.0, 0.8 Hz, 1H), 2.69 (ddd, J = 17.4, 7.5, 0.8 Hz, 1H), 2.45 – 2.37 (m, 1H), 1.93 – 1.87 
(m, 2H), 1.80 (dd, J = 9.0, 3.8 Hz, 2H), 1.73 – 1.67 (m, 1H), 1.41 – 1.28 (m, 4H), 1.28 – 1.17 (m, 
1H); 13C NMR (125 MHz, CDCl3) δ 156.25, 149.81, 147.38, 144.06, 128.82, 126.79, 124.48, 
123.85, 114.22, 63.55, 44.17, 39.04, 30.57, 30.54, 25.91, 25.74; MS (ESI): m/z = 383.83 
(M+H)+. 
1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole (5h). The 
title compound was prepared by reaction of  3-(4-nitrophenyl)-1-(thiophen-2-yl)prop-2-en-1-one 
(E31) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The residue obtained after solvent removal was used for the next step 
without further purification; orange solid; yield: 0.44 g (58%); MS (ESI): m/z = 383.71 (M+H)+. 
1-(3-chlorophenyl)-3-(furan-2-yl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5i). The title 
compound was prepared by reaction of 1-(furan-2-yl)-3-(4-nitrophenyl)prop-2-en-1-one (E32) 
and 3-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The residue obtained after solvent removal was used for the next step without further 
purification; orange solid; yield: 0.44 g (61%); MS (ESI): m/z = 367.66 (M+H)+. 
3-(2-chlorophenyl)-1-(3-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5j). The 
title compound was prepared by reaction of  1-(2-chlorophenyl)-3-(4-nitrophenyl)prop-2-en-1-
one (E33) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis. The residue obtained after solvent removal was used for the next step 
without further purification; orange solid; yield: 0.42 g (51%); MS (ESI): m/z = 411.73 (M+H)+. 
1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-(2-(trifluoromethyl)phenyl)-4,5-dihydro-1H-
pyrazole (5k). The title compound was prepared by reaction of (E)-3-(4-nitrophenyl)-1-(2-
(trifluoromethyl)phenyl)prop-2-en-1-one (E34) and 3-chlorophenylhydrazine hydrochloride 
according to the general procedure for pyrazoline synthesis. The residue obtained after solvent 
removal was used for the next step without further purification; orange solid; yield: 0.47 g (53%) 
; MS (ESI): m/z = 445.67 (M+H)+. 
1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-(o-tolyl)-4,5-dihydro-1H-pyrazole (5l). The title 
compound was prepared by reaction of  (E)-3-(4-nitrophenyl)-1-(o-tolyl)prop-2-en-1-one (E35) 
and 3-chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. The residue obtained after solvent removal was used for the next step without further 
purification; orange solid; yield: 0.37 g (47.5%); MS (ESI): m/z = 391.87 (M+H)+. 
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1-(3-chlorophenyl)-3-(2-methoxyphenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5m). 
The title compound was prepared by reaction of 1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-
en-1-one (E36) and 3-chlorophenylhydrazine  hydrochloride according to the general procedure 
for pyrazoline synthesis. The residue obtained after solvent removal was used for the next step 
without further purification; orange solid; yield: 0.34 g (42%); MS (ESI): m/z = 408.02 (M+H).+ 
3-(benzo[d][1,3]dioxol-5-yl)-1-(3-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole 
(5n). The title compound was prepared by reaction of 1-(benzo[d][1,3]dioxol-5-yl)-3-(4-
nitrophenyl)prop-2-en-1-one (E37) and 3-chlorophenylhydrazine hydrochloride according to the 
general procedure for pyrazoline synthesis. The residue obtained after solvent removal was used 
for the next step without further purification; yield: orange solid; 0.51 g (61%); MS (ESI): m/z = 
421.71 (M+H)+. 
4-(3-(tert-butyl)-1-(2,4-difluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6b). The title 
compound was prepared by reduction of 3-(tert-butyl)-1-(2,4-difluorophenyl)-5-(4-nitrophenyl)-
4,5-dihydro-1H-pyrazole (5b) according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); buff solid; yield: 0.24 g (75%); mp 139-140 oC; 1H NMR (500 MHz, 
DMSO-d6) δ 7.28 (td, J = 9.3, 6.2 Hz, 1H), 6.98 (ddd, J = 12.1, 9.0, 2.9 Hz, 1H), 6.84 (tdd, J = 
9.2, 2.9, 1.2 Hz, 1H), 6.78 – 6.73 (m, 2H), 6.38 – 6.33 (m, 2H), 5.10 – 5.04 (m, 1H), 4.93 (s, 2H), 
3.37 – 3.30 (m, 1H), 2.79 (dd, J = 17.1, 4.7 Hz, 1H), 1.20 (s, 9H); 13C NMR (125 MHz, DMSO-
d6) δ 160.98, 156.17 (dd, 1JC-F =  239.0, 3JC-F =  11.2 Hz), 150.99 (dd, 1JC-F =  246.7, 3JC-F = 12.0 
Hz), 147.88, 131.45 (dd, 2JC-F = 9.8, 4JC-F = 3.1 Hz), 128.28, 126.90, 120.26 (dd, 3JC-F =  9.1, 5.0 
Hz), 113.60, 110.62 (dd, 2JC-F = 21.4, 4JC-F =  3.2 Hz), 103.94 (dd, 2JC-F =  26.4, 24.5 Hz), 65.95, 
41.67, 33.53, 27.87.; MS (ESI): m/z =  329.89 (M+H)+. 
4-(3-(tert-butyl)-1-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6c). The title 
compound was prepared by reduction of 3-(tert-butyl)-1-(3-chlorophenyl)-5-(4-nitrophenyl)-4,5-
dihydro-1H-pyrazole according to the general reduction procedure  (5c). The product was 
purified by CC (CH2Cl2); tan solid; yield: 0.20g (62%); mp 136.4 oC; 1H NMR (500 MHz, 
DMSO-d6) δ 7.09 – 7.03 (m, 1H), 6.89 – 6.85 (m, 3H), 6.72 (ddd, J = 8.4, 2.2, 0.9 Hz, 1H), 6.61 
(ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.52 – 6.47 (m, 2H), 5.02 – 4.97 (m, 3H), 3.45 (dd, J = 17.6, 11.6 
Hz, 1H), 2.65 (dd, J = 17.6, 6.2 Hz, 1H), 1.18 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 160.30, 
147.90, 146.64, 133.22, 130.12, 129.18, 126.40, 116.71, 114.17, 111.81, 110.94, 62.85, 42.68, , 
33.46, 27.88.; MS (ESI): m/z = 328.06 (M+H)+. 
3-(3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6d). The title 
compound was prepared by reduction of 3-(tert-butyl)-1-(4-chlorophenyl)-5-(3-nitrophenyl)-4,5-
dihydro-1H-pyrazole (5d) according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); yellow solid; yield: 0.24 g (74%); mp 104-106 oC; 1H NMR (500 MHz, 
DMSO-d6) δ 7.15 – 7.09 (m, 2H), 6.99 – 6.92 (m, 1H), 6.84 – 6.78 (m, 2H), 6.44 – 6.36 (m, 3H), 
5.08 (s, 2H), 4.92 (dd, J = 11.8, 7.2 Hz, 1H), 3.50 (dd, J = 17.6, 11.8 Hz, 1H), 2.66 (dd, J = 17.6, 
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7.2 Hz, 1H), 1.17 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 159.79, 149.26, 144.49, 143.42, 
128.38, 125.11, 121.11, 115.82, 113.82, 112.99, 110.33, 63.71, 42.78, 33.42, 27.93; MS (ESI): 
m/z = 327.87 (M+H)+. 
4-(1-(3-chlorophenyl)-3-cyclopropyl-4,5-dihydro-1H-pyrazol-5-yl)aniline (6e). The title 
compound was prepared by reduction of 1-(3-chlorophenyl)-3-cyclopropyl-5-(4-nitrophenyl)-
4,5-dihydro-1H-pyrazole (5e) according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); beige solid; yield: 0.24 g (77%) ; mp 90.5-92.5 oC; 1H NMR (500 
MHz, DMSO-d6) δ 7.08 – 7.02 (m, 1H), 6.89 – 6.83 (m, 3H), 6.69 (ddd, J = 8.4, 2.2, 0.9 Hz, 
1H), 6.61 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.52 – 6.47 (m, 2H), 5.02 (s, 2H), 4.95 (dd, J = 11.6, 
6.5 Hz, 1H), 3.27 (dd, J = 17.6, 11.6 Hz, 1H), 2.43 (dd, J = 17.5, 6.5 Hz, 1H), 1.84 (tt, J = 8.3, 
5.0 Hz, 1H), 0.87 – 0.81 (m, 2H), 0.81 – 0.69 (m, 2H).13C NMR (125 MHz, DMSO-d6) δ 155.22, 
147.92, 146.49, 133.24, 130.12, 129.01, 126.45, 116.60, 114.16, 111.72, 110.80, 62.36, 43.16, 
11.28, 5.84, 5.53; MS (ESI): m/z = 311.91 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(1-methylcyclopropyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6f). 
The title compound was prepared by reduction of 1-(3-chlorophenyl)-3-(1-methylcyclopropyl)-5-
(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5f) according to the general reduction procedure. The 
product was purified by CC (CH2Cl2); beige solid; yield: 0.27g (83%); mp 106.2 oC; 1H NMR 
(500 MHz, DMSO-d6) δ 7.09 – 7.03 (m, 1H), 6.89 – 6.84 (m, 3H), 6.71 (ddd, J = 8.4, 2.2, 0.9 
Hz, 1H), 6.61 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.52 – 6.46 (m, 2H), 5.02 (s, 2H), 4.96 (dd, J = 
11.5, 6.6 Hz, 1H), 3.27 (dd, J = 17.4, 11.5 Hz, 1H), 2.43 (dd, J = 17.4, 6.7 Hz, 1H), 1.35 (s, 3H), 
0.98 – 0.88 (m, 2H), 0.71 – 0.64 (m, 2H); 13C NMR (125 MHz, DMSO-d6) δ 157.32, 147.93, 
146.63, 133.22, 130.11, 129.05, 126.44, 116.64, 114.17, 111.76, 110.87, 63.03, 42.94, 21.18, 
16.90, 13.71, 13.48; MS (ESI): m/z = 325.91 (M+H)+. 
4-(1-(4-chlorophenyl)-3-cyclohexyl-4,5-dihydro-1H-pyrazol-5-yl)aniline (6g). The title 
compound was prepared by reduction of 1-(4-chlorophenyl)-3-cyclohexyl-5-(4-nitrophenyl)-4,5-
dihydro-1H-pyrazole (5g)  according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); tan solid; yield: 0.31 g (88%); mp 145-146 oC; 1H NMR (500 MHz, 
DMSO-d6) δ 7.12 – 7.06 (m, 2H), 6.89 – 6.84 (m, 2H), 6.84 – 6.78 (m, 2H), 6.51 – 6.46 (m, 2H), 
5.00 ( s, 2H), 4.92 (dd, J = 11.6, 6.6 Hz, 1H), 3.44 – 3.34 (m, 1H), 2.59 (dd, J = 17.8, 6.4 Hz, 
1H), 2.39 – 2.31 (m, 1H), 1.82 (dd, J = 16.1, 8.5 Hz, 2H), 1.73 (dt, J = 7.0, 4.8 Hz, 2H), 1.63 (d, 
J = 12.4 Hz, 1H), 1.40 – 1.13 (m, 5H); MS (ESI): m/z = 353.80 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6h). The title 
compound was prepared by reduction of 1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-(thiophen-2-yl)-
4,5-dihydro-1H-pyrazole (5h) according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); greenish yellow solid; yield: 0.19 g (53%); mp 154.4 oC;1H NMR (500 
MHz, DMSO-d6) δ 7.62 (dt, J = 5.1, 2.3 Hz, 1H), 7.28 (dd, J = 3.6, 1.1 Hz, 1H), 7.28 (dd, J = 
3.6, 1.1 Hz, 1H), 7.11 (dd, J = 5.0, 3.6 Hz, 1H), 6.96 (t, J = 2.1 Hz, 1H), 6.94 – 6.90 (m, 2H), 
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6.84 (ddd, J = 8.4, 2.2, 0.9 Hz, 1H), 6.72 – 6.68 (m, 1H), 6.53 – 6.48 (m, 2H), 5.29 (dd, J = 11.9, 
6.0 Hz, 1H), 5.06 (s, 2H), 3.85 (dd, J = 17.3, 12.0 Hz, 1H), 3.08 (dd, J = 17.3, 6.0 Hz, 1H); 13C 
NMR (125 MHz, DMSO-d6) δ 148.15, 145.27, 144.91, 135.48, 133.38, 130.34, 130.03,  128.41, 
127.84, 127.72, 126.53, 117.65, 114.19, 112.20, 111.41, 62.93, 43.88; MS (ESI): m/z = 353.74 
(M+H)+. 
4-(1-(3-chlorophenyl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6i). The title 
compound was prepared by reduction of 1-(3-chlorophenyl)-3-(furan-2-yl)-5-(4-nitrophenyl)-
4,5-dihydro-1H-pyrazole (5i) according to the general reduction procedure. The product was 
purified by CC (CH2Cl2); tan solid; yield: 0.22g (64%) ; mp 115.2-116.9 oC; 1H NMR (500 MHz, 
DMSO-d6) δ 7.82 (dd, J = 1.8, 0.7 Hz, 1H), 7.15 – 7.09 (m, 1H), 6.99 (t, J = 2.1 Hz, 1H), 6.92 – 
6.88 (m, 2H), 6.84 (ddd, J = 8.4, 2.2, 0.9 Hz, 1H), 6.81 (dd, J = 3.4, 0.7 Hz, 1H), 6.70 (ddd, J = 
7.9, 2.1, 0.9 Hz, 1H), 6.61 (ddd, J = 7.5, 3.4, 1.8 Hz, 1H), 6.52 – 6.47 (m, 2H), 5.27 (dd, J = 
11.9, 5.8 Hz, 1H), 5.06 (s, 2H), 3.77 (dd, J = 17.3, 12.0 Hz, 1H), 2.98 (dd, J = 17.3, 5.8 Hz, 1H); 
13C NMR (125 MHz, DMSO-d6) δ 148.14, 147.30, 145.35, 144.41, 140.46, 133.39, 130.32, 
128.27, 126.51, 117.66, 114.18, 112.30, 112.00, 111.41, 111.21, 62.26, 43.03; MS (ESI): m/z = 
337.85 (M+H)+. 
4-(3-(2-chlorophenyl)-1-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6j). The title 
compound was prepared by reduction of 3-(2-chlorophenyl)-1-(3-chlorophenyl)-5-(4-
nitrophenyl)-4,5-dihydro-1H-pyrazole (5j) according to the general reduction procedure. The 
product was purified by CC (CH2Cl2/hexane 4:1); yellow solid; yield: 0.20 g (52%); mp. 170-
171 oC); 1H NMR (500 MHz, DMSO-d6) δ 7.77 – 7.74 (m, 1H), 7.39 (ddd, J = 5.4, 2.9, 1.7 Hz, 
2H), 7.22 – 7.19 (m, 1H), 7.17 – 7.12 (m, 2H), 7.03 (t, J = 2.1 Hz, 1H), 6.88 (ddd, J = 8.4, 2.2, 
0.8 Hz, 1H), 6.73 (ddd, J = 7.9, 2.0, 0.9 Hz, 1H), 6.56 – 6.50 (m, 2H), 6.29 (t, J = 5.9 Hz, 1H), 
5.33 (dd, J = 12.0, 5.9 Hz, 1H), 4.21 (s, Hz, 2H), 3.96 (dd, J = 17.6, 12.0 Hz, 1H), 3.18 (dd, J = 
17.5, 5.9 Hz, 1H). 13C NMR (125 MHz, DMSO-d6) δ 148.16, 146.86, 145.30, 140.11, 133.41, 
131.00, 130.84, 130.72,130.25, 130.00, 128.24, 127.33, 127.19, 126.61, 118.08, 112.51, 111.60, 
62.76, 46.44; MS (ESI): m/z = 381.72 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline  
(6k). The title compound was prepared by reduction of  1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-
(2-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazole (5k) according to the general reduction 
procedure. The product was purified by CC (CH2Cl2/hexane 4:1); tan solid; yield: 0.083 (20%); 
mp 159-160 oC;  1H NMR (500 MHz, DMSO-d6) δ 7.87 (d, J = 7.8 Hz, 1H), 7.74 – 7.69 (m, 2H), 
7.63 – 7.57 (m, 1H), 7.15 (dd, J = 10.6, 5.7 Hz, 1H), 7.02 – 6.99 (m, 1H), 6.97 – 6.92 (m, 2H), 
6.86 (ddd, J = 8.4, 2.2, 0.8 Hz, 1H), 6.73 (ddd, J = 7.9, 2.0, 0.8 Hz, 1H), 6.54 – 6.49 (m, 2H), 
5.34 (dd, J = 12.1, 6.0 Hz, 1H), 5.09 (s, 2H), 3.93 (dd, J = 17.5, 12.1 Hz, 1H), 3.08 (dd, J = 17.5, 
6.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 148.18, 146.15, 145.35, 133.39, 132.56, 131.31, 
130.37, 128.97, 128.33, 127.04, 126.57, 126.53 , 125.97 (q, 2JC-F = 30.8 Hz), 124.10 (q, 1JC-F = 
273.3 Hz), 118.10, 114.19, 112.48, 111.47, 62.81, 45.70; MS (ESI): m/z = 415.78 (M+H)+. 
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4-(1-(3-chlorophenyl)-3-(o-tolyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6l). The title 
compound was prepared by reduction of 1 1-(3-chlorophenyl)-5-(4-nitrophenyl)-3-(o-tolyl)-4,5-
dihydro-1H-pyrazole (5l) according to the general reduction procedure. The product was purified 
by CC (CH2Cl2); brown solid; yield: 0.21 g (59%); mp 122.2 oC; 1H NMR (500 MHz, DMSO-d6) 
δ 7.45 – 7.41 (m, 1H), 7.34 – 7.31 (m, 1H), 7.30 – 7.23 (m, 2H), 7.18 – 7.13 (m, 1H), 6.98 (t, J = 
2.1 Hz, 1H), 6.96 – 6.92 (m, 2H), 6.89 (ddd, J = 8.4, 2.2, 0.9 Hz, 1H), 6.74 – 6.68 (m, 1H), 6.54 
– 6.48 (m, 2H), 5.24 (dd, J = 11.9, 5.9 Hz, 1H), 5.06 (s, 2H), 3.92 (dd, J = 17.3, 12.0 Hz, 1H), 
3.13 (dd, J = 17.3, 6.0 Hz, 1H), 2.68 (s, 3H); 13C NMR (125 MHz, DMSO-d6)δ 149.35, 148.07, 
145.62, 136.48, 133.39, 131.45, 130.66, 130.35, 128.75, 128.51, 128.18, 126.59, 126.00, 117.56, 
114.21, 112.20, 111.42, 61.87, 45.24, 23.42 ; MS (ESI): m/z = 361.77 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6m). 
The title compound was prepared by reduction of 1-(3-chlorophenyl)-3-(2-methoxyphenyl)-5-(4-
nitrophenyl)-4,5-dihydro-1H-pyrazole (5m) according to the general reduction procedure. The 
product was purified by CC (CH2Cl2); tan solid; yield: 0.25 g (66%); mp 122.9 oC; 1H NMR (500 
MHz, DMSO-d6) δ 7.89 (dd, J = 7.8, 1.7 Hz, 1H), 7.37 (ddd, J = 8.4, 7.3, 1.8 Hz, 1H), 7.14 – 
7.10 (m, 1H), 7.08 (dd, J = 8.4, 1.0 Hz, 1H), 7.03 – 6.99 (m, 2H), 6.95 – 6.90 (m, 2H), 6.86 (ddd, 
J = 8.4, 2.2, 0.9 Hz, 1H), 6.71 – 6.67 (m, 1H), 6.53 – 6.48 (m, 2H), 5.21 (dd, J = 12.0, 6.1 Hz, 
1H), 5.04 (s, 2H), 3.94 – 3.86 (m, 1H), 3.79 (s, 3H), 3.15 (dd, J = 18.1, 6.2 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6) δ 157.35, 148.02, 147.82, 145.68, 133.37, 130.44, 130.26, 128.95, 128.22, 
126.48, 121.06, 120.67, 117.41, 114.20, 112.30, 112.24, 111.33, 62.78, 55.60, 46.52; MS (ESI): 
m/z = 377.72 (M+H)+. 
4-(3-(benzo[d][1,3]dioxol-5-yl)-1-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)aniline (6n). 
The title compound was prepared by reduction of 3-(benzo[d][1,3]dioxol-5-yl)-1-(3-
chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (5n) according to the general 
reduction procedure. The product was purified by CC (CH2Cl2); brown solid; yield: 0.34 g 
(87%); mp 140.4 oC; 1H NMR (500 MHz, DMSO-d6) δ 7.40 – 7.38 (m, 1H), 7.17 (dd, J = 8.1, 
1.7 Hz, 1H), 7.13 – 7.09 (m, 1H), 7.03 (t, J = 2.1 Hz, 1H), 6.97 – 6.94 (m, 1H), 6.93 – 6.89 (m, 
2H), 6.87 (ddd, J = 8.4, 2.2, 0.9 Hz, 1H), 6.68 (ddd, J = 7.9, 2.1, 0.9 Hz, 1H), 6.53 – 6.47 (m, 
2H), 6.07 (s, 2H), 5.24 (dd, J = 12.0, 6.1 Hz, 1H), 5.04 (s, 2H), 3.78 (dd, J = 17.5, 12.0 Hz, 1H), 
3.02 (dd, J = 17.5, 6.1 Hz, 1H); 13C NMR (125 MHz, DMSO-d6) δ 148.41, 148.09, 148.07, 
147.71, 145.61, 133.38, 130.23, 128.77, 126.54, 126.43, 120.62, 117.37, 114.18, 112.19, 111.30, 
108.31, 105.42, 101.32, 62.85, 43.36; MS (ESI): m/z = 391.68 (M+H)+. 
4-(1-(3-chlorophenyl)-3-(2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazol-5-yl)-2-
fluorophenol (9). The title compound was prepared by demethylation of 1-(3-chlorophenyl)-5-
(3-fluoro-4-methoxyphenyl)-3-(2-methoxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole (8) using 
BBr3 (6 equiv) according to the general procedure for ether dealkylation. The product was 
purified by CC (CH2Cl2); beige solid; yield: 0.27 g (69%); mp 160.1-161.4 oC; 1H NMR (500 
MHz, DMSO-d6) δ 10.30 (s, 1H), 9.87 (s, 1H), 7.56 (ddd, J = 6.1, 4.5, 1.6 Hz, 1H), 7.31 – 7.24 
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(m, 1H), 7.20 (dd, J = 12.7, 4.6 Hz, 1H), 7.04 (dd, J = 12.0, 2.1 Hz, 1H), 6.99 – 6.96 (m, 2H), 
6.93 – 6.90 (m, 1H), 6.90 – 6.85 (m, 2H), 6.84 – 6.80 (m, 1H), 6.78 (ddd, J = 7.9, 2.0, 0.8 Hz, 
1H), 5.11 (d, J = 3.5 Hz, 1H), 3.71 (qd, J = 7.1, 3.5 Hz, 1H), 1.35 (d, J = 7.2 Hz, 3H); 13C NMR 
(125 MHz, DMSO-d6) δ 156.26, 154.88, 150.94 (d, 1JC-F = 241.8 Hz), 144.47, 144.30 (d, 2JC-F = 
12.1 Hz), 133.70, 131.68 (d, 3JC-F = 5.0 Hz), 130.71, 130, 128.40, 121.68 (d, 4JC-F = 2.9 Hz), 
119.59, 118.31, 118.27, 116.47, 115.96, 113.63 (d, 2JC-F = 18.8 Hz), 112.15, 111.35, 68.33, 
50.92, 18.63 ; MS (ESI): m/z = 396.74 (M+H) +. 
 
4-(3-(tert-butyl)-1-(4-chlorophenyl)-1H-pyrazol-5-yl)-2-chlorophenol (11). The title 
compound was prepared by demethylation of 3-(tert-butyl)-5-(3-chloro-4-methoxyphenyl)-1-(4-
chlorophenyl)-1H-pyrazole (10) using BBr3 (3 equiv) according to the general procedure for 
ether dealkylation. The product was purified by CC (CH2Cl2); off-white solid; yield: 0.18 g 
(50%); mp 176.5-177.5 oC; 1H NMR (500 MHz, DMSO-d6) δ 10.49 (s, 1H), 7.47 – 7.43 (m, 2H), 
7.28 – 7.24 (m, 3H), 6.94 – 6.89 (m, 2H), 6.53 (s, 1H), 1.31 (s, 9H); 13C NMR (125 MHz, 
DMSO-d6) δ 161.85, 153.16, 141.69, 138.68, 131.28, 129.72, 128.90, 128.29, 126.36, 122.04, 
119.75, 116.60, 104.90, 31.89, 30.23. ; MS (ESI): m/z = 360.77 (M+H)+. 
(E)-3-(4-(tert-butoxy)phenyl)-1-phenylprop-2-en-1-one (E2). Synthesized according to the 
general procedure for enone synthesis using acetophenone and 4-(tert-butoxy)benzaldehyde; 
yellow solid; yield: 2.46 g (88 %); mp 117.5-119 °C; 1H NMR (500 MHz, DMSO-d6) δ 8.18 – 
8.08 (m, 2H), 7.85 – 7.79 (m, 3H), 7.72 (d, J = 15.6 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.60 – 7.54 
(m, 2H), 7.08 – 7.02 (m, 2H), 1.35 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 189.07, 157.72, 
143.77, 137.73, 132.96, 130.11, 129.16, 128.73, 128.41, 123.02, 120.45, 78.89, 28.53. 
(E)-3-(4-(tert-butoxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (E3). Synthesized 
according to the general procedure for enone synthesis using 1-(2-hydroxyphenyl)ethanone and 
4-(tert-butoxy)benzaldehyde, the product was precipitated after neutralization with 2M HCl; 
yellow solid; yield: 2.57 g (87 %); mp 137-138 °C; 1H NMR (500 MHz, DMSO-d6) δ 9.35 (s, 
1H), 7.89 – 7.84 (m, 1H), 7.76 (d, J = 15.9 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.68 (d, J = 11.3 Hz, 
1H), 7.66 – 7.61 (m, 3H), 6.92 (td, J = 7.5, 0.8 Hz, 1H), 6.86 (t, J = 7.4 Hz, 1H), 1.39 (s, 9H). 
(E)-3-(4-(tert-butoxy)phenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E4). Synthesized 
according to the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 
4-(tert-butoxy)benzaldehyde; yellow oil; yield: 2.51g (81 %); 1H NMR (300 MHz, CDCl3) δ 
7.59 (dd, J = 8.7, 7.0 Hz, 2H), 7.54 – 7.45 (m, 3H), 7.31 – 7.23 (m, 1H), 7.08 – 6.96 (m, 4H), 
3.90 (s,3H), 1.40 (s, 9H). 
(E)-3-(4-(tert-butoxy)phenyl)-1-(2-ethoxyphenyl)prop-2-en-1-one (E5). Synthesized 
according to the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 4-
(tert-butoxy)benzaldehyde; yellow oil; yield: 2.65 g (82%); 1H NMR (500 MHz, CDCl3) δ 7.64 
(dd, J = 7.6, 1.8 Hz, 1H), 7.60 (d, J = 15.9 Hz, 1H), 7.51 – 7.47 (m, 2H), 7.44 – 7.40 (m, 1H), 
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7.38 (d, J = 15.9 Hz, 1H), 7.02 – 6.98 (m, 3H), 6.97 – 6.93 (m, 1H),  4.11 (q, J = 7.0 Hz, 2H), 
1.41 (t, J = 7.0 Hz, 3H), 1.38 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 192.66, 157.66, 157.48, 
142.37, 132.66, 130.32, 129.87, 129.46, 129.12, 125.79, 123.58, 120.55, 112.56, 79.13, 64.14, 
28.80, 14.74 
(E)-3-(4-(tert-butoxy)phenyl)-1-(2-chlorophenyl)prop-2-en-1-one (E6). Synthesized according 
to the general procedure for enone synthesis using 1-(2-chlorophenyl)ethanone and 4-(tert-
butoxy)benzaldehyde; yellow oil; yield: 2.85 g (91 %); 1H NMR (500 MHz, CDCl3) δ 7.68 (dd, J 
= 7.6, 1.8 Hz, 1H), 7.58 (d, J = 15.9 Hz, 1H), 7.53 – 7.49 (m, 2H), 7.49 – 7.47 (m, 1H), 7.47 – 
7.44 (m, 1H), 7.39 – 7.35 (m, 2H), 7.03 (td, J = 7.5, 0.9 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 1.36 
(s, 9H). 
(E)-3-(4-(tert-butoxy)phenyl)-1-(thiophen-2-yl)prop-2-en-1-one (E7). Synthesized according 
to the general procedure for enone synthesis using 1-(thiophen-2-yl)ethanone and 4-(tert-
butoxy)benzaldehyde; yellowish white solid ; yield: 2.57 g (90 %); mp 128.1 °C; 1H NMR (500 
MHz, DMSO-d6) δ 8.30 (dd, J = 3.8, 1.1 Hz, 1H), 8.04 (dd, J = 4.9, 1.1 Hz, 1H), 7.83 – 7.79 (m, 
2H), 7.77 (d, J = 15.6 Hz, 1H), 7.70 (d, J = 15.6 Hz, 1H), 7.31 (dt, J = 10.0, 5.0 Hz, 1H), 7.08 – 
7.02 (m, 2H), 1.35 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 181.53, 157.75, 145.66, 142.86, 
135.27, 133.36, 130.12, 128.99, 128.85, 122.99, 120.28, 78.91, 28.53. 
(E)-3-(4-(tert-butoxy)phenyl)-1-(pyridin-2-yl)prop-2-en-1-one (E8). Synthesized according to 
the general procedure for enone synthesis using 1-(pyridin-2-yl)ethanone and 4-(tert-
butoxy)benzaldehyde; greenish yellow solid; yield: 2.56 g (91 %); mp 117.1-118.5 °C; 1H NMR 
(500 MHz, DMSO-d6) δ 8.79 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 8.17 (d, J = 16.1 Hz, 1H), 8.11 – 
8.09 (m, 1H), 8.07 – 8.03 (m, 1H), 7.85 – 7.81 (m, 1H), 7.76 – 7.73 (m, 2H), 7.69 (ddd, J = 7.5, 
4.7, 1.4 Hz, 1H), 7.08 – 7.03 (m, 2H), 1.35 (s, 9H); 13C NMR (125 MHz, DMSO-d6) δ 188.52, 
157.95, 153.55, 149.13, 143.79, 137.69, 129.98, 129.01, 127.50, 123.04, 122.38, 119.12, 78.95, 
28.52.  
(E)-3-(4-(tert-butoxy)phenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one  (E9). Synthesized 
according to the general procedure for enone synthesis using 1-(1H-pyrrol-2-yl)ethanone and 4-
(tert-butoxy)benzaldehyde; yellowish white solid; yield: 2.26 g (84 %); mp 116.5-118.5 °C; 1H 
NMR (500 MHz, CDCl3) δ 9.92 (s, 1H), 7.81 (d, J = 15.6 Hz, 1H), 7.58 – 7.54 (m, 2H), 7.27 (d, 
J = 15.7 Hz, 1H), 7.11 (td, J = 2.7, 1.3 Hz, 1H), 7.07 (ddd, J = 3.7, 2.3, 1.3 Hz, 1H), 7.05 – 7.00 
(m, 2H), 6.35 (dt, J = 3.8, 2.5 Hz, 1H), 1.40 (s, 9H);13C NMR (125 MHz, CDCl3) δ 178.97, 
157.75, 141.95, 133.24, 129.81, 129.25, 125.14, 123.76, 120.49, 116.03, 110.88, 79.31, 28.89. 
(E)-1-(4-aminophenyl)-3-(4-(tert-butoxy)phenyl)prop-2-en-1-one (E10). Synthesized 
according to the general procedure for enone synthesis using 1-(4-aminophenyl)ethanone and 4-
(tert-butoxy)benzaldehyde; yellow solid; yield: 2.30 g (78 %); mp 113.7-115.5 °C; 1H NMR 
(300 MHz, DMSO-d6) δ 7.90 (d, J = 8.6 Hz, 2H), 7.77 – 7.69 (m, 3H), 7.57 (d, J = 15.5 Hz, 1H), 
7.02 (d, J = 8.6 Hz, 2H), 6.61 (d, J = 8.2 Hz, 2H), 6.09 (s, 2H), 1.35 (s, 9H). 
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(E)-1-(3-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E11). Synthesized according to the 
general procedure for enone synthesis using pinacolone and 3-methoxybenzaldehyde; yellow oil; 
yield: 1.87 g (86 %); 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 15.6 Hz, 1H), 7.33 – 7.24 (m, 
1H), 7.19 – 7.14 (m, 1H), 7.08 (dd, J = 5.3, 2.6 Hz, 2H), 6.92 (dt, J = 7.2, 3.6 Hz, 1H), 3.83 (s, 
3H), 1.23 (s, 9H). 
1-(4-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E12). Synthesized according to general 
procedure for enone synthesis using pinacolone and 4-methoxybenzaldehyde; yellow oil; yield: 
1.97 g (90.5 %).1 
1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one (E13). Synthesized according to the general 
procedure for enone synthesis pinacolone and 4-chlorobenzaldehyde; white solid; yield: 2.11 g 
(95 %); mp 85-87 °C. 2 
(E)-1-(3-fluoro-4-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E14). Synthesized according 
to the general procedure for enone synthesis using pinacolone and 3-fluoro-4-
methoxybenzaldehyde; yellowish white solid; yield: 2.22 g (94 %); mp 84.6 °C; 1H NMR (500 
MHz, DMSO-d6) δ 7.80 (dd, J = 12.9, 2.1 Hz, 1H), 7.52 (dd, J = 5.5, 4.3 Hz, 1H), 7.48 (d, J = 
15.6 Hz, 1H), 7.35 (d, J = 15.6 Hz, 1H), 7.21 – 7.16 (m, 1H), 3.88 (s, 3H), 1.15 (s, 9H); 13C 
NMR (125 MHz, DMSO-d6) δ 203.24, 151.53 (d, 1JC-F = 244.2 Hz), 148.83 (d, 2JC-F = 10.9 Hz), 
140.80, 127.86 (d, 3JC-F = 6.8 Hz), 126.67 (d, 4JC-F = 2.9 Hz), 120.49, 114.79 (d, 2JC-F = 18.4 Hz), 
113.66, 56.09, 42.76, 25.76. 
(E)-1-(3-chloro-4-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E15). Synthesized according 
to the general procedure for enone synthesis using pinacolone and 3-chloro-4-
methoxybenzaldehyde; white solid; yield: 2.24 g (89 %); mp 75.2-77.1 °C; 1H NMR (500 MHz, 
DMSO-d6) δ 8.00 (d, J = 2.1 Hz, 1H), 7.70 (dd, J = 8.7, 2.1 Hz, 1H), 7.47 (d, J = 15.6 Hz, 1H), 
7.38 (d, J = 15.6 Hz, 1H), 7.19 – 7.15 (m, 1H), 3.90 (s, 3H), 1.16 (s, 9H); 13C NMR (125 MHz, 
DMSO-d6) δ 203.27, 155.89, 140.44, 129.73, 129.26, 128.27, 121.69, 120.52, 112.77, 56.30, 
42.77, 25.76. 
(E)-1-(4-fluoro-3-methoxyphenyl)-4,4-dimethylpent-1-en-3-one (E16). Synthesized according 
to the general procedure for enone synthesis using pinacolone and 4-fluoro-3-
methoxybenzaldehyde; yellow oil; yield: 1.96 g (83 %); 1H NMR (300 MHz, DMSO) δ 7.91 – 
7.83 (m, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 15.6 Hz, 1H), 7.27 (dd, J = 15.6, 1.0 Hz, 1H), 
6.98-6.93 (m, 1H), 3.80 (s, 3H), 1.16 (s, 9H). 
3-(3,4-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E17). Synthesized according 
to the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 3,4-
dimethoxybenzaldehyde; yellow oil; yield: 2.38 g (80 %).3  
(E)-3-(3-fluoro-4-methoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E18). Synthesized 
according to the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 
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3-fluoro-4-methoxybenzaldehyde; yellow solid; yield: 2.66 g (93 %); mp 97.5 °C; 1H NMR (500 
MHz, DMSO-d6) δ 7.70 (dd, J = 12.7, 2.1 Hz, 1H), 7.55 – 7.50 (m, 2H), 7.47 (dd, J = 7.6, 1.6 
Hz, 1H), 7.43 (d, J = 15.9 Hz, 1H), 7.31 (d, J = 15.9 Hz, 1H), 7.23 – 7.16 (m, 2H), 7.07 – 7.02 
(m, 1H), 3.88 (s, 3H), 3.85 (s, 3H).13C NMR (125 MHz, DMSO-d6) δ 192.14, 157.59, 151.53 (d, 
1JC-F = 244.5 Hz), 149.04 (d, 2JC-F = 10.9 Hz), 141.58 (d, 4JC-F = 2.2 Hz), 132.82, 129.37, 128.98, 
127.77 (d, 3JC-F = 6.8 Hz), 126.40 (d, 4JC-F = 2.9 Hz), 126.02, 120.48, 114.99 (d, 2JC-F = 18.4 Hz), 
113.85, 112.28, 56.12, 55.78. 
(E)-3-(4-ethoxy-3,5-difluorophenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E19). 
Synthesized according to the general procedure for enone synthesis using 1-(2-
methoxyphenyl)ethanone and 4-ethoxy-3,5-difluorobenzaldehyde; yellow solid; yield: 2.92 g (92 
%); mp 85.6 °C; 1H NMR (500 MHz, DMSO-d6) δ 7.64 – 7.58 (m, 2H), 7.55 (ddd, J = 8.4, 7.3, 
1.8 Hz, 1H), 7.48 (dt, J = 6.6, 2.4 Hz, 1H), 7.42-7.39 (m, 1H), 7.19 (d, J = 15.9 Hz, 1H), 7.06 (td, 
J = 7.4, 0.9 Hz, 1H), 6.95 – 6.89 (m, 1H), 4.22 (q, J = 7.0 Hz, 2H), 3.86 (s, 3H), 1.30 (t, J = 7.0 
Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 191.97, 157.78, 155.28 (dd, 1JC-F = 246.3, 3JC-F 6.5 
Hz), 139.87, 135.95 (t, 2JC-F = 14.7 Hz), 133.87, 130.26 (t, 3JC-F = 9.3 Hz), 129.49, 128.68, 
128.17, 120.49, 112.54 (dd, 2JC-F = 17.6, 4JC-F = 5.7 Hz), 112.31, 70.11, 55.82, 15.23. 
(E)-3-(2,3-difluoro-4-methoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (E20). 
Synthesized according to the general procedure for enone synthesis using 1-(2-
methoxyphenyl)ethanone and 2,3-difluoro-4-methoxybenzaldehyde; yellow solid; yield: 2.91 g 
(96 %); mp 128-130 °C; 1H NMR (500 MHz, DMSO-d6) δ 7.66 (td, J = 8.8, 2.2 Hz, 1H), 7.58 – 
7.53 (m, 1H), 7.53 – 7.50 (m, 1H), 7.45 (dd, J = 15.6, 13.2 Hz, 2H), 7.20 (dd, J = 8.5, 0.7 Hz, 
1H), 7.13 – 7.08 (m, 1H), 7.08 – 7.04 (m, 1H), 3.93 (s, 3H), 3.87 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 191.57, 157.83, 150.14, 149.45 (dd, 1JC-F = 251.6, 2JC-F =10.6 Hz), 140.16 (dd, 1JC-F 
= 245.6, 2JC-F 14.3 Hz), 133.60, 133.30, 129.63, 128.48, 127.99, 124.37, 120.60, 116.20, 112.39, 
109.51, 56.79, 55.79. 
(E)-1-(2,4-dimethoxyphenyl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-1-one (E21). 
Synthesized according to the general procedure for enone synthesis using 1-(2,4-
dimethoxyphenyl)ethanone and 3-fluoro-4-methoxybenzaldehyde; yellow solid; yield: 2.71 g (86 
%); mp 85-86 °C; 1H NMR (500 MHz, DMSO-d6) δ 7.65 (dt, J = 14.9, 3.5 Hz, 1H), 7.59 (d, J = 
8.6 Hz, 1H), 7.53 – 7.45 (m, 2H), 7.43 (d, J = 15.8 Hz, 1H), 7.21 (dd, J = 11.0, 6.5 Hz, 1H), 6.68 
(d, J = 2.3 Hz, 1H), 6.63 (dd, J = 8.6, 2.3 Hz, 1H), 3.89 (d, J = 2.3 Hz, 6H), 3.85 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 189.30, 163.83, 160.12, 151.53 (d, 1JC-F = 244.4 Hz), 148.80 (d, 
2JC-F = 10.8 Hz), 140.19, 131.91, 128.09 (d, 3JC-F = 6.8 Hz), 126.11, 126.06 (d, 4JC-F = 2.9 Hz), 
121.50, 114.84 (d, 2JC-F = 18.3 Hz), 113.87, 105.88, 98.60, 56.10, 55.91, 55.56. 
1-(4-fluorophenyl)-4,4-dimethylpent-1-en-3-one (E22). Synthesized according to the general 
procedure for enone synthesis using pinacolone and 4-fluorobenzaldehyde; yellow solid; yield: 
1.73 g (84 %); mp 42.5-44.1 °C.4  
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1-(4-bromophenyl)-4,4-dimethylpent-1-en-3-one (E23). Synthesized according to the general 
procedure for enone synthesis using pinacolone and 4-bromobenzaldehyde; white solid; yield: 
2.48 g (93 %); mp 102-103 °C.5,6  
4-(4,4-dimethyl-3-oxopent-1-en-1-yl)benzonitrile (E24). Synthesized according to the general 
procedure for enone synthesis using pinacolone and 4-formylbenzonitrile; white solid; yield: 
1.95 g (92 %); mp 131-133 °C.7,8  
3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one (E25). Synthesized according to the general 
procedure for enone synthesis using acetophenone and 4-methoxybenzaldehyde; yellow solid; 
yield: 1.88 g (79 %); mp 73-74 °C.9 
4,4-dimethyl-1-(4-nitrophenyl)pent-1-en-3-one (E26). Synthesized according to the the 
general procedure for enone synthesis using pinacolone and 4-nitrobenzaldehyde; beige solid; 
yield: 2.23 g (96 %); mp 107-109 °C.10  
4,4-dimethyl-1-(3-nitrophenyl)pent-1-en-3-one (E27). Synthesized according to the general 
procedure for enone synthesis using pinacolone and 3-nitrobenzaldehyde; yellow solid; yield: 
2.16 g (93 %); mp 92-94 °C.11 
1-cyclopropyl-3-(4-nitrophenyl)prop-2-en-1-one (E28). Synthesized according to the general 
procedure for enone synthesis using 1-cyclopropylethanone and 4-nitrobenzaldehyde; yellowish 
white solid; yield: 1.82 g (84 %); mp 118.9-120 °C.12  
(E)-1-(1-methylcyclopropyl)-3-(4-nitrophenyl)prop-2-en-1-one (E29). Synthesized according 
to the general procedure for enone synthesis using 1-(1-methylcyclopropyl)ethanone and 4-
nitrobenzaldehyde; yellowish white solid; yield: 1.96 g (85 %); mp 133.1 °C; 1H NMR (500 
MHz, CDCl3) δ 8.29 – 8.22 (m, 2H), 7.74 – 7.69 (m, 2H), 7.62 (d, J = 16.1 Hz, 1H), 6.98 (d, J = 
16.1 Hz, 1H), 2.26 (s, 3H), 1.24 – 1.18 (m, 2H), 1.07 – 1.01 (m, 2H), 13C NMR (125 MHz, 
CDCl3) δ 199.41, 148.46, 140.97, 138.72, 129.77, 128.77, 124.15, 23.12,  20.26, 11.90. 
(E)-1-cyclohexyl-3-(4-nitrophenyl)prop-2-en-1-one (E30). Synthesized according to the 
general procedure for enone synthesis using 1-cyclohexylethanone and 4-nitrobenzaldehyde; 
beige solid; yield: 2.53 g (98 %); mp 132-134 °C; 1H NMR (300 MHz, CDCl3) δ 8.25 (d, J = 8.3 
Hz, 2H), 7.71 (d, J = 8.5 Hz, 2H), 7.61 (d, J = 16.0 Hz, 1H), 6.93 (d, J = 15.9 Hz, 1H), 2.76 – 
2.56 (m, 1H), 1.90 (dd, J = 22.1, 11.2 Hz, 4H), 1.54 – 1.18 (m, 6H). 
3-(4-nitrophenyl)-1-(thiophen-2-yl)prop-2-en-1-one (E31). Synthesized according to the 
general procedure for enone synthesis using 1-(thiophen-2-yl)ethanone and 4-nitrobenzaldehyde; 
yellow solid; yield: 2.14 g (83 %); mp 207-209 °C.13  
1-(furan-2-yl)-3-(4-nitrophenyl)prop-2-en-1-one (E32). Synthesized according to the general 
procedure for enone synthesis using 1-(furan-2-yl)ethanone and 4-nitrobenzaldehyde; yellow 
solid; yield: 2.13 g (88 %); mp 224.4 °C.14  
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1-(2-chlorophenyl)-3-(4-nitrophenyl)prop-2-en-1-one (E33). Synthesized according to the 
general procedure for enone synthesis using 1-(2-chlorophenyl)ethanone and 4-
nitrobenzaldehyde; yellow solid; yield: 2.21 g (77 %); mp 162-163 °C.15  
(E)-3-(4-nitrophenyl)-1-(2-(trifluoromethyl)phenyl)prop-2-en-1-one (E34). Synthesized 
according to the general procedure for enone synthesis using 1-(2-
(trifluoromethyl)phenyl)ethanone and 4-nitrobenzaldehyde; yellow solid; yield: 2.85 g (89 %); 
mp 142-144 °C; 1H NMR (500 MHz, CDCl3) δ 8.23 – 8.18 (m, 2H), 7.70 – 7.64 (m, 2H), 7.51 – 
7.46 (m, 2H), 7.41 (ddd, J = 8.0, 4.4, 1.2 Hz, 2H), 7.34 (ddd, J = 7.5, 6.5, 2.1 Hz, 1H), 7.22 (d, J 
= 16.1 Hz, 1H). 
(E)-3-(4-nitrophenyl)-1-(o-tolyl)prop-2-en-1-one (E35). Synthesized according to the general 
procedure for enone synthesis using 1-(o-tolyl)ethanone and 4-nitrobenzaldehyde; yellowish 
white solid; yield: 2.16 g (81 %); mp 128-129 °C; 1H NMR (500 MHz, CDCl3) δ 8.27 – 8.20 (m, 
2H), 8.07 – 7.97 (m, 1H), 7.73 – 7.66 (m, 2H), 7.55 – 7.48 (m, 2H), 7.41 (ddd, J = 8.9, 6.2, 2.4 
Hz, 1H), 7.30 – 7.28 (m, 1H), 7.26 (d, J = 16.0 Hz, 1H), 2.46 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 194.98, 148.58, 142.02, 140.84, 138.17, 137.58, 131.64, 129.97, 128.88, 128.59, 
128.33, 125.63, 123.74, 20.40. 
1-(2-methoxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one (E36). Synthesized according to the 
general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 4-
nitrobenzaldehyde; yellowish white solid; yield: 2.43 g (86 %); mp 116.5-118 °C.16  
1-(benzo[d][1,3]dioxol-5-yl)-3-(4-nitrophenyl)prop-2-en-1-one (E37). Synthesized according 
to the general procedure for enone synthesis using 1-(benzo[d][1,3]dioxol-5-yl)ethanone and 4-
nitrobenzaldehyde;  dark yellow solid; yield: 2.34 g (79   %); mp 182.4 °C.17  
2) Supplementary Table S1. Hit compound 1a does not inhibit other potential target kinases in 
the NF-ĸB pathway nor PKCβII 
Kinase (human) % inhibition at 10 µM of 1a 
IKKβ n.i. 
PKCι n.i. 
RIPK2 n.i. 
p38α MAPK 10% 
TAK1 n.i. 
TBK1 n.i. 
PKCβII n.i. 
 
 n.i.: no inhibition. Each value is representative of at least two independent 
assays which essentially gave the same results. 
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3) Table S2. Wilcoxon´s signed rank test 
Group 1: low potency (less than 75% inhibition at 62.5 µM in the cell free assay) 
compound # % inhibition at 5 µM (U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) 
1g 40.7 3n 9.3 6e 24.5 
1l 23.5 3o 20.1 6f 47.7 
1m 48.7 3p 2.9 6g 30.9 
1n 50.2 3q 50.8 6h 44.9 
1o 51.8 4b 35 6i 26.1 
1p 41.5 4c 37.3 6j 24.4 
1q 12.3 5a 5.9 6K 50.8 
2d 26.5 6a 22.7 6l 31.3 
2e 48.2 6b 23.5 6m 28.2 
2f 38.7 6C 42.3 6n 22.2 
3l 3.7 6d 21.9 7a 25.5 
3m 5.5         
Group 2: moderate potency (IC50 = 5-15 µM in the cell free assay) 
compound # % inhibition at 5 µM (U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) 
1a 75.1 1h 64.6 4a 89.9 
1b 63.8 2j 70.2 4i 75.1 
1c 58.4 2l 42.3 4j 81.7 
1e 62.9         
Group 3: high potency (IC50 <5 µM in the cell free assay) 
compound # % inhibition at 5 µM (U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) compound # 
% inhibition at 5 µM 
(U937 cells) 
1i 73.5 1t 84.2 4f 92.8 
1j 89.7 2c 68.2 4g 62 
1k 73.7 4d 95 4h 71.7 
1r 92 4e 85 4k 87.4 
1s 90.1         
 
Group 1 vs. group 2, exact P value is 0.002; group 1 vs. group 3, exact P value is 0.0017; group 2 vs. group 3, exact P value is 0.0273. 
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4) Table S3. MTT toxicity assay using RAW 264.7 cells* 
Compound 
(7.5 µM) 
% living cells compared to 
DMSO control* 
Compound 
(7.5 µM) 
% living cells compared to 
DMSO control* 
1a 97 2e 92 
1b 78 2f 95 
1c 100 2g 94 
1d 9 2h 90 
1e 95 2i 94 
1f 49 2j 89 
1g 99 2k 100 
1h 92 2l 92 
1i 100 3o 88 
1j 88 4a 92 
1k 86 4b 63 
1l 98 4d 100 
1m 83 4e 99 
1n 90 4f 98 
1o 95 4g 99 
1p 94 4h 100 
1q 100 4i 92 
1r 100 4j 84 
1s 96 4k 100 
1t 100 6a 91 
1u 100 6c 85 
2a 83 6h 84 
2b 84 9 100 
2c 94 11 100 
2d 93   
 
* Average of at least two independent experiments. 
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5) Supplementary Table S4. Selectivity profile of 4f vs. PKC family and some AGC kinases, 
Kinase (human) % inhibition at 10 µM of 4f 
PKCα 4 
PKCβI n.i. 
PKCβII 12 
PKCγ 6 
PKCδ n.i. 
PKCε n.i. 
PKCη n.i. 
PKCθ n.i. 
PKCι n.i. 
PDK1  8 
PKA n.i. 
 RSK1 3 
MSK1 11 
 p70S6K n.i. 
SGK1 18 
                                n.i.: no inhibition. Each value is representative of at least two independent assays which 
essentially gave the same results. 
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6) Supplementary Figure S1. Molecular electrostatic potentials (MEP) mapped on the isoelectronic density 
surfaces of 0.002 e/a03. The ab initio calculations of the lowest energy conformers  and the electrostatic potentials 
were carried out at the B3LYP density functional scheme with the  6-31G** basis set in water, as implemented in 
the Gaussian 03 suite of programs.18 The color codes were uniformly adjusted to range from -150 to +390 kJ/mol. 
The arrow points to the hydrogen of the phenolic hydroxyl, which shows a higher positive potential in compounds 
from panel (A) than in those from (B). Hence the OH hydrogen in compounds from (A) is expected to exhibit a 
higher donor strength. 
2c
2l
2a
2d 2e
2g2j
A
B kJ/mol
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3.2 Trisubstituted and Tetrasubstituted Pyrazolines as a 
Novel Class of Cell-growth Inhibitors in Tumor Cells 
with Wild Type p53 
A major part of this chapter is submitted to the Journal of Bioorganic and Medicinal Chemistry  
Abstract: Derivatives with scaffolds of 1,3,5-tri-substituted pyrazoline and 1,3,4,5-tetra-
substituted pyrazoline were synthesized and tested for their inhibitory effects versus the p53+/+ 
HCT116 and p53-/- H1299 human tumor cell lines. Several compounds were active against the 
two cell lines displaying IC50 values in the low micromolar range with a clearly more 
pronounced effect on the p53+/+ HCT116 cells. The compound class shows excellent 
developability due to the modular synthesis, allowing independent optimization of all three to 
four key substituents to improve the properties of the molecules.  
Introduction 
The pro-apoptotic p53 protein is a transcription factor that responds to various stress 
stimuli such as DNA damage and oxidative stress by increasing the expression of proteins 
involved in DNA repair, cell cycle arrest and induction of apoptosis.1 Consistent with its role as a 
tumor-suppressor, p53 is deleted or mutated in approximately 50% of human cancers. In other 
tumors, p53 is retained in its wild type form, but its activity is effectively inhibited by the 
negative regulator murine double minute 2 (Mdm2). Mdm2, also known as E3 ubiquitin-protein 
ligase Mdm2, is a protein that is encoded by the MDM2 gene in which the human homolog is 
sometimes referred to as Hdm2. Mdm2 serves to down regulate p53 levels by C-terminal 
ubiquitination and subsequent proteasomal degradation. In addition, Mdm2 has been shown to 
inhibit p53 transcriptional activity through direct binding to the p53 transactivation domain.2-4 
The interaction between Mdm2 and p53 involves a short helix formed by residues 13-29 of p53 
and a hydrophobic cleft in Mdm2.  
The realization that p53 most contributing residues to this interaction are Phe19, Trp23 
and Leu26 stimulated the efforts to identify drug-like inhibitors of this protein-protein 
interaction. Such inhibitors are expected to release p53 from the negative control of Mdm2, and 
activate the apoptotic p53 pathway in tumors expressing wild type p53. However, tumors with 
mutated or deleted p53 are expected to be less responsive.5-7 Such compounds may be useful for 
indications such as colorectal cancer chemoprevention or the treatment of precancerous 
conditions (e.g. adenomatous polyps) where p53 is functional but inhibited by Mdm2.  
The prototypes for such class of inhibitors are imidazoline derivatives known as nutlins I-
III (Figure 1). Structure activity relationships show that the cis-imidazoline represents a useful 
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scaffold to project functional groups similar to a helical peptide. Nutlins are tetrasubstsituted 
imidazoline derivatives with two orthogonal halophenyls projecting in a non-coplanar style 
relative to the core ring, other substituents are an alkoxyphenyl substituent and a tertiary amide 
substituent. The alkoxyphenyl is directed towards the Phe19 pocket, one of the halo-phenyl 
group sits deeply in the Trp23 pocket while the other occupies the Leu26 pocket. Galatin and 
Abraham proposed a pharmacophore model based on the crystal structure of p53 peptide in 
complex with Mdm2 and several known non-peptidic small molecule inhibitors of Mdm2, with 
the three lipophlilc groups at particular distances from each other.8 
 
Figure 1: Previously reported Mdm-2 antagonists I-V. 
Later, other structurally related compounds followed including the benzodiazepinedione 
IV and the spiroindole V (Figure1), all sharing at least two haloaryl groups projecting from a 
core diazepindione or pyrolidine ring with nutlins.9-11 
Although several of these inhibitors exhibited cellular activity, extensive optimization of 
the selectivity towards the Mdm2 binding pocket might be required, since a hydrophobic groove 
is characteristic of many “hot spots” at protein-protein interaction sites; bearing in mind that such 
hot spot binding pockets can possess a high conformational adaptivity and that hydrophobic 
contacts are not directional and thus less specific in their interactions. The chosen scaffolds for 
inhibitors should offer high synthetic flexibility to allow for the generation of a great variety of 
analogues during the optimization process.12 Hence the search for additional rigid scaffolds 
appropriate to inhibit the Mdm2-p53 interaction and showing favorable synthetic tractability 
(good “developability”) is still ongoing. 
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In this report, we describe the design and synthesis of forty-six novel small organic 
molecules with core pyrazoline ring and two orthogonal dihalophenyl, and alkoxyphenyl or 
tertiary-butyl (1-44) substituent to mimic the potential three hydrophobic residues (Phe19, 
Trp23, and Leu26) of p53. Moreover two of the compounds contain an additional tertiary amide 
substituent (45, 46). As a first assay, the compounds were tested for their growth inhibitory 
activity against p53 wild-type (+/+) HCT116 human colorectal carcinoma and p53 null (-/-) 
H1299 human lung adenocarcinoma cell lines.  
Design of compounds 
Our main objective was to develop a new class of potential p53-Mdm2 antagonists with 
an excellent synthetic tractability, thus providing the option to independently vary each key 
moiety for the optimization of potency, selectivity and pharmacokinetic properties. To this end, a 
synopsis of the hitherto published inhibitor classes led us to the design of the tri- and tetra-
substituted pyrazoline derivatives.  
 
Thus, three sets of pyrazolines were designed with a 1,3,5-trisubstituted pyrazoline 
scaffold. The 1st group is represented by compounds (1-29) in which the phenyls at positions 1 
and 5 are mono-substituted with a chlorine atom and the 3-phenyl is mono- (1-27) or 
disubstituted (28, 29) with methoxy functions.  The position of the chlorine atoms and the 
methoxy group(s) was varied in a systematic way to define the optimum substitution pattern that 
shows the best potency and selectivity. The dimethoxy substitution was made in a later stage in 
compounds 28 and 29 to test the effect of the 2nd methoxy group on the activity of compound 4, 
the most potent growth inhibitor against the HCT116 tumor cell line in the series.  
 
In the 2nd set of compounds (30-35) t-butyl group was used as a lipophilic substituent 
instead of the methoxyphenyl at position 3 of the pyrazoline. Besides, several lipophilic groups 
were employed at position 5 like naphthyl, biphenyl, 2,4-dichlorophenyl, 4-chlorophenyl and 4-
bromophenyl. In the third set (36-44), haloaryl and carboaryls at positions 1 and 5 of pyrazoline 
were used similar to the first and second sets. However the 2-ethoxy phenyl part reported in 
nutlin-2 is used at position 3. In the last 2 compounds (45-46), we introduced a 4th substitution at 
position 4 of the pyrazoline with morpholinocarbonyl group to test the effect of introducing a 
tertiary amide on activity and to improve the water solubility.  
 
To check the validity of our design, a three-dimensional overlay of the energy minimized 
forms of the 1,3.5-triphenylpyrazolinre scaffold (for which different substitution patterns are 
tried in compounds 1-29) and compound 45 with nutlin-2 from PDB 1RV1 was done. It can be 
seen that all the substituents relevant to the binding of nutlin-2 to Mdm-2 overlapped well with 
the corresponding moieties of our compounds (Figure 2). 
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Figure 2: An overlay of the energy minimized forms the unsubstituted 1,3,5-triphenylpyrazoline scaffold (yellow) 
and  compound 45 (blue) with nutlin-2 (red) from PDB 1RV1, showing spatial similarity. Energy minimization was 
done by MMFF94x forcefield and followed by automatic overlaying using MOE software. 
Results and Discussion 
Chemistry 
The synthesis of the desired pyrazolines was carried out in two steps. In the first step 
(Scheme 1), a Claisen-Schmidt condensation was carried out between aromatic aldehydes and 
pinacolone or acetophenone analogues, using 10% aq. KOH as a catalyst in methanol, in order to 
afford the required enones. In the second step, these enones were reacted to give the desired 
pyrazolines using the previously reported regioselective synthesis of 1,3,5-triarylpyrazolines.13 
This was accomplished via enone-arylhydrazine hydrochloride condensation reaction under an 
inert atmosphere using DMF as solvent while heating for 5 hours at 85oC. To introduce the 
morpholinocarbonyl group at position 4 of the respective pyrazoline derivative (34, 36), 
deprotonation was carried out by LDA at -78oC to create the anion which reacted with 
morpholinecarbonyl chloride to give the desired product (Scheme 1).13  
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Scheme 1: 
 
Reagents and conditions: (i) 10%KOH, MeOH, ice cooling then room temperature, over night (ii) 1.5 equiv Ar-NH-
NH2.HCl, DMF, 85 oC, 5h (iii) 1.5 equiv 4-morpholinecarbonylchloride, 1.5 equiv LDA, THF, -78 oC then room 
temperature, 20h 
 
Compound # 
 
C 
 
R1 
 
R2 
 
R3 
 
1 1 4-chlorophenyl 4-methoxyphenyl 2-chloro 
2 1 4-chlorophenyl 4-methoxyphenyl 3-chloro 
3 1 4-chlorophenyl 4-methoxyphenyl 4-chloro 
4 2 3-chlorophenyl 4-methoxyphenyl 2-chloro 
5 2 3-chlorophenyl 4-methoxyphenyl 3-chloro 
6 2 3-chlorophenyl 4-methoxyphenyl 4-chloro 
7 3 2-chlorophenyl 4-methoxyphenyl 2-chloro 
8 3 2-chlorophenyl 4-methoxyphenyl 3-chloro 
9 3 2-chlorophenyl 4-methoxyphenyl 4-chloro 
10 4 4-chlorophenyl 3-methoxyphenyl 2-chloro 
11 4 4-chlorophenyl 3-methoxyphenyl 3-chloro 
12 4 4-chlorophenyl 3-methoxyphenyl 4-chloro 
13 5 3-chlorophenyl 3-methoxyphenyl 2-chloro 
14 5 3-chlorophenyl 3-methoxyphenyl 3-chloro 
15 5 3-chlorophenyl 3-methoxyphenyl 4-chloro 
16 6 2-chlorophenyl 3-methoxyphenyl 2-chloro 
17 6 2-chlorophenyl 3-methoxyphenyl 3-chloro 
18 6 2-chlorophenyl 3-methoxyphenyl 4-chloro 
19 7 4-chlorophenyl 2-methoxyphenyl 2-chloro 
20 7 4-chlorophenyl 2-methoxyphenyl 3-chloro 
21 7 4-chlorophenyl 2-methoxyphenyl 4-chloro 
22 8 3-chlorophenyl 2-methoxyphenyl 2-chloro 
23 8 3-chlorophenyl 2-methoxyphenyl 3-chloro 
24 8 3-chlorophenyl 2-methoxyphenyl 4-chloro 
25 9 2-chlorophenyl 2-methoxyphenyl 2-chloro 
26 9 2-chlorophenyl 2-methoxyphenyl 3-chloro 
27 9 2-chlorophenyl 2-methoxyphenyl 4-chloro 
28 10 3-chlorophenyl 3,4-dimethoxyphenyl 2-chloro 
29 11 3-chlorophenyl 2,4-dimethoxyphenyl 2-chloro 
30 12 naphthalen-2-yl t-Bu 4-chloro 
31 13 [1,1'-biphenyl]-4-yl t-Bu 4-chloro 
32 14 4-chlorophenyl t-Bu 4-chloro 
33 15 3,4-dichlorophenyl t-Bu 4-chloro 
34 16 4-bromophenyl t-Bu 4-bromo 
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35 14 4-chlorophenyl t-Bu 4-bromo 
36 17 4-chlorophenyl 2-ethoxyphenyl 4-chloro 
37 18 4-bromophenyl 2-ethoxyphenyl 4-bromo 
38 19 5-bromothiophen-2-yl 2-ethoxyphenyl 4-bromo 
39 17 4-chlorophenyl 2-ethoxyphenyl 4-bromo 
40 20 naphthalen-2-yl 2-ethoxyphenyl 4-chloro 
41 21 [1,1'-biphenyl]-4-yl 2-ethoxyphenyl 4-chloro 
42 22 3,4-dichlorophenyl 2-ethoxyphenyl 4-chloro 
43 23 2,4-dichlorophenyl 2-ethoxyphenyl 4-chloro 
44 24 4-fluorophenyl 2-ethoxyphenyl 4-chloro 
45 14 4-chlorophenyl t-Bu 4-chloro 
46 17 4-chlorophenyl 2-ethoxyphenyl 4-chloro 
 
Biological Activity 
To evaluate whether our new scaffolds are active in cells and in addition show indications 
of the desired mechanism of action, we screened all of the synthesized pyrazolines for their 
ability to inhibit the growth of HCT116 and H1299 cell lines at 20 µM (higher concentrations 
could not be used to avoid solubility problems of some compounds). IC50 values were 
determined in concentration-response studies for compounds which showed more than 50 % 
inhibition in the single dose screen. H1299 is a human non-small cell lung carcinoma cell line 
derived from the lymph node; which has a homozygous partial deletion of the TP53 gene and as 
a result, does not express the p53 protein. On the other hand, HCT116 cells are human colorectal 
carcinoma cells with wild type p53 that are widely used to study the effect of small molecule 
Mdm2 antagonists.  
 
Nutlin-3 was used as a positive control to benchmark the activity of the new derivatives. 
Mdm2 antagonists are expected to show greater potency to inhibit the growth of HCT116 cells 
compared to H1299 cells, as was observed for nutlin-3 (showing IC50 values of 1.6 µM vs. 14.7 
µM, respectively). The results are shown in Table 1. 
 
Structure activity relationship 
Generally, active cell-growth inhibitors showed preferential inhibition of HCT116 cells 
containing wild type p53 in a behavior analogous to nutlin-3 (compounds 4, 16, 22, 23, 30, 33, 
35 and 45). Compounds 32 and 46 were the only exceptions and were found to display almost 
equivalent growth inhibition in both tumor cell lines.  
 
In the first set of compounds (1-27), the activity was sharply dependent on the halogen 
substitution pattern at the 1- and 5-phenyls and several clear relationships between structure and 
cell-growth inhibition could be observed for the most favorable substitutions. 
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Table 1*. Inhibition of HCT116 and H1299 cell lines 
Compound # IC50 HCT116 (µM) IC50 H1299 (µM) 
1 ND ND 
2 ND ND 
3 ND ND 
4 1.5 7.2 
5 ND ND 
6 ND ND 
7 ND ND 
8 ND ND 
9 ND ND 
10 ND ND 
11 ND ND 
12 ND ND 
13 ND ND 
14 ND ND 
15 18.5 ND 
16 2.5 13.6 
17 ND ND 
18 ND ND 
19 ND ND 
20 ND ND 
21 ND ND 
22 1.9 13.4 
23 1.6 11.7 
24 ND ND 
25 ND ND 
26 ND ND 
27 ND ND 
28 ND ND 
29 ND ND 
30 12.7 ND 
31 ND ND 
32 17.3 19.3 
33 5.3 14.8 
34 ND ND 
35 4.3 19.4 
36 ND ND 
37 ND ND 
38 ND ND 
39 ND ND 
40 ND ND 
41 ND ND 
42 ND ND 
43 ND ND 
44 ND ND 
45 3.5 14.2 
46 8.0 8.4 
Nutlin 3 1.6 14.7 
 
*Values are mean values of at least two experiments; standard deviation <10%. 
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At the 1-phenyl moiety, a chlorine substituent in ortho position was a consistent feature 
in three of the most potent growth inhibitors (4, 16 and 22). Compound 23 the meta-chloro 
analogue of 22 showed comparable activities. On the other hand, none of the para-chloro 
derivatives showed significant activity. Similar to the 1-phenyl, substitution with 4-chloro at the 
phenyl ring in position 5 did not lead to active compounds, while shifting the chlorine to meta 
position was optimal for the activity, as demonstrated by 3 of the most potent member of the 1st 
set bearing a meta-chloro substituent at their 5-phenyl moiety (4, 22, 23). Nevertheless, ortho-
chloro at the 1-phenyl could still give potent compounds (16).  
 
Concerning the methoxy substitution at the 3-phenyl, it was tolerated at all positions with 
high potency whether ortho (compounds 22 and 23), meta (compound 16) or para (4) indicating 
that this moiety does not significantly affect potency. However, in compound 4, the most potent 
growth inhibitor against both cell lines, introducing a second methoxy either at meta or ortho 
positions was deleterious to the activity as exemplified by compounds 28 and 29. 
 
For the second set of compounds, the 3-t-butyl derivatives, four out of the six analogues 
showed growth inhibitory activity, indicating that t-Bu group could act as a possible replacement 
for the methoxyphenyl group in the first set of compounds. However, none of the compounds 
were more potent than the triphenylpyrazolines in the first set. Compound 32 with bis-1,5-(4-
chlorophenyl) moieties showed marginal activity towards both tumor cell lines. Replacement of 
the 4-chlorophenyl at position 5 of the pyrazoline in compound 32 by a 2-naphthyl substituent 
(compound 30) caused a slight improvement in activity towards HCT116 cells only, while the 
biphenyl moiety in compound 31 seemed too bulky to be tolerated.  
 
On the other hand, adding another chlorine at position 3 of the 5-phenyl (33) or replacing 
the 4-Cl at the 1-phenyl by 4-Br (35) caused a 3-4 fold increase in the inhibitory activity towards 
HCT116 cell line with slight or no improvement in the activity towards H1299 cell line. 
Surprisingly, replacement of the two chlorine atoms in compound 32 by bromine atoms was 
inferior for activity (34). 
 
Unexpectedly, adapting the 2-ethoxyphenyl at the 3 position of the pyrazoline abolished 
the activity (compounds 36-44). This negative result might be due to the sterical requirements of 
the ethoxy group that are not provided by the potential receptor pocket. Interestingly, introducing 
morpholinocarbonyl at position 4 of compound 36 (compound 46) recovered some the potency 
on both cell lines equally. This might be due to a direct interaction achieved by the introduced 
group, or its effect on the relative orientation and conformation of the other substituents arising 
from the pyrazoline core. In addition, the morpholinocarbonyl group is expected to have a 
profound effect in enhancing the hydrophilic characteristics, which might improve the 
performance of the compound in the assay conditions. Similarly, the 4th substitution with 
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morpholinocarbonyl group in compound 32 (compound 45) has increased the selectivity, with an 
improved potency by more than 4 fold against HCT116 cell line. 
 
In summary, the 1,3,5-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoline scaffolds 
yielded potent inhibitors of the colorectal cancer line HCT116 in the low micro molar range, 
showing a good SAR with clear dependence on the halogen substitution pattern at the 1- and 5- 
phenyl rings as described herein. Many compounds showed a preferential inhibition pattern 
similar to nutlin-3 when comparing HCT116 and H1299 cell lines, proposing Mdm2 as a 
potential molecular target. Thus, we tested whether the compounds were able to displace a 
fluorescence-labeled peptide (derived from p53) in a concentration-dependent manner from its 
complex with Mdm2 or MdmX, respectively. Successful displacement leads to a substantial 
decrease in fluorescence anisotropy reported as a relative value (%FA) in comparison to 
lithocholic acid as a positive control leading to a complete displacement of the fluorescence-
labeled peptide (0 %FA).  
 
Protein expression and purification, as well as the setup of the FP assay were performed 
as described recently.14 To facilitate measurements despite solubility issues of various 
compounds, we have been using 10% v/v DMSO for all experiments. Under these conditions 
compounds used as positive controls did not indicate deviations from standard conditions. For 
none of the compounds identified as hits in cell lines a reduction to at least 50% FA was found 
when titrating from 5µM up to concentrations of 1mM. Among the compounds with inhibitory 
potency in cell lines, 4, 15, 16, 22, 23, and 46 showed intrinsic fluorescence possibly interfering 
with the assay. Still, only for 16 an irregular FP curve was retrieved showing increase of 
fluorescence instead of the expected decrease. Compounds 30, 32, 33, 35, and 45 showed no 
intrinsic fluorescence, but also no decrease beyond 70% relative fluorescence anisotropy for both 
Mdm2 and MdmX. Of course, all these results can be biased by solubility issues of the 
compounds under the used assay conditions. However, clearly none of the compounds showed 
binding to Mdm2 or MdmX similar to the positive controls. Thus, it remains unclear through 
which mode of action the encouraging results in the cell lines can be explained. These results 
suggest that substantial modifications to improve polarity and solubility characteristics should be 
useful to elucidate our findings and might lead to new p53-Mdm2 antagonists.     
 
EXPERIMENTAL SECTION 
 
Chemistry 
 
Solvents and reagents were obtained from commercial suppliers and used as received. A Bruker 
DRX 500 spectrometer was used to obtain 1H NMR and 13C NMR spectra. The chemical shifts 
are referenced to the residual protonated solvent signals or TMS was used as a reference. At least 
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95% purity in all the tested compounds (table 1) was obtained by means of HPLC coupled with 
mass spectrometry.  Mass spectra (HPLC-ESI-MS) were obtained using a TSQ quantum 
(Thermo Electron Corporation) instrument prepared with a triple quadrupole mass detector 
(Thermo Finnigan) and an ESI source. All samples were inserted using an autosampler 
(Surveyor, Thermo Finnigan) by an injection volume of 10 µL. The MS detection was 
determined using a  source CID of 10 V and carried out at a spray voltage of 4.2 kV, a nitrogen 
sheath gas pressure of 4.0 X 105Pa, a capillary temperature of 400 oC , a capillary voltage of 35 
V and an auxiliary gas pressure of 1.0 X 105 Pa.  The stationary phase used was an RP C18 
NUCLEODUR 100-3 (125 X 3 mm) column (Macherey-Nagel). The solvent system consisted of 
water containing 0.1% TFA (A) and 0.1% TFA in acetonitrile (B). HPLC-Method: flow rate 400 
µL/min. The percentage of B started at an initial of 5%, was increased up to 100% during 16 
min, kept at 100% for 2 min, and flushed back to 5% in 2 min. Melting points were determined 
using a Mettler FP1 melting point apparatus and are uncorrected. 
 
General procedure for enone synthesis.  
 
To a an ice-cooled solution of the appropriate ketone (10 mmol) in MeOH (50 mL), 10 % 
KOH aq. solution (30 ml) was added, followed by gradual addition of the corresponding aryl 
aldehyde (10 mmol). The mixture was left to attain room temperature and stirred overnight. The 
solid product was filtered and washed three times with MeOH/H2O mixture (5:3) and left to dry. 
In case of oily products the reaction mixture was extracted by CH2Cl2 (4 x 20 mL) and the 
combined organic layers were washed with water, filtered over anhydrous MgSO4, evaporated 
under reduced pressure and used without further purification. 
 
(E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (C1) . Synthesized according to 
the general procedure for enone synthesis using 1-(4-methoxyphenyl) ethanone and 4-
chlorobenzaldehyde; yellow solid; yield: 2.61 g (96 %); mp 125-126 °C.15  
(E)-3-(3-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (C2). Synthesized according to 
the general procedure for enone synthesis using 1-(4-methoxyphenyl) ethanone and 3-
chlorobenzaldehyde; yellow solid; yield: 2.32 g (85 %); mp 97-99 °C.16 
  
(E)-3-(2-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (C3). Synthesized according to 
the general procedure for enone synthesis using 1-(4-methoxyphenyl)ethanone and 2-
chlorobenzaldehyde; yellow solid; yield: 2.48 g (91 %); mp 79-80 °C.17  
 
(E)-3-(4-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (C4). Synthesized according to 
the general procedure for enone synthesis using 1-(3-methoxyphenyl)ethanone and 4-
chlorobenzaldehyde; yellow oil; yield: 2.21 g (81 %).18 
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(E)-3-(3-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (C5). Synthesized according to 
the general procedure for enone synthesis using 1-(3-methoxyphenyl)ethanone and 3-
chlorobenzaldehyde; yellow oil; yield: 2.4 g (88 %).19 
 
(E)-3-(2-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one (C6). Synthesized according to 
the general procedure for enone synthesis using 1-(3-methoxyphenyl)ethanone and 2-
chlorobenzaldehyde; yellow solid; yield: 2.56 g (94 %); mp 117-117 °C.20 
 
 (E)-3-(4-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (C7). Synthesized according to 
the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 4-
chlorobenzaldehyde; yellow oil; yield: 2.51 g (92 %).21 
 
(E)-3-(3-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (C8). Synthesized according to 
the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 3-
chlorobenzaldehyde; yellow solid; yield: 2.37 g (87 %); mp 96-98 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.48 (dd, J = 7.6, 1.8 Hz, 1H), 7.40 (dd, J = 8.8, 6.9 Hz, 2H), 7.33 (ddd, J = 8.4, 7.4, 
1.8 Hz, 1H), 7.30 (dt, J = 7.1, 1.6 Hz, 1H), 7.25 – 7.16 (m, 3H), 6.90 – 6.87 (m, 1H), 6.85 (d, J = 
15.8 Hz, 1H), 3.76 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 192.41, 158.24, 141.15, 137.08, 
134.86, 133.16, 130.45, 130.08, 129.98, 129.01, 128.25, 127.93, 126.60, 120.82, 111.67, 55.79. 
 
(E)-3-(2-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-1-one (C9). Synthesized according to 
the general procedure for enone synthesis using 1-(2-methoxyphenyl)ethanone and 2-
chlorobenzaldehyde; yellow solid; yield: 2.29 g (84 %); mp 60-62 °C.22  
 
(E)-3-(3-chlorophenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (C10). Synthesized 
according to the general procedure for enone synthesis using 1-(3,4-dimethoxyphenyl)ethanone 
and 3-chlorobenzaldehyde; yellow solid; yield: 2.75 g (91 %); mp 110-111 °C;1H NMR (500 
MHz, CDCl3) δ 7.60 (d, J = 15.6 Hz, 1H), 7.58 – 7.53 (m, 1H), 7.53 – 7.49 (m, 2H), 7.42 (d, J = 
15.6 Hz, 1H), 7.37 (ddd, J = 6.4, 2.3, 1.5 Hz, 1H), 7.27 – 7.20 (m, 2H), 6.83 – 6.78 (m, 1H), 3.85 
(d, J = 0.8 Hz, 6H); 13C NMR (125 MHz, CDCl3) δ 188.12, 153.50, 149.36, 142.17, 136.95, 
134.93, 131.06, 130.15, 130.11, 127.77, 126.73, 123.13, 122.91, 110.80, 110.01, 56.10, 56.06. 
 
(E)-3-(3-chlorophenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one (C11). Synthesized 
according to the general procedure for enone synthesis using 1-(2,4-dimethoxyphenyl)ethanone 
and 3-chlorobenzaldehyde; yellow oil; yield: 2.66 g (88 %).23 
 
(E)-4,4-dimethyl-1-(naphthalen-2-yl)pent-1-en-3-one (C12). Synthesized according to the 
general procedure for enone synthesis using pinacolone and 2-naphthaldehyde; yellow solid; 
yield: 2.24 g (94 %); mp 117-119 °C.24  
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(E)-1-([1,1'-biphenyl]-4-yl)-4,4-dimethylpent-1-en-3-one (C13). Synthesized according to the 
general procedure for enone synthesis using pinacolone and [1,1'-biphenyl]-4-carbaldehyde; 
yellow solid; yield: 2.3 g (87 %); mp 128-130 °C.25  
 
(E)-1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one (C14). Synthesized according to the 
general procedure for enone synthesis pinacolone and 4-chlorobenzaldehyde; white solid; yield: 
2.11 g (95 %); mp 85-87 °C.26 
 
 (E)-1-(3,4-dichlorophenyl)-4,4-dimethylpent-1-en-3-one (C15). Synthesized according to the 
general procedure for enone synthesis using pinacolone and 3,4-dichlorobenzaldehyde; yellow 
solid; yield: 2.08 g (81 %); mp 94-96°C.27  
 
(E)-1-(4-bromophenyl)-4,4-dimethylpent-1-en-3-one (C16). Synthesized according to the 
general procedure for enone synthesis using pinacolone and 4-bromobenzaldehyde; yellow solid; 
yield: 2.48 g (93 %); mp 102-103 °C.26  
  
(E)-3-(4-chlorophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C17). Synthesized according to 
the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 4-
chlorobenzaldehyde; yellow oil; yield: 2.32 g (81 %); 1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J 
= 7.6, 1.8 Hz, 1H), 7.45 (d, J = 15.9 Hz, 1H), 7.40 – 7.36 (m, 2H), 7.36 – 7.30 (m, 2H), 7.26 – 
7.20 (m, 2H), 6.90 (td, J = 7.5, 0.9 Hz, 1H), 6.83 (dd, J = 11.9, 4.4 Hz, 1H), 4.00 (q, J = 7.0 Hz, 
2H), 1.29 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 192.33, 157.76, 140.79, 135.91, 
133.83, 133.18, 130.63, 129.35, 129.14, 127.71, 120.77, 116.32, 112.62, 64.25, 14.84. 
 
(E)-3-(4-bromophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C18). Synthesized according to 
the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 4-
bromobenzaldehyde; yellow oil; yield: 2.84 g (86 %); 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.68 
(m, 1H), 7.60 (d, J = 15.9 Hz, 1H), 7.57 – 7.53 (m, 3H), 7.51 – 7.45 (m, 3H), 7.06 (td, J = 7.5, 
0.8 Hz, 1H), 6.99 (dd, J = 12.8, 6.3 Hz, 1H), 4.17 (q, J = 7.0 Hz, 2H), 1.45 (t, J = 7.0 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 192.29, 157.77, 140.80, 134.25, 133.20, 132.09, 130.63, 129.57, 
129.09, 127.79, 124.22, 120.76, 112.60, 64.23, 14.83. 
 
(E)-3-(5-bromothiophen-2-yl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C19). Synthesized 
according to the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 5-
bromothiophene-2-carbaldehyde; yellow oil; yield: 3 g (89 %); 1H NMR (500 MHz, CDCl3) δ 
7.91 (dt, J = 4.2, 2.1 Hz, 1H), 7.87 (d, J = 15.4 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.51 – 7.47 (m, 
1H), 7.26 – 7.21 (m, 3H), 7.19 – 7.16 (m, 1H), 4.38 – 4.32 (m, 2H), 1.69 (t, J = 7.0 Hz, 3H); 13C 
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NMR (125 MHz, CDCl3) δ 191.28, 157.94, 142.56, 133.71, 133.35, 131.62, 131.20, 130.79, 
128.78, 126.56, 120.75, 115.53, 112.54, 64.25, 14.89. 
 
(E)-1-(2-ethoxyphenyl)-3-(naphthalen-2-yl)prop-2-en-1-one (C20). Synthesized according to 
the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 2-
naphthaldehyde; yellow solid; yield: 2.74 g (91 %); mp 89-91 °C.28 
 
(E)-3-([1,1'-biphenyl]-4-yl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C21). Synthesized according 
to the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and [1,1'-
biphenyl]-4-carbaldehyde; yellow solid; yield: 3.08 g (94 %); mp 98-99 °C;1H NMR (500 MHz, 
CDCl3) δ 7.48 – 7.45 (m, 3H), 7.44 (d, J = 2.4 Hz, 2H), 7.43 – 7.39 (m, 4H), 7.31 (d, J = 15.9 
Hz, 1H), 7.27 – 7.21 (m, 2H), 7.15 (ddt, J = 5.1, 3.9, 1.9 Hz, 1H), 6.82 (td, J = 7.5, 0.9 Hz, 1H), 
6.77 (d, J = 8.3 Hz, 1H), 3.94 (q, J = 7.0 Hz, 2H), 1.23 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 192.69, 157.71, 142.86, 142.08, 140.23, 134.27, 132.97, 130.58, 129.43, 128.87, 
128.77, 127.78, 127.52, 127.14, 127.01, 120.74, 112.65, 64.29, 14.87. 
 
(E)-3-(3,4-dichlorophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C22). Synthesized according 
to the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 3,4-
dichlorobenzaldehyde; yellow solid; yield: 2.53 g (79 %); mp 80-82 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.47 (dd, J = 7.7, 1.8 Hz, 1H), 7.44 (d, J = 2.0 Hz, 1H), 7.30 – 7.26 (m, 2H), 7.26 – 
7.23 (m, 2H), 7.20 – 7.16 (m, 1H), 6.81 (ddd, J = 4.9, 3.3, 1.0 Hz, 1H), 6.78 – 6.75 (m, 1H), 3.93 
(q, J = 7.0 Hz, 2H), 1.22 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 191.87, 157.90, 
139.16, 135.49, 133.83, 133.47, 133.19, 130.86, 130.74, 130.34, 129.63, 128.82, 127.20, 120.83, 
112.61, 64.27, 14.85. 
 
(E)-3-(2,4-dichlorophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-one (C23). Synthesized according 
to the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 2,4-
dichlorobenzaldehyde; yellow solid; yield: 2.79 g (87 %); mp 75-77 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.72 (d, J = 15.9 Hz, 1H), 7.45 (dt, J = 8.5, 4.3 Hz, 1H), 7.42 – 7.37 (m, 1H), 7.27 – 
7.20 (m, 3H), 7.04 (dd, J = 8.3, 1.5 Hz, 1H), 6.84 – 6.78 (m, 1H), 6.74 (t, J = 9.5 Hz, 1H), 3.94 – 
3.88 (m, 2H), 1.19 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 192.12, 157.80, 136.75, 
135.98, 135.90, 133.36, 132.21, 130.74, 130.04, 129.88, 128.88, 128.22, 127.47, 120.82, 112.57, 
64.25, 14.84. 
 
(E)-1-(2-ethoxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (C24). Synthesized according to 
the general procedure for enone synthesis using 1-(2-ethoxyphenyl)ethanone and 4-
fluorobenzaldehyde; yellow oil; yield: 2.51 g (93%); 1H NMR (500 MHz, CDCl3) δ 7.82 (dt, J = 
5.8, 2.9 Hz, 1H), 7.78 – 7.69 (m, 3H), 7.63 – 7.59 (m, 1H), 7.57 (d, J = 15.5 Hz, 1H), 7.27 – 7.21 
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(m, 2H), 7.21 – 7.16 (m, 1H), 7.14 (dd, J = 5.8, 2.5 Hz, 1H), 4.29 (dd, J = 9.2, 4.8 Hz, 2H), 1.58 
(t, J = 7.0 Hz, 3H). 
 
General procedure for pyrazoline synthesis.  
A mixture of the enone derivative (2 mmol) and the corresponding phenylhydrazine 
hydrochloride (3 mmol) in 15 mL of anhydrous DMF was heated to 85 °C for 5 hours under 
argon atmosphere. The reaction solution was cooled to room temperature and partitioned 
between 50 mL of diethyl ether and 20 mL of water. The organic layer was separated and 
washed with three 20 mL-portions of water. The aqueous layers were combined and extracted 
with three 20 mL-portions of diethyl ether. The organic layers were combined, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified using column 
chromatography or used in the next step without further purification. 
 
1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (1). 
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C1) and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; light brown solid; yield: 0.35 g (45%); mp162-
163 oC; 1H NMR (500 MHz, CDCl3) δ 7.73 – 7.68 (m, 2H), 7.40 (dd, J = 12.5, 6.9 Hz, 1H), 7.19 
(dt, J = 9.4, 4.7 Hz, 1H), 7.12 – 7.05 (m, 5H), 6.97 – 6.92 (m, 2H), 6.88 – 6.83 (m, 1H), 5.79 (dd, 
J = 11.3, 4.6 Hz, 1H), 3.85 (s, 3H), 3.75 (dt, J = 28.6, 14.3 Hz, 1H), 3.32 (dd, J = 16.8, 4.6 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 149.96, 142.94, 139.56, 133.39, 131.12, 130.22, 128.62, 
128.14, 127.54, 127.09, 125.18, 124.59, 124.06, 123.54, 114.11, 65.51, 55.38, 42.64; MS (ESI): 
m/z = 397.05 (M+H)+. 
 
1-(3-chlorophenyl)-5-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (2). 
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C1)  and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.28 g (36%); mp121-122oC; 
1H NMR (500 MHz, CDCl3) δ 7.67 – 7.62 (m, 2H), 7.32 – 7.28 (m, 2H), 7.24 – 7.19 (m, 2H), 
7.15 (t, J = 2.1 Hz, 1H), 7.04 (t, J = 8.1 Hz, 1H), 6.93 – 6.89 (m, 2H), 6.72 (dddd, J = 8.2, 4.6, 
2.1, 0.8 Hz, 2H), 5.17 (dd, J = 12.2, 6.7 Hz, 1H), 3.85 – 3.76 (m, 4H), 3.07 (dd, J = 17.0, 6.7 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 160.50, 147.71, 145.82, 140.62, 134.82, 133.50, 129.88, 
129.43, 127.43, 127.25, 124.90, 118.78, 114.11, 113.39, 110.99, 63.53, 55.36, 43.78; MS 
(ESI):m/z = 397.02 (M+H)+. 
 
1,5-bis(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (3). The title 
compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-
1-one (C1)  and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
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pyrazoline synthesis; beige solid; yield: 0.4 g (51%); mp111-112oC;1H NMR (500 MHz, CDCl3) 
δ 7.67 – 7.60 (m, 2H), 7.30 – 7.26 (m, 2H), 7.20 (dd, J = 11.0, 7.2 Hz, 2H), 7.13 – 7.07 (m, 2H), 
6.94 – 6.87 (m, 4H), 5.15 (dd, J = 12.1, 7.1 Hz, 1H), 3.84 – 3.75 (m, 4H), 3.07 (dd, J = 17.0, 7.1 
Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.67, 147.63, 143.74, 140.95, 133.74, 130.22, 129.06, 
127.58, 127.56, 125.27, 124.09, 114.64, 114.35, 64.09, 55.61, 44.08; MS (ESI):m/z = 397.01 
(M+H)+. 
 
1-(2-chlorophenyl)-5-(3-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (4). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C2)  and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.37 g (47%); mp130-131 oC; 
1H NMR (500 MHz, CDCl3) δ 7.73 – 7.65 (m, 2H), 7.41 (dt, J = 6.4, 3.2 Hz, 1H), 7.20 (dd, J = 
8.0, 1.4 Hz, 1H), 7.16 (dd, J = 2.6, 1.4 Hz, 1H), 7.12 – 7.01 (m, 4H), 6.96 – 6.90 (m, 2H), 6.85 
(ddd, J = 7.9, 7.5, 1.6 Hz, 1H), 5.76 (dd, J = 11.3, 4.8 Hz, 1H), 3.84 (s, 3H), 3.76 (dd, J = 16.8, 
11.3 Hz, 1H), 3.32 (dd, J = 16.8, 4.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.77, 150.19, 
143.33, 143.14, 134.48, 130.02, 128.11, 127.82, 127.33, 127.14, 125.38, 125.14, 124.97, 124.36, 
123.80, 114.41, 114.36, 65.94, 55.63, 42.93; MS (ESI): m/z = 397.06 (M+H)+. 
 
1,5-bis(3-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (5). The title 
compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-
1-one (C2) and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; brown solid; yield: 0.43 g (55%); mp146-147 oC; 1H NMR (500 MHz, 
CDCl3) δ 7.66 – 7.60 (m, 2H), 7.30 – 7.26 (m, 1H), 7.26 – 7.21 (m, 2H), 7.18 – 7.12 (m, 2H), 
7.03 (t, J = 8.1 Hz, 1H), 6.93 – 6.86 (m, 2H), 6.71 (tdd, J = 8.6, 2.1, 0.8 Hz, 2H), 5.14 (dd, J = 
12.2, 6.8 Hz, 1H), 3.85 – 3.79 (m, 4H), 3.08 (dd, J = 17.1, 6.8 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 160.52, 147.71, 145.84, 144.28, 135.12, 134.84, 130.58, 129.90, 128.03, 127.45, 
125.97, 124.85, 123.95, 118.85, 114.10, 113.41, 110.95, 63.67, 55.36, 43.78; MS (ESI): m/z = 
397.05 (M+H)+. 
5-(3-chlorophenyl)-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (6). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C2) and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid ; yield: 0.31 g (39%); mp 106-108 
oC; 1H NMR (500 MHz, CDCl3) δ, 7.68 – 7.61 (m, 2H), 7.35 – 7.29 (m, 2H), 7.27 – 7.24 (m, 
1H), 7.17 (dt, J = 6.8, 1.9 Hz, 1H), 7.14 – 7.09 (m, 2H), 6.95 – 6.93 (m, 1H), 6.92 (q, J = 2.1 Hz, 
2H), 6.91 – 6.90 (m, 1H), 5.14 (dd, J = 12.2, 7.2 Hz, 1H), 3.85 – 3.78 (m, 4H), 3.10 (dd, J = 
17.1, 7.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.44, 147.39, 144.38, 143.50, 135.10, 
130.58, 129.28, 128.84, 128.00, 127.36, 126.06, 124.01, 123.89, 114.38, 114.11, 63.96, 55.37, 
43.83; MS (ESI): m/z = 396.99 (M+H)+. 
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1,5-bis(2-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (7). The title 
compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-
1-one (C3) and 2-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; yellowish white solid; yield:  0.5 g (63%); mp 142-143 oC; 1H NMR (500 
MHz, CDCl3) δ 7.72 – 7.65 (m, 2H), 7.44 (dd, J = 8.2, 1.5 Hz, 1H), 7.32 (ddd, J = 6.9, 4.9, 1.9 
Hz, 2H), 7.27 – 7.24 (m, 1H), 7.12 (dtdd, J = 14.7, 8.8, 7.4, 1.4 Hz, 3H), 6.93 – 6.86 (m, 3H), 
6.15 (dd, J = 11.3, 6.4 Hz, 1H), 3.86 – 3.81 (m, 4H), 3.09 (dd, J = 16.6, 6.4 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 160.49, 149.65, 142.87, 139.05, 132.08, 130.96, 129.66, 128.54, 127.91, 
127.59, 127.10, 127.06, 125.19, 124.49, 123.40, 121.59, 114.04, 63.01, 55.36, 42.02; MS (ESI): 
m/z = 397.07 (M+H)+. 
 
5-(2-chlorophenyl)-1-(3-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (8). 
The title compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C3) and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.23 g (29%); mp148-149 
oC;1H NMR (500 MHz, CDCl3) δ 7.76 – 7.71 (m, 2H), 7.51 (dddd, J = 6.9, 6.5, 1.2, 0.5 Hz, 1H), 
7.31 – 7.20 (m, 4H), 7.11 (dt, J = 5.5, 4.8 Hz, 1H), 7.01 – 6.95 (m, 2H), 6.82 – 6.77 (m, 1H), 
6.71 (ddd, J = 8.3, 2.2, 0.9 Hz, 1H), 5.65 (dd, J = 12.2, 6.4 Hz, 1H), 4.01 (dd, J = 17.2, 12.2 Hz, 
1H), 3.89 (s, 3H), 3.11 (dd, J = 17.2, 6.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.49, 
148.10, 145.63, 138.76, 134.90, 131.79, 129.96, 129.94, 128.92, 127.66, 127.45, 127.18, 124.98, 
118.68, 114.07, 113.23, 110.71, 60.96, 55.35, 42.28; MS (ESI): m/z = 397.07 (M+H)+. 
 
5-(2-chlorophenyl)-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (9). 
The title compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(4-
methoxyphenyl)prop-2-en-1-one (C3) and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.35 g (44%); mp149-151 oC; 
1H NMR (500 MHz, CDCl3) δ 7.67 – 7.63 (m, 1H), 7.45 – 7.43 (m, 1H), 7.28 – 7.24 (m, 2H), 
7.23 – 7.16 (m, 2H), 7.15 – 7.10 (m, 2H), 7.01 – 6.96 (m, 1H), 6.93 – 6.86 (m, 3H), 5.57 (dd, J = 
12.2, 6.7 Hz, 1H), 3.95 (dd, J = 17.1, 12.2 Hz, 1H), 3.83 (s, 3H), 3.03 (dd, J = 17.2, 6.7 Hz, 1H) ; 
MS (ESI) :m/z = 397 (M+H)+. 
 
1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (10).  
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C4) and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.24 g (30%); mp 112-113 oC; 
1H NMR (500 MHz, CDCl3) δ 7.43 (dd, J = 8.1, 1.5 Hz, 1H), 7.39 (dd, J = 2.5, 1.5 Hz, 1H), 7.36 
– 7.31 (m, 1H), 7.30 (dt, J = 7.6, 1.3 Hz, 1H), 7.21 (dd, J = 8.0, 1.4 Hz, 1H), 7.15 – 7.07 (m, 5H), 
6.94 (ddd, J = 8.0, 2.6, 1.2 Hz, 1H), 6.89 (ddd, J = 7.9, 7.4, 1.6 Hz, 1H), 5.85 (dd, J = 11.5, 4.7 
Hz, 1H), 3.87 (s, 3H), 3.79 (dd, J = 16.9, 11.5 Hz, 1H), 3.36 (dd, J = 16.9, 4.7 Hz, 1H); 13C 
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NMR (125 MHz, CDCl3) δ 159.78, 149.77, 142.52, 139.37, 133.74, 133.46, 130.22, 129.63, 
128.64, 128.10, 127.09, 124.66, 124.31, 123.74, 118.69, 115.23, 110.73, 65.62, 55.34, 42.45.; 
MS (ESI):m/z= 397.05 (M+H)+. 
 
1-(3-chlorophenyl)-5-(4-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (11). 
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C4) and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.46 g (58%); mp 91.6-93 oC; 
1H NMR (500 MHz, CDCl3) δ 7.27 – 7.22 (m, 4H), 7.17 (ddt, J = 9.0, 4.4, 3.2 Hz, 3H), 7.12 (t, J 
= 2.1 Hz, 1H), 6.99 (t, J = 8.1 Hz, 1H), 6.87 – 6.83 (m, 1H), 6.69 (dddd, J = 8.0, 5.9, 2.1, 0.9 Hz, 
2H), 5.16 (dd, J = 12.3, 6.7 Hz, 1H), 3.81 (s, 3H), 3.77 (dd, J = 17.1, 12.3 Hz, 1H), 3.03 (dd, J = 
17.1, 6.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.00, 147.84, 145.65, 140.62, 135.08, 
133.82, 133.71, 130.15, 129.88, 129.70, 127.43, 119.37, 118.83, 115.38, 113.76, 111.37, 111.03, 
63.79, 55.60, 43.84; MS (ESI): m/z= 397.06 (M+H)+. 
 
1,5-bis(4-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (12). The title 
compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-
1-one (C4) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; light brown solid; yield: 0.29 g (37%); 156-158 oC; 1H NMR (500 MHz, 
CDCl3) δ 7.34 – 7.28 (m, 4H), 7.26 – 7.19 (m, 3H), 7.16 – 7.10 (m, 2H), 6.98 – 6.94 (m, 2H), 
6.91 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 5.22 (dd, J = 12.3, 7.0 Hz, 1H), 3.89 – 3.80 (m, 4H), 3.11 
(dd, J = 17.1, 7.0 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.05, 147.50, 143.35, 140.73, 
133.86, 133.83, 129.88, 129.69, 129.10, 127.52, 124.47, 118.77, 115.27, 114.79, 111.04, 64.14, 
55.59, 43.91; MS (ESI): m/z = 397.05 (M+H)+. 
 
1-(2-chlorophenyl)-5-(3-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (13). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C5) and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.41 g (52%); mp 99.8 oC; 1H 
NMR (500 MHz, CDCl3) δ 7.57 (dd, J = 8.1, 1.5 Hz, 1H), 7.53 – 7.50 (m, 1H), 7.43 (ddd, J = 
9.0, 7.7, 4.6 Hz, 2H), 7.35 (dt, J = 6.1, 3.1 Hz, 1H), 7.31 (s, 1H), 7.27 – 7.19 (m, 4H), 7.08 (ddd, 
J = 8.0, 2.6, 1.1 Hz, 1H), 7.03 (ddd, J = 8.9, 5.9, 1.6 Hz, 1H), 5.94 (dd, J = 11.5, 4.9 Hz, 1H), 
4.01 (s, 3H), 3.93 (dd, J = 16.9, 11.5 Hz, 1H), 3.50 (dd, J = 16.9, 4.9 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 159.82, 149.77, 142.90, 142.49, 134.28, 133.71, 130.30, 129.81, 129.63, 127.96, 
127.09, 126.87, 124.88, 124.84, 124.39, 123.79, 118.74, 115.30, 110.80, 65.83, 55.37, 42.53; MS 
(ESI): m/z = 397.08 (M+H)+. 
 
1,5-bis(3-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (14). The title 
compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-
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1-one (C5)  and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; beige solid; yield: 0.52 g (66%); mp 80-82 oC; 1H NMR (500 MHz, CDCl3) 
δ 7.36 – 7.30 (m, 2H), 7.29 (dd, J = 4.9, 2.9 Hz, 2H), 7.27 – 7.25 (m, 2H), 7.19 (t, J = 2.1 Hz, 
1H), 7.18 – 7.14 (m, 1H), 7.06 (t, J = 8.1 Hz, 1H), 6.94 – 6.89 (m, 1H), 6.79 – 6.71 (m, 2H), 5.21 
(dd, J = 12.4, 6.7 Hz, 1H), 3.88 – 3.80 (m, 4H), 3.12 (dd, J = 17.2, 6.7 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 159.80, 147.64, 145.46, 144.06, 135.18, 134.89, 133.45, 130.64, 129.95, 129.65, 
128.14, 125.94, 123.92, 119.23, 118.65, 115.25, 113.57, 111.12, 110.83, 63.72, 55.39, 43.64; MS 
(ESI):m/z= 397.04 (M+H)+. 
 
5-(3-chlorophenyl)-1-(4-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (15). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C5)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.21 g (27%); mp 137-139 oC; 
1H NMR (500 MHz, CDCl3) δ 7.28 (ddd, J = 8.0, 5.7, 2.9 Hz, 3H), 7.26 – 7.23 (m, 2H), 7.22 – 
7.19 (m, 1H), 7.16 – 7.13 (m, 1H), 7.13 – 7.09 (m, 2H), 6.96 – 6.92 (m, 2H), 6.89 (ddd, J = 8.2, 
2.6, 0.9 Hz, 1H), 5.18 (dd, J = 12.4, 7.1 Hz, 1H), 3.86 – 3.78 (m, 4H), 3.10 (dd, J = 17.1, 7.1 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 159.80, 147.26, 144.15, 143.10, 135.15, 133.56, 130.61, 
129.63, 128.88, 128.08, 126.02, 124.27, 123.96, 118.54, 115.08, 114.52, 110.78, 64.00, 55.34, 
43.66; MS (ESI):m/z = 397 (M+H)+. 
 
1,5-bis(2-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (16). The title 
compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(3-methoxyphenyl)prop-2-en-
1-one (C6)  and 2-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; light brown solid; yield: 0.27 g (34%); mp 122-124 oC; 1H NMR (500 
MHz, CDCl3) δ 7.44 (dd, J = 8.2, 1.5 Hz, 1H), 7.32 (ddd, J = 9.2, 5.0, 1.4 Hz, 2H), 7.28 (tt, J = 
4.2, 2.2 Hz, 2H), 7.26 – 7.23 (m, 2H), 7.16 – 7.05 (m, 3H), 6.91 – 6.85 (m, 2H), 6.20 (dd, J = 
11.5, 6.5 Hz, 1H), 3.89 – 3.83 (m, 4H), 3.11 (dd, J = 16.7, 6.6 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 159.77, 149.31, 142.44, 138.82, 133.83, 132.11, 130.98, 129.72, 129.56, 128.62, 
127.89, 127.10, 127.08, 124.60, 123.67, 121.87, 118.73, 115.28, 110.76, 63.14, 55.35, 41.90; MS 
(ESI):m/z = 397.06 (M+H)+. 
 
5-(2-chlorophenyl)-1-(3-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (17). 
The title compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C6)  and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.38 g (47.5%); mp153-154 
oC; 1H NMR (500 MHz, CDCl3) δ 7.52 (t, J = 7.4 Hz, 1H), 7.41 – 7.39 (m, 1H), 7.37 (t, J = 7.9 
Hz, 1H), 7.34 – 7.28 (m, 2H), 7.28 – 7.26 (m, 1H), 7.24 (d, J = 4.2 Hz, 2H), 7.15 (dd, J = 14.0, 
6.0 Hz, 1H), 7.00 – 6.94 (m, 1H), 6.87 – 6.81 (m, 1H), 6.77 – 6.72 (m, 1H), 5.71 (dd, J = 12.3, 
6.3 Hz, 1H), 4.03 (dd, J = 17.3, 12.3 Hz, 1H), 3.94 (s, 3H), 3.13 (dd, J = 17.3, 6.3 Hz, 1H); 13C 
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NMR (125 MHz, CDCl3) δ 159.79, 148.04, 145.28, 138.56, 134.94, 133.57, 131.77, 130.02, 
129.98, 129.61, 129.01, 127.69, 127.12, 119.07, 118.66, 115.23, 113.40, 110.89, 110.78, 61.03, 
55.38, 42.17; MS (ESI):m/z = 397.04 (M+H)+. 
 
5-(2-chlorophenyl)-1-(4-chlorophenyl)-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole (18). 
The title compound was prepared by reaction of (E)-3-(2-chlorophenyl)-1-(3-
methoxyphenyl)prop-2-en-1-one (C6)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.43 g (54%); mp 98-99 oC; 
1H NMR (500 MHz, CDCl3) δ 7.58 – 7.53 (m, 1H), 7.42 (dt, J = 4.2, 2.1 Hz, 1H), 7.40 (t, J = 7.9 
Hz, 1H), 7.38 – 7.35 (m, 1H), 7.35 – 7.32 (m, 1H), 7.29 – 7.22 (m, 4H), 7.05 – 6.98 (m, 3H), 
5.73 (dd, J = 12.4, 6.6 Hz, 1H), 4.07 (dd, J = 17.2, 12.4 Hz, 1H), 3.97 (s, 3H), 3.16 (dd, J = 17.2, 
6.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 160.04, 147.87, 143.16, 138.92, 133.93, 132.05, 
130.25, 129.85, 129.23, 129.17, 127.92, 127.46, 124.32, 118.81, 115.33, 114.53, 110.98, 61.48, 
55.60, 42.41; MS (ESI):m/z = 397.02 (M+H)+. 
 
1-(2-chlorophenyl)-5-(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (19). 
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C7)  and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.33 g (41%); mp 103-105 oC; 
1H NMR (500 MHz, DMSO) δ 7.82 (dd, J = 7.7, 1.8 Hz, 1H), 7.44 – 7.35 (m, 2H), 7.31 – 7.17 
(m, 5H), 7.17 – 7.07 (m, 2H), 7.02 (td, J = 7.5, 1.1 Hz, 1H), 6.93 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H), 
5.76 (dd, J = 11.1, 5.6 Hz, 1H), 3.89 (dd, J = 17.8, 11.2 Hz, 1H), 3.82 (s, 3H), 3.38 (dd, J = 17.7, 
5.6 Hz, 1H) ; MS (ESI):m/z = 397.08 (M+H)+. 
 
1-(3-chlorophenyl)-5-(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (20). 
The title compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C7)  and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.42 g (53%); mp 111-112 
oC; 1H NMR (500 MHz, CDCl3) δ 7.97 (td, J = 7.9, 1.7 Hz, 1H), 7.43 – 7.40 (m, 1H), 7.35 – 7.28 
(m, 2H), 7.19 – 7.14 (m, 3H), 7.06 – 7.01 (m, 1H), 7.01 – 6.96 (m, 1H), 6.89 (dd, J = 8.3, 0.8 Hz, 
1H), 6.74 – 6.68 (m, 1H), 6.66 – 6.61 (m, 1H), 5.56 (dd, J = 12.3, 6.5 Hz, 1H), 4.09 (dd, J = 
18.2, 12.3 Hz, 1H), 3.80 (s, 3H), 3.21 (dd, J = 18.2, 6.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
157.63, 148.11, 145.61, 139.06, 134.87, 131.77, 130.38, 129.89, 129.61, 128.76, 127.61, 121.50, 
120.88, 118.70, 113.32, 111.53, 110.80, 61.06, 55.43, 45.24; MS (ESI): m/z = 397.07 (M+H)+. 
 
1,5-bis(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (21). The title 
compound was prepared by reaction of (E)-3-(4-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-
1-one (C7)  and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; yellow solid; yield: 0.48 g (61%); mp 159-160 oC;1H NMR (500 MHz, 
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CDCl3) δ 7.41 (dd, J = 8.2, 1.4 Hz, 1H), 7.37 – 7.33 (m, 1H), 7.33 – 7.27 (m, 2H), 7.28 – 7.20 
(m, 2H), 7.15 – 7.06 (m, 3H), 6.97 (tt, J = 7.6, 3.8 Hz, 1H), 6.87 (ddd, J = 10.0, 8.8, 4.9 Hz, 2H), 
6.10 (dd, J = 11.3, 6.8 Hz, 1H), 4.00 (dd, J = 17.5, 11.3 Hz, 1H), 3.81 (s, 3H), 3.24 (dd, J = 17.5, 
6.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 157.65, 149.69, 142.87, 139.26, 132.09, 130.91, 
130.32, 129.00, 128.38, 127.96, 126.99, 124.71, 123.37, 121.53, 120.83, 63.21, 55.44, 44.91; MS 
(ESI): m/z = 397.06 (M+H)+. 
 
1-(2-chlorophenyl)-5-(3-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (22). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C8) and 2-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.35 g (44%); mp 117-119 oC; 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.29 (m, 3H), 7.27 – 7.23 (m, 2H), 7.19 – 7.15 (m, 1H), 
7.14 – 7.10 (m, 2H), 7.00 (td, J = 7.7, 1.0 Hz, 1H), 6.96 – 6.92 (m, 2H), 6.90 (d, J = 8.3 Hz, 1H), 
5.10 (dt, J = 22.0, 11.0 Hz, 1H), 4.00 (dd, J = 18.1, 12.3 Hz, 1H), 3.81 (s, 3H), 3.28 (dd, J = 
18.1, 7.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 157.81, 147.70, 144.92, 143.76, 135.24, 
130.72, 130.58, 129.43, 129.05, 128.07, 127.25, 126.66, 126.34, 124.29, 124.15, 121.71, 121.17, 
114.73, 111.78, 64.47, 55.64, 47.12; MS (ESI):m/z = 397.06 (M+H)+. 
 
1,5-bis(3-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (23). The title 
compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-
1-one (C8)  and 3-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; beige solid; yield: 0.2 g (25%); mp 126-127 oC 1H NMR (500 MHz, 
CDCl3) δ 8.01 (dd, J = 7.8, 1.7 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.26 – 7.23 (m, 2H), 7.18 – 7.15 
(m, 2H), 7.06 – 6.98 (m, 2H), 6.89 (dd, J = 8.3, 1.0 Hz, 1H), 6.75 – 6.71 (m, 2H), 5.12 (dd, J = 
12.3, 7.0 Hz, 1H), 3.99 (dd, J = 18.1, 12.3 Hz, 1H), 3.79 (s, 3H), 3.27 (dd, J = 18.1, 7.0 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 157.55, 147.78, 145.81, 144.55, 134.98, 134.78, 130.48, 130.43, 
129.86, 128.86, 127.84, 125.97, 123.96, 121.28, 120.90, 118.82, 113.46, 111.47, 111.02, 63.85, 
55.35, 46.82 ; MS (ESI): m/z = 397.07 (M+H)+. 
5-(3-chlorophenyl)-1-(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (24). 
The title compound was prepared by reaction of (E)-3-(3-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C8)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.27 g (34%); mp123-125 oC; 
1H NMR (500 MHz, CDCl3) δ 8.12 (dt, J = 5.6, 2.8 Hz, 1H), 7.48 – 7.42 (m, 3H), 7.40 – 7.35 
(m, 2H), 7.30 (ddd, J = 6.6, 3.9, 2.2 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.16 – 7.11 (m, 1H), 7.10 – 
7.06 (m, 2H), 7.04 (dd, J = 8.4, 0.9 Hz, 1H), 5.25 (dd, J = 12.3, 7.4 Hz, 1H), 4.13 (dd, J = 18.1, 
12.3 Hz, 1H), 3.94 (s, 3H), 3.41 (dd, J = 18.1, 7.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
157.52, 147.43, 144.65, 143.47, 134.96, 130.47, 130.33, 129.18, 128.79, 127.81, 126.40, 124.02, 
123.85, 121.40, 120.89, 114.44, 111.48, 64.17, 55.36, 46.85; MS (ESI): m/z = 397.06 (M+H)+. 
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1,5-bis(2-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (25). The title 
compound was prepared by reaction of  (E)-3-(2-chlorophenyl)-1-(2-methoxyphenyl)prop-2-en-
1-one (C9)  and 2-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; buff solid; yield: 0.3 g (38%); mp 138.5-139.5 oC; 1H NMR (500 MHz, 
CDCl3) δ 8.10 (dd, J = 7.7, 1.7 Hz, 1H), 7.56 (dd, J = 8.2, 1.5 Hz, 1H), 7.52 – 7.42 (m, 3H), 7.42 
– 7.37 (m, 1H), 7.30 – 7.20 (m, 3H), 7.15 – 7.09 (m, 1H), 7.02 (ddd, J = 9.7, 8.9, 4.9 Hz, 2H), 
6.25 (dd, J = 11.3, 6.8 Hz, 1H), 4.15 (dd, J = 17.5, 11.3 Hz, 1H), 3.95 (s, 3H), 3.39 (dd, J = 17.5, 
6.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 157.62, 149.69, 142.85, 139.23, 132.07, 130.91, 
130.31, 129.56, 128.98, 128.37, 127.94, 127.02, 126.99, 124.67, 123.35, 121.79, 121.48, 120.81, 
111.41, 63.17, 55.40, 44.89. ; MS (ESI): m/z = 397.07 (M+H)+. 
 
5-(2-chlorophenyl)-1-(3-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (26). 
The title compound was prepared by reaction of  (E)-3-(2-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C9)  and 3-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.44 g (56%); mp 165-166 
oC; 1H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 7.8, 1.7 Hz, 1H), 7.49 (ddd, J = 7.6, 1.3, 0.6 Hz, 
1H), 7.39 – 7.35 (m, 1H), 7.28 – 7.23 (m, 4H), 7.13 – 7.09 (m, 1H), 7.09 – 7.04 (m, 1H), 6.99 – 
6.93 (m, 1H), 6.81 – 6.76 (m, 1H), 6.74 – 6.69 (m, 1H), 5.64 (dd, J = 12.3, 6.4 Hz, 1H), 4.16 (dd, 
J = 18.2, 12.3 Hz, 1H), 3.87 (s, 3H), 3.28 (dd, J = 18.2, 6.4 Hz, 1H); 13C NMR (125 MHz, 
CDCl3) δ 157.59, 148.08, 145.55, 139.02, 134.84, 131.74, 130.37, 129.90, 129.87, 128.85, 
128.74, 127.59, 127.20, 121.43, 120.85, 118.66, 113.27, 111.47, 110.75, 61.00, 55.40, 45.22; MS 
(ESI):m/z = 397.07 (M+H)+. 
 
5-(2-chlorophenyl)-1-(4-chlorophenyl)-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole (27). 
The title compound was prepared by reaction of  (E)-3-(2-chlorophenyl)-1-(2-
methoxyphenyl)prop-2-en-1-one (C9)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.37 g (46%); mp173-175 oC; 
1H NMR (500 MHz, CDCl3) δ 7.92 (dd, J = 7.8, 1.7 Hz, 1H), 7.29 – 7.22 (m, 3H), 7.22 – 7.13 
(m, 2H), 7.07 – 7.02 (m, 2H), 6.97 – 6.92 (m, 1H), 6.92 – 6.81 (m, 3H), 5.08 (dd, J = 12.2, 7.3 
Hz, 1H), 3.93 (dd, J = 18.0, 12.2 Hz, 1H), 3.75 (s, 3H), 3.21 (dd, J = 18.0, 7.3 Hz, 1H); 13C 
NMR (125 MHz, CDCl3) δ 157.55, 147.44, 143.49, 140.98, 133.30, 130.30, 130.06, 129.00, 
128.77, 127.33, 126.49, 123.84, 121.50, 120.99, 114.48, 111.53, 111.30, 64.06, 55.53, 46.87; MS 
(ESI):m/z = 397.06 (M+H)+. 
 
1-(2-chlorophenyl)-5-(3-chlorophenyl)-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(28). The title compound was prepared by reaction of  (E)-3-(3-chlorophenyl)-1-(3,4-
dimethoxyphenyl)prop-2-en-1-one (C10)  and 2-chlorophenylhydrazine hydrochloride according 
to the general procedure for pyrazoline synthesis; beige solid; yield: 0.32 g (37%); mp118-119 
oC; 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 2.0 Hz, 1H), 7.57 (dt, J = 8.3, 1.7 Hz, 1H), 7.35 
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(dd, J = 8.0, 1.5 Hz, 1H), 7.33 – 7.29 (m, 1H), 7.28 – 7.17 (m, 5H), 7.04 – 6.99 (m, 2H), 5.90 
(dd, J = 11.4, 4.8 Hz, 1H), 4.10 (s, 3H), 4.06 (s, 3H), 3.92 (dd, J = 16.8, 11.4 Hz, 1H), 3.49 (dd, J 
= 16.8, 4.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 150.32, 150.07, 149.27, 143.01, 142.78, 
134.23, 130.25, 129.77, 127.88, 127.06, 126.88, 125.38, 124.90, 124.26, 123.69, 119.45, 110.70, 
108.43, 103.76, 65.77, 56.00, 55.96, 42.60; MS (ESI): m/z = 426.96 (M+H)+. 
 
1-(2-chlorophenyl)-5-(3-chlorophenyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(29). The title compound was prepared by reaction of  (E)-3-(3-chlorophenyl)-1-(2,4-
dimethoxyphenyl)prop-2-en-1-one (C11)  and 2-chlorophenylhydrazine hydrochloride according 
to the general procedure for pyrazoline synthesis; beige solid; yield: 0.40 g (47%); mp 154-156 
oC; 1H NMR (500 MHz, CDCl3) δ 8.02 (t, J = 8.5 Hz, 1H), 7.40 – 7.37 (m, 1H), 7.36 – 7.29 (m, 
2H), 7.27 – 7.22 (m, 2H), 7.12 (t, J = 8.1 Hz, 1H), 6.82 – 6.77 (m, 2H), 6.65 (dd, J = 8.7, 2.4 Hz, 
1H), 6.53 (d, J = 2.4 Hz, 1H), 5.17 (dd, J = 12.2, 7.0 Hz, 1H), 4.04 (dd, J = 18.0, 12.2 Hz, 1H), 
3.92 (s, 3H), 3.87 (s, 3H), 3.33 (dd, J = 18.1, 7.1 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
161.91, 158.85, 147.84, 146.11, 144.74, 134.97, 134.76, 130.45, 129.87, 129.83, 127.79, 126.01, 
124.01, 118.57, 114.28, 113.38, 110.94, 105.51, 98.66, 63.77, 55.46, 55.37, 46.85; MS (ESI): 
m/z = 427.10 (M+H)+. 
 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole (30). The 
title compound was prepared by reaction of  (E)-4,4-dimethyl-1-(naphthalen-2-yl)pent-1-en-3-
one (C12)  and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; off-white solid; yield: 0.46 g (63%); mp 126-127 oC; 1H NMR (500 MHz, 
CDCl3) δ 7.84 – 7.77 (m, 3H), 7.73 (d, J = 6.9 Hz, 1H), 7.50 – 7.42 (m, 2H), 7.37 (dd, J = 8.5, 
1.8 Hz, 1H), 7.06 – 7.01 (m, 2H), 6.92 – 6.87 (m, 2H), 5.11 (dd, J = 11.8, 8.0 Hz, 1H), 3.53 (dd, 
J = 17.3, 11.8 Hz, 1H), 2.80 (dt, J = 37.9, 19.0 Hz, 1H), 1.23 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 159.44, 144.93, 140.06, 133.53, 132.88, 129.24, 128.64, 127.85, 127.75, 126.38, 
125.97, 124.58, 123.78, 123.33, 114.40, 65.26, 43.26, 33.89, 28.25; MS (ESI): m/z = 363.22 
(M+H)+. 
5-([1,1'-biphenyl]-4-yl)-3-(tert-butyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (31). The 
title compound was prepared by reaction of  (E)-1-([1,1'-biphenyl]-4-yl)-4,4-dimethylpent-1-en-
3-one (C13) and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; beige solid; yield: 0.45 g (58%); mp139.5-141 oC; 1H NMR (500 MHz, 
CDCl3) δ 7.56 (ddd, J = 8.2, 5.1, 1.6 Hz, 4H), 7.46 – 7.38 (m, 2H), 7.37 – 7.28 (m, 3H), 7.11 – 
7.03 (m, 2H), 6.92 – 6.84 (m, 2H), 4.99 (dd, J = 11.7, 7.9 Hz, 1H), 3.48 (dd, J = 17.3, 11.8 Hz, 
1H), 2.79 (dd, J = 17.3, 7.9 Hz, 1H), 1.23 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 159.34, 
144.82, 141.64, 140.59, 140.45, 128.76, 128.64, 127.81, 127.34, 127.01, 126.26, 123.27, 114.37, 
64.72, 43.27, 33.84, 28.24; MS (ESI):m/z = 389.21 (M+H)+. 
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3-(tert-butyl)-1,5-bis(4-chlorophenyl)-4,5-dihydro-1H- pyrazole (32). The title compound was 
prepared by reaction of (E)-1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one (C14) and 4-
chlorophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis. white solid; yield: 0.34 g (49.5%); mp 85.3-87 oC; 1H NMR (500 MHz, CDCl3) δ 7.33 
– 7.28 (m, 2H), 7.21 – 7.17 (m, 2H), 7.10 – 7.05 (m, 2H), 6.85 – 6.80 (m, 2H), 4.94 (dd, J = 
11.7, 7.6 Hz, 1H), 3.46 (dd, J = 17.2, 11.7 Hz, 1H), 2.71 (dd, J = 17.2, 7.6 Hz, 1H), 1.21 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 159.25, 144.53, 141.07, 133.26, 129.29, 128.68, 127.24, 123.48, 
114.33, 64.28, 43.14, 33.82, 28.20; MS (ESI): m/z = 347.16 (M+H)+. 
 
3-(tert-butyl)-1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole (33). The 
title compound was prepared by reaction of  (E)-1-(3,4-dichlorophenyl)-4,4-dimethylpent-1-en-
3-one (C15)  and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; yellow solid; yield: 0.54 g (71%); mp 86-87 oC;1H NMR (500 MHz, 
CDCl3) δ 7.42 – 7.35 (m, 2H), 7.12 – 7.04 (m, 3H), 6.85 – 6.77 (m, 2H), 4.90 (dd, J = 11.8, 7.7 
Hz, 1H), 3.46 (dd, J = 17.3, 11.8 Hz, 1H), 2.70 (dd, J = 17.3, 7.7 Hz, 1H), 1.21 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 159.31, 144.41, 142.90, 133.25, 131.60, 131.19, 128.78, 127.88, 
125.17, 123.83, 114.38, 63.96, 43.08, 33.85, 28.19; MS (ESI): m/z = 381.03 (M+H)+. 
 
1,5-bis(4-bromophenyl)-3-(tert-butyl)-4,5-dihydro-1H-pyrazole (34). The title compound was 
prepared by reaction of  (E)-1-(4-bromophenyl)-4,4-dimethylpent-1-en-3-one (C16)  and 4-
bromophenylhydrazine hydrochloride according to the general procedure for pyrazoline 
synthesis; beige solid; yield: 0.42 g (48%); mp132.5-133.5 oC; 1H NMR (500 MHz, CDCl3) δ 
7.47 – 7.42 (m, 2H), 7.22 – 7.17 (m, 2H), 7.14 – 7.10 (m, 2H), 6.79 – 6.73 (m, 2H), 4.92 (dd, J = 
11.8, 7.5 Hz, 1H), 3.45 (dd, J = 17.3, 11.8 Hz, 1H), 2.70 (dd, J = 17.3, 7.5 Hz, 1H), 1.20 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 159.31, 144.84, 141.53, 132.26, 131.57, 127.56, 121.34, 114.78, 
110. 64.16, 43.08, 33.83, 28.19; MS (ESI): m/z = 436.99 (M+H)+. 
 
1-(4-bromophenyl)-3-(tert-butyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole (35). The title 
compound was prepared by reaction of  (E)-1-(4-chlorophenyl)-4,4-dimethylpent-1-en-3-one 
(C14)  and 4-bromophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; light brown solid; yield: 0.46 g (59%); mp132-134 oC; 1H NMR (500 MHz, 
CDCl3) δ 7.30 – 7.26 (m, 2H), 7.21 – 7.13 (m, 4H), 6.78 – 6.72 (m, 2H), 4.92 (dd, J = 11.7, 7.5 
Hz, 1H), 3.44 (dd, J = 17.3, 11.8 Hz, 1H), 2.69 (dd, J = 17.3, 7.5 Hz, 1H), 1.19 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 159.33, 144.87, 141.01, 133.29, 131.58, 129.32, 127.23, 114.79, 
110.73, 64.12,  43.14, 33.85, 28.21; MS (ESI): m/z = 392.10 (M)+. 
 
1,5-bis(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole (36). The title 
compound was prepared by reaction of  (E)-3-(4-chlorophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-
one (C17)  and 4-chlorophenylhydrazine hydrochloride according to the general procedure for 
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pyrazoline synthesis; greenish yellow solid ; yield: 0.54 g (66%); mp 107-109 oC; 1H NMR (500 
MHz, CDCl3) δ 7.30 – 7.21 (m, 4H), 7.20 – 7.15 (m, 2H), 7.09 – 7.02 (m, 2H), 6.96 – 6.86 (m, 
3H), 6.83 (d, J = 8.3 Hz, 1H), 5.09 (dd, J = 12.2, 6.9 Hz, 1H), 4.03 – 3.92 (m, 3H), 3.23 (dd, J = 
17.9, 6.9 Hz, 1H), 1.32 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 156.91, 147.52, 
143.45, 140.94, 133.29, 130.25,129.28,  128.82, 127.35, 126.41, 123.77, 121.60, 120.76, 114.42, 
112.28, 63.96, 63.87, 46.85, 14.80; MS (ESI): m/z = 411.06 (M+H)+. 
 
1,5-bis(4-bromophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole (37). The title 
compound was prepared by reaction of  (E)-3-(4-bromophenyl)-1-(2-ethoxyphenyl)prop-2-en-1-
one (C18) and 4-bromophenylhydrazine hydrochloride according to the general procedure for 
pyrazoline synthesis; beige solid; yield: 0.54 g (54%); mp164.5-166 oC;1H NMR (500 MHz, 
CDCl3) δ7.96 (dd, J = 7.8, 1.7 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.30 (ddt, J = 8.4, 5.3, 1.7 Hz, 1H), 
7.27 – 7.23 (m, 2H), 7.20 – 7.11 (m, 3H), 6.99 (tt, J = 4.9, 2.4 Hz, 1H), 6.92 – 6.86 (m, 2H), 5.18 
– 5.07 (m, 1H), 4.12 – 3.97 (m, 3H), 3.29 (dd, J = 17.9, 6.9 Hz, 1H), 1.38 (t, J = 7.0 Hz, 2H); 13C 
NMR (125 MHz, CDCl3) δ 156.66, 147.35, 143.54, 141.15, 131.98, 130.04, 128.57, 128.47, 
127.43, 126.38, 121.29, 120.51, 114.63, 110.80, 109.68, 63.73, 63.62, 46.54, 14.71; MS (ESI): 
m/z = 501.01 (M+H)+. 
 
1-(4-bromophenyl)-5-(5-bromothiophen-2-yl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(38). The title compound was prepared by reaction of  (E)-3-(5-bromothiophen-2-yl)-1-(2-
ethoxyphenyl)prop-2-en-1-one (C19)  and 4-bromophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.44 g (43%); mp 144-145 oC; 
1H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 7.8, 1.7 Hz, 1H), 7.31 – 7.25 (m, 3H), 7.02 – 6.96 
(m, 3H), 6.86 (dd, J = 13.2, 5.8 Hz, 2H), 6.73 (dd, J = 3.8, 0.6 Hz, 1H), 5.33 (dd, J = 11.6, 6.3 
Hz, 1H), 4.08 – 4.01 (m, 2H), 3.95 (dd, J = 17.8, 11.6 Hz, 1H), 3.43 (dd, J = 17.8, 6.4 Hz, 1H), 
1.39 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 156.98, 148.33, 147.30, 143.98, 132.26, 
131.70, 130.49, 129.62, 128.92, 127.39, 124.58, 120.79, 115.44, 112.24, 111.74, 63.91, 60.64, 
46.94, 14.84; MS (ESI): m/z = 506.79 (M+H)+. 
 
1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole. (39) 
The title compound was prepared by reaction of  (E)-3-(4-chlorophenyl)-1-(2-
ethoxyphenyl)prop-2-en-1-one (C17)  and 4-bromophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; beige solid; yield: 0.47 g (52%); mp 150-152 oC; 
1H NMR (500 MHz, CDCl3) δ 7.99 – 7.94 (m, 1H), 7.54 – 7.46 (m, 2H), 7.36 – 7.19 (m, 6H), 
6.93 – 6.85 (m, 3H), 5.15 (dd, J = 12.2, 6.8 Hz, 1H), 4.10 – 3.98 (m, 3H), 3.29 (dd, J = 18.0, 6.8 
Hz, 1H), 1.38 (t, J = 7.0 Hz, 3H) ; MS (ESI): m/z = 457.12 (M+H)+. 
 
1-(4-chlorophenyl)-3-(2-ethoxyphenyl)-5-(naphthalen-2-yl)-4,5-dihydro-1H-pyrazole (40). 
The title compound was prepared by reaction of  (E)-1-(2-ethoxyphenyl)-3-(naphthalen-2-
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yl)prop-2-en-1-one (C20)  and 4-chlorophenylhydrazine hydrochloride according to the general 
procedure for pyrazoline synthesis; yellow solid; yield: 0.37 g (43%); mp 164-165 oC; 1H NMR 
(500 MHz, CDCl3) δ 8.05 – 7.99 (m, 1H), 7.85 – 7.74 (m, 4H), 7.50 – 7.44 (m, 2H), 7.43 (dd, J = 
8.5, 1.8 Hz, 1H), 7.32 – 7.25 (m, 1H), 7.10 – 7.05 (m, 2H), 7.05 – 6.96 (m, 3H), 6.88 (dd, J = 
8.3, 0.6 Hz, 1H), 5.33 (dd, J = 12.2, 7.4 Hz, 1H), 4.13 – 3.97 (m, 3H), 3.40 (dd, J = 18.0, 7.4 Hz, 
1H), 1.35 (t, J = 7.0 Hz, 3H);13C NMR (125 MHz, CDCl3) δ 156.94, 147.61, 143.82, 139.95, 
133.50, 132.92, 130.15, 129.28, 128.87, 128.71, 127.86, 127.76, 126.35, 125.95, 124.73, 123.88, 
123.61, 121.78, 120.75, 114.50, 112.31, 64.95, 63.88, 46.99, 14.79; MS (ESI): m/z = 427.05 
(M+H)+. 
 
5-([1,1'-biphenyl]-4-yl)-1-(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(41). The title compound was prepared by reaction of  (E)-3-([1,1'-biphenyl]-4-yl)-1-(2-
ethoxyphenyl)prop-2-en-1-one (C21)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; brown solid; yield: 0.52 g (57%); mp 191-192 oC; 
1H NMR (500 MHz, CDCl3) δ 7.98 (s, 1H), 7.58 (d, J = 24.3 Hz, 4H), 7.49 – 7.18 (m, 6H), 7.10 
(dd, J = 18.8, 14.3 Hz, 2H), 7.01 (dd, J = 7.9, 3.5 Hz, 3H), 6.88 (s, 1H), 5.21-5.17 (m, 1H), 4.04-
3.98 (m, 3H), 3.36 (dd, J = 12.8, 5.0 Hz, 1H), 1.38 (t, J = 7.0 Hz, 3H) ; MS (ESI): m/z = 453.18 
(M+H)+. 
 
1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(42). The title compound was prepared by reaction of  (E)-3-(3,4-dichlorophenyl)-1-(2-
ethoxyphenyl)prop-2-en-1-one (C22)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.65 g (73%); mp 170-171 
oC; 1H NMR (500 MHz, CDCl3) δ 8.08 (dd, J = 7.8, 1.7 Hz, 1H), 7.54 – 7.49 (m, 2H), 7.45 – 
7.39 (m, 1H), 7.28 – 7.22 (m, 3H), 7.11 (tt, J = 7.4, 2.9 Hz, 1H), 7.08 – 7.03 (m, 2H), 7.01 (dd, J 
= 8.3, 0.7 Hz, 1H), 5.23 (dd, J = 12.2, 6.9 Hz, 1H), 4.22 – 4.06 (m, 3H), 3.41 (dd, J = 18.0, 7.0 
Hz, 1H), 1.51 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 156.91, 147.55, 143.31, 
142.81, 133.20, 131.62, 131.18, 130.40, 129.27, 128.87, 128.85, 127.98, 126.33, 125.30, 124.06, 
121.35, 120.78, 114.43, 112.26, 63.88, 63.59, 46.78, 14.81; MS (ESI): m/z = 445.05 (M+H)+. 
1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazole 
(43). The title compound was prepared by reaction of  (E)-3-(2,4-dichlorophenyl)-1-(2-
ethoxyphenyl)prop-2-en-1-one (C23)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.55 g (61%); mp 162-163 
oC; 1H NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 7.8, 1.8 Hz, 1H), 7.50 – 7.45 (m, 1H), 7.34 – 
7.24 (m, 2H), 7.20 – 7.08 (m, 3H), 6.99 (td, J = 7.7, 1.1 Hz, 1H), 6.93 – 6.86 (m, 3H), 5.51 (dd, J 
= 12.2, 6.4 Hz, 1H), 4.24 – 3.96 (m, 3H), 3.24 (dd, J = 18.1, 6.5 Hz, 1H), 1.41 (t, J = 7.0 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ 156.95, 147.93, 143.05, 137.75, 133.83, 132.48, 130.37, 
129.07, 128.93, 128.77, 128.35, 127.87, 123.90, 121.44, 120.75, 114.16, 112.32, 63.92, 60.86, 
45.22, 14.76; MS (ESI): m/z = 445.06 (M+H)+. 
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1-(4-chlorophenyl)-3-(2-ethoxyphenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (44). 
The title compound was prepared by reaction of  (E)-1-(2-ethoxyphenyl)-3-(4-
fluorophenyl)prop-2-en-1-one (C24)  and 4-chlorophenylhydrazine hydrochloride according to 
the general procedure for pyrazoline synthesis; yellow solid; yield: 0.36 g (46%); mp 112-114 
oC; 1H NMR (500 MHz, CDCl3) δ 7.50 – 7.37 (m, 4H), 7.27 – 7.22 (m, 2H), 7.21 – 7.12 (m, 3H), 
7.12 – 7.07 (m, 2H), 7.03 (dd, J = 8.3, 0.7 Hz, 1H), 5.31 (dd, J = 12.1, 6.9 Hz, 1H), 4.22 – 4.11 
(m, 3H), 3.43 (dd, J = 17.9, 6.9 Hz, 1H), 1.52 (t, J = 7.0 Hz, 3H) ; MS (ESI): m/z = 395.12 
(M+H)+. 
 
 (3-(tert-butyl)-1,5-bis(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-4-
yl)(morpholino)methanone (45). To a three-necked flask containing 20 mL of dry THF, a 0.75 
mL of lithium diisopropylamide (LDA), 2M solution in THF/n-heptane/ethylbenzene was added 
under argon atmosphere, followed by a solution of 347 mg (1 mmol) of 3-(tert-butyl)-1,5-bis(4-
chlorophenyl)-4,5-dihydro-1H-pyrazole (32) in 10 mL of THF via a syringe at -78 °C. The 
mixture was stirred for 1h. Afterward, 4-morpholinecarbonyl chloride (0.175 mL, 1.5 mmol) was 
added to the solution, the resulting mixture was stirred at –78 °C for 30 min, then left to attain 
room temperature and stirred for 20h. The reaction was quenched with 10 mL of brine, the 
aqueous layer was separated and extracted with two 10 mL-portions of  CH2Cl2, the combined 
organic layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by CC 
(CH2Cl2/hexane, 5:1) to afford (45); white solid; yield : 0.29 g (63%); mp 170-171 °C; 1H NMR 
(500 MHz, DMSO) δ 7.41 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.9 Hz, 2H), 
6.81 (d, J = 8.9 Hz, 2H), 5.28 (s, 1H), 4.31 (s, 1H), 3.71 – 3.42 (m, 8H), 1.15 (s, 9H); MS (ESI): 
m/z = 460.19 (M+H)+. 
 
(1,5-bis(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-pyrazol-4 -yl) (morpholino) 
methanone (46) .  The title compound is obtained using the same procedure applied for the 
previous compound 45 using 1,5-bis(4-chlorophenyl)-3-(2-ethoxyphenyl)-4,5-dihydro-1H-
pyrazole (36). The product was obtained as white solid; yield : 0.40 g (76%); mp 180-181 °C; 1H 
NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 7.6, 1.7 Hz, 1H), 7.28 – 7.23 (m, 3H), 7.22 – 7.18 (m, 
2H), 7.03 – 6.97 (m, 2H), 6.94 (td, J = 7.5, 1.0 Hz, 1H), 6.87 – 6.80 (m, 2H), 6.81 – 6.74 (m, 
1H), 5.39 (d, J = 6.0 Hz, 1H), 4.64 (d, J = 6.0 Hz, 1H), 3.95 – 3.88 (m, 2H), 3.64 – 3.46 (m, 2H), 
3.37 – 3.23 (m, 3H), 3.23 – 3.04 (m, 2H), 2.80 – 2.71 (m, 1H), 1.12 (t, J = 7.0 Hz, 3H); MS 
(ESI): m/z = 522.05 (M+H)+. 
 
Cell Culture 
 
Cancer cell lines cultured included wild type p53 cell line (HCT-116) and a p53 null cell 
line (H1299) and were obtained from the American Type Culture Collection (ATCC).  Both cell 
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lines were cultured in a 37°C humidified incubator with 5% CO2 with the same medium (RPMI-
1640 supplemented with 5% fetal bovine serum), and passaged twice weekly. Only cultures 
exhibiting greater than 95% viability were used in growth inhibition experiments (determined by 
trypan blue exclusion).  
 
Growth Inhibition Assay: 
 
Cells were seeded in 96-well tissue culture-treated assay plates at a density of 1.5 x 104 
cells/cm2, then allowed to attach overnight before addition of experimental compounds.  
Compounds were dissolved in DMSO, then diluted to the final concentration indicated so as to 
ensure that DMSO concentration is less than 0.2%. After treatment with either a single screening 
concentration or a titration series of concentrations of compounds, cells were incubated for an 
additional 72 h. Relative cell growth was determined by addition of Promega CellTiter Glo 
luciferase-based assay of ATP content.  The resultant luminescence was measured, and each data 
set was analyzed using DMSO (vehicle control) as a baseline value for growth inhibition.  
GraphPad Prism software was used to develop dose-response curves and IC50 values for active 
compounds. 
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4 Discussion, Conclusion and Outlook 
The main aim of this thesis was to develop PKCζ potent and isoform selective inhibitors 
through targeting the PIF pocket on the kinase catalytic domain as described in chapter 3.1. The 
development strategy was based on the previously reported PKCζ moderate allosteric inhibitors 
4-benzimidazolyl-3-phenylbutanoic acids which were proven to target the PIF pocket. As shown 
in Figure 16, cell and cell free potency optimization was intended through: 
1) Rigidification of the three flexible bonds connecting the two aryls. 
2) Replacement of the essential carboxylate function, which can impair cellular 
permeability, by another HBA function to improve the permeability characteristics.  
 
Figure 16: The optimization strategy adapted starting from the previously reported 4-benzimidazolyl-3-
phenylbutanoic acids, based on the PIF pocket structure as proposed from the closely related PKCɩ crystal structure. 
      The two requirements were found to be satisfied by using the pyrazoline scaffold which 
supplies the 1- and 5- phenyls to presumably interact with the two mostly hydrophobic PIF 
subpockets, in a similar way to the two aryls from the previous scaffold, as shown in the lower 
part of Figure 16. In addition, the imine nitrogen was assumed to replace the carboxylate in its 
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interaction with Lys301. The substituent at position three of the pyrazoline was expected to be 
solvent exposed, yet, it can be utilized to improve pharmacokinetic characteristics, with a 
possible interaction with Lys301, as can be seen in figure 16.    
 
Figure 17: Structure of the hit compound 1a and different modifications adapted. The pyrazoline scaffold is rich in 
modifiable sites; at positions 1, 3, 4, and 5, in addition to the possibility of oxidation to the planar pyrazole. 
The first pyrazolines synthesized were bearing a halogen substitution at both the 1- and 5-
phenyls similar to the previously reported inhibitors, as this was expected to suit the nature of 
two mostly hydrophobic PIF-subpockets; however, this did not lead to active compounds. It was 
then hypothesized that substituting the 5-phenyl with a hydroxyl group to interact as a HBD with 
one of the two backbone carbonyls in subpocket 1 (shown in figure 16) can improve the binding 
affinity. This successfully led to the hit compound 1a with a cell free IC50 of 10.7 µM and 3.2 
µM in the reporter gene assay in U937 cells (Figure 17). Several modifications were done to 
optimize both the cell and cell free potencies of the hit compound 1a as shown in Figure 17. 
The optimization process led to many potent compounds with an IC50 of less than 0.1 µM 
in the cell free assay and a submicromolar IC50 in U937 cells. The phenolic OH at the 5-phenyl 
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was found to be an essential irreplaceable feature in all active compounds in both types of 
assays. 
 
Figure 18: The most active compounds as PKCζ inhibitors from the pyrazoline series. PS185 is the most active 
compound form the previously reported 4-benzimidazolyl-3-phenylbutanoic acids. The IC50 values for the cell free 
and U937 cell assays are shown. ND: not determined.  
The most active compounds obtained in the new series are shown in Figure 18, where 
their IC50 values are displayed in comparison with PS185, the most potent compound form the 
previously reported butanoic acid inhibitors. As can be observed, one order of magnitude 
improvement was achieved in the cell assay results compared with the previous inhibitors; 
however, this fold of improvement was not as high as that observed in the cell free assay, which 
is most probably due to non-specific protein binding inside the cells. A conclusion which is 
augmented by the observation that adding serum albumin to the cell assay medium dramatically 
reduced compounds’ potency when compared to serum albumin free conditions, especially with 
compounds having plain phenyl or heteroaryl at position three of the pyrazoline. To overcome 
this, we have just started a second phase of development to have compounds with increased 
polarity and improved physicochemical characteristics  in which more drug-like moieties like 
imidazole, triazole and thiazole are adapted at the highly tolerant 3-position of the pyrazoline 
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ring. This is also important for testing the compounds using in vivo disease models, where 
solubility and a suitable logP range are limiting factors for successful results. 
The improved potency and selectivity for PKCζ vs. the whole PKC family and related 
kinases makes the discovered and optimized compounds good pharmacological tools to further 
study PKCζ as drug target, as well as studying the possible therapeutic applications together with 
the probable side effects resulting from its inhibition. 
The inhibition of PKCζ can launch a field of treatment of many important diseases 
including bronchial asthma, hepatitis, autoimmune diseases and B cell lymphomas; however the 
exact indication of the developed inhibitors is still under investigation using the suitable disease 
models. To aid in the attempts of investigation, we currently started validation experiments using 
real time PCR to analyze the effect of some potent compounds like compound 4f on cytokines 
expression. The preliminary data in hand showed that 4f down regulated the expression of 
several cytokines and chemokine receptors in U937 cells which have been differentiated into 
monocytes. 
On the other hand, the involvement of PKCζ in many important cellular responses in 
different tissues can limit the medicinal use of the developed inhibitors as a result of the possible 
side effects.  However, if side effects are proven, tissue specific drug delivery may overcome the 
problem, for instance, using inhalation dosage forms for treatment of bronchial asthma or 
adapting certain structural modifications for selective tissue uptake.   
All the synthesized pyrazolines were obtained as racemates, the poor resolution on the 
chiral column hindered the study of enantio-selectivity in the inhibitors’ interaction with the PIF 
pocket, which makes the design of enantio-selective synthesis in the next step of development an 
important requirement to study such effect. 
  The three dimensional shape of the tri-substituted pyrazoline scaffold suggested that it 
can also fit into other surface pockets like the Mdm2 pocket, to disrupt its interaction with p53, 
as was discussed in chapter 3.2. The pyrazoline scaffold seemed to represent an ideal protein-
protein interaction inhibitor scaffold, useful to generate ligands for surface protein interaction 
pockets which normally accommodate two adjacent lipophilic residues like aromatic rings of 
Phe, Tyr or Trp, or lipophilic side chains of Leu for example. The scaffold might mimic the 
correct positioning of the respective aromatic rings or lipophilic side chains when they are either 
protruding from a short α-helix with the usual 2-3 residues spacers (like p53) or from loops with 
two amino acid residues as spacer like in the case of the HM peptide (FXXF). The suitability of 
the tri- and tetra-substituted pyrazoline scaffolds as Mdm2 inhibitor was also suggested by the 
structure overlay of the designed inhibitors with nutlin-2 from its crystal structure with Mdm2. 
Discussion, Conclusion and Outlook 
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Although some of the synthesized compounds were able to show potent and preferential 
growth inhibition against HCT116 cells with wild-type p53 vs. H1299 cells which lack p53 
expression, in a comparable behavior to nulin-3, the promising hits failed to displace a 
fluorescence-labeled peptide from its complex with Mdm2 on verifying the binding to Mdm2. 
The lack of activity in the latter assay was attributed to many reasons including solubility 
problems and compounds’ native fluorescence. This finding suggests that further modifications 
are required to improve polarity and solubility characteristics, and highlights the need to 
optimize the assay conditions. 
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